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Abstract
This Thesis investigates the concept that molecular mimicry may be instrumental to the 
appearance and/or maintenance of liver autoimmunity, with a main focus on primary 
biliary cirrhosis (PBC).
The first part of the study concentrates on the investigation of immunological cross­
reactivity between pyruvate dehydrogenase complex E2 (PDC-E2)212-226, the 
immunodominant mitochondrial autoepitope in PBC and microbial mimics. Several 
bacterial and viral sequences were identified that share extensive homology with PDC- 
E2212-226 and while some from mycobacteria, lactobacillus and E. coli, acted as target of 
cross-reactivity, similarly good mimicking sequences from other micro-organisms were 
unreactive. The possible bearing on the mechanism of the disease of this selective cross­
reactivity is discussed.
Next is the identification of cross-reactive immune responses between hepatitis C virus 
(HCV) polyprotein and cytochrome P450IID6 (CYP2D6)252-27i, the major autoepitope 
of anti-liver kidney microsomal type-1 antibody (LKM1), the serological hallmark of 
autoimmune hepatitis type-2. Viral/self cross-reactivity was documented only in those 
patients possessing the HLA B51 allele. The evolution of immunological cross­
reactivity was investigated over a 10-year period in a girl who developed primary and 
secondary LKM1 response following HCV infection resulting in a florid autoimmune 
hepatitis 9 years later. A study in a cohort of subjects vaccinated against hepatitis B 
provided the opportunity to document the appearance of cross-reactivity between viral 
sequences and mimics on myelin antigens.
The findings of the present Thesis demonstrate that disease-specific microbial/self 
cross-reactive responses do occur and may be of pathogenic significance.
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1.1 The lymphoid liver
Classically, lymphoid organs were considered to be those tissues with exclusively 
immunological functions, for example, the thymus, lymph nodes and spleen (Miller and 
Davies, 1964). This definition has recently been expanded to include organs whose 
primary function is not immunological but which clearly require dedicated and often 
elaborate immunological mechanisms to mediate their functions. The gut and the uterus, 
for example, fall into this category; the liver is also regarded as a lymphoid organ with 
unique immunological properties (Head, 1996, Abreu-Martin and Targan, 1996, 
Doherty and O'Farrelly, 2000). Because of its location and function, the liver is 
continuously exposed to a large antigenic load that includes pathogens, toxins, tumor 
cells, dietary and self-antigens. The range of local immune mechanisms required to cope 
with this diverse immunological challenge has been the focus of ongoing studies. The 
liver has an ‘epithelial constitution’ and contains large numbers of phagocytic cells, 
antigen presenting cells (APC) and lymphocytes and is a site for the production of 
cytokines, complement components and acute phase proteins (Doherty and O'Farrelly, 
2000).
In the normal liver, the hepatocytes comprise 70% of the total number of cells. The 
remaining 30% cells are mostly concerned with immunological functions and include 
lymphocytes, sinusoidal endothelial cells, Kupffer cells, biliary epithelial cells and 
hepatic stellate cells (Hata et al., 1990, Norris et al., 1998, Norris et al., 1999, Doherty 
et a l , 1999, Doherty and O'Farrelly, 2000). Cell numbers and proportions are shown in 
Figure 1.1.
The normal human liver has an intrinsic lymphocyte population mainly resident in the 
portal tract but also scattered throughout the parenchyma. One to two million of these 
lymphoid cells are retrievable from 200 mg of normal liver tissue, indicating that an 
average human liver of 1.5 kg contains approximately 1 x 1010 lymphocytes. 
Intrahepatic lymphocytes (IHL) consist of natural killer T (NKT) lymphocytes (50% of 
the IHL), T-cells (25% of IHL), natural killer (NK) cells (20%) and B lymphocytes 
(5%) (Figure 1.1). The relative proportions among IHL of different classes of 
lymphocytes differ widely from those in the peripheral blood where up to 80% are T- 
cells, 20% B-cells, 13% NK-cells, and 0.2-2% are NKT-cells (Hata et al., 1990, Norris
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et al., 1998, Norris et al., 1999, Doherty et a l , 1999, Doherty and O’Farrelly, 2000, 
Mehal et a l, 2001).
The relative frequencies of lymphocyte subpopulations can also vary dramatically from 
individual to individual. This is likely to reflect differences in each individual’s 
immunological status that would be influenced by factors such as genetic background, 
history of infections, and current antigenic exposure. Ongoing immune challenges to the 
liver would presumably affect the relative proportions of resident hepatic lymphocytes 
and infiltrating circulating lymphocytes that are present in the liver (Crispe, 2003, Kita 
et a l, 2001).
The liver is an organ in which blood from the intestines, rich in bacterial and dietary 
antigens intermingles with the circulating lymphocytes. The constitutive presence of 
antigenic material imposes constraints on immune responses that are generated in the 
liver and distinctive control mechanisms have to determine whether antigen encounter 
will result in immunological un-responsiveness (tolerance) (Crispe, 2003, Kita et a l, 
2001). It is obvious that liver autoimmunity implies loss of self-tolerance, and the 
question arises as to how this happens. An insight to the basic characteristics of liver 
tolerance comes from a better understanding of aspects of immunological tolerance in 
general (Crispe, 2003).
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D istr ib u tion  o f  ce ll su b se ts  in  n orm al liv er  (% )
Non-Parenchymal Cells 
(20-30%)
Kupffer Cells 
(25%)
Lymphocytes
(25%)
Stellate Cells 
(few, proportion uknown)
Biliary Epithelial Cells 
(3 -5%)
Sinusoidal Epithelial Cells 
(50%)
NKT cells 
(0-2%)
NKT cells 
(26 -50 %)
NK cells 
( 13-20 %)
NK cells 
(20 -31%)
T cells
(75 -80%)
T  cells
(2 5 -37%)
B cells 
( 10-20 %)
B cells 
(5 - 10%)
C ell co m p o sitio n  in p erip h eral b lood  (% )
Percentage proportions o f different cell types in the normal liver and comparison with lymphocyte subsets in blood. NKT, natural killer T-cells; 
NK, natural killer (see 1.1) adopted from Mackay (2002) and modified according to Hata et al. (1990), Norris et al. (1998, 1999), Doherty and 
O ’Farrely (2000)
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1.2 Immunological tolerance and the liver
Early in the history of experimental transplantation, immunologists were surprised to 
discover that in many species, allogeneic liver grafts could be established and 
maintained with minimal immunosuppression, while skin, kidney and other allografts 
were rejected rapidly (Caine et al., 1969, Caine, 2000). Reasons to explain why the liver 
is often a site of immune tolerance have not been fully clarified, but it has been 
suggested that it is because the liver is a site where harmless food antigens from the gut 
are processed and presented to the immune system (Crispe, 2003). However, the liver is 
also subjected to invasion by pathogens that breach the intestinal mucosa and invade the 
circulation (Caine, 2000). Immune tolerance towards such invaders would not be 
advantageous, which indicates that liver lymphocytes must be able to switch rapidly 
from a tolerant to a responsive state (Cantor and Dumont, 1967, Caine, 2000, Crispe, 
2003).
Tolerance is the controlled inability to respond to antigens to which an individual has 
the potential for response (Kamradt and Mitchison, 2001). Self-tolerance refers to lack 
of responsiveness to an individual's antigens, and obviously it underlies our ability to 
live in harmony with our own cells and tissues (Miller and Basten, 1996, Kamradt and 
Mitchison, 2001). Several mechanisms, albeit not well understood, have been postulated 
to explain the tolerant state. Tolerance is antigen specific and is achieved through 
deletion of lymphocytes (clonal deletion) or their inactivation (clonal anergy) or through 
a mechanism of suppression/regulation (Miller and Basten, 1996, Kamradt and 
Mitchison, 2001). Clonal deletion is prominent in T lymphocyte tolerance (Akkaraju et 
al., 1997, Ferber et al., 1994, Critchfield et al., 1994) whilst anergy is the main 
mechanism of B lymphocyte tolerance (Goodnow et al., 1988).
Tolerance may be induced centrally, in the primary lymphoid organs (thymus for the T- 
cell tolerance, bone marrow for B-cells) or in the periphery (Miller and Morahan, 1992, 
Miller and Basten, 1996, Kamradt and Mitchison, 2001, Mathis and Benoist, 2004).
1.2.1 Central tolerance
In order to establish a complete immune repertoire, thymus and bone marrow generate 
potentially reactive T and B lymphocytes by a process referred as positive selection 
(Miller and Basten, 1996, Kamradt and Mitchison, 2001). The next step involves clonal
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deletion of self-reactive T and B lymphocytes during their maturation in the central 
lymphoid organs. Clonal deletion of developing intrathymic T-cells has been 
extensively investigated. It is proposed that many autologous protein antigens are 
processed and presented by thymic antigen-presenting cells in association with self 
Major Histocompatibility Complex (MHC) molecules (Miller and Basten, 1996, 
Kamradt and Mitchison, 2001). The developing T-cells that express high-affinity 
receptors for such self-antigens are negatively selected, or deleted, and therefore the 
peripheral T-cell pool is lacking or deficient in self-reactive cells. As with T-cells, 
clonal deletion is also operative for B-cells (Kamradt and Mitchison, 2001). When 
developing B-cells encounter a membrane-bound antigen within the bone marrow, they 
undergo apoptosis. Clonal deletion of self-reactive lymphocytes, however, is far from 
perfect. Although this process eliminates a significant fraction of autoreactive 
lymhocytes, other potentially self reactive, naive cells (not subject to the thymic or bone 
marrow negative selection process) escape and are found in the periphery. These 
lymphocytes ‘evade’ negative selection, either because their affinity to the ‘self 
determinants in the thymus is too low or their specific antigens are not expressed in the 
thymus (Miller and Basten, 1996, Kamradt and Mitchison, 2001). There is similar 
‘slippage’ in the B-cell system as well. T and B-cells that bear receptors for a variety of 
self-antigens, can be found in the peripheral blood of healthy individuals (Kitze et al., 
1988, Naquet et a l , 1988, Kamradt and Mitchison, 2001).
1.2.2 Peripheral tolerance
Those self-reactive lymphocytes that escape negative selection can inflict tissue injury 
unless they are deleted or muzzled in the peripheral tissues (Miller and Morahan, 1992). 
Several ‘back-up’ mechanisms that silence such potentially autoreactive lymphocytes 
are known to exist, the major being ignorance, anergy and suppression/regulation 
(Miller and Morahan, 1992).
Ignorance relates to prevention of contact between autoreactive lymphocytes and self­
antigens (Barker and Billingham, 1977, Butcher and Picker, 1996, Kamradt and 
Mitchison, 2001).
Anergy refers to prolonged or irreversible functional inactivation of lymphocytes, 
induced by encounter with antigens under certain conditions (Quill, 1996, Delves and 
Roitt, 2000a). Activation of antigen-specific T-cells requires two signals: recognition of 
peptide antigen in association with self MHC molecules on the surface of APC and a set
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of second costimulatory signals provided by APC (Quill, 1996, Delves and Roitt, 
2000b). To initiate second signals, certain T-cell-associated molecules must bind to 
their ligands on the APC (Lenschow et a l , 1996, Grewal and Flavell, 1998, Holter et 
al., 1996). If the antigen is presented by cells that do not bear these ligands, a negative 
signal is delivered, and the cell becomes anergic (Lenschow et a l , 1996, Grewal and 
Flavell, 1998, Holter et a l, 1996, Kamradt and Mitchison, 2001). Such a cell then fails 
to be activated even if the relevant antigen is presented by competent APC (e.g., 
macrophages, dendritic cells) that can deliver costimulation (Kamradt and Mitchison,
2001). Because costimulatory molecules are not expressed or are weakly expressed on 
most tissues, the encounter between autoreactive lymphocytes and their specific self­
antigens leads to clonal anergy. Clonal anergy therefore affects autoreactive 
lymphocytes not only in the thymus but also in the tissues (Miller and Morahan, 1992). 
It is believed that if B-cells encounter an antigen in the absence of specific helper T- 
cells, the antigen-receptor complex is down-regulated, and such cells never re-express 
their immunoglobulin receptors (Kamradt and Mitchison, 2001). Understandably, such 
cells are unable to respond to subsequent antigenic stimulation. In addition to antigen- 
induced loss of surface immunoglobulin receptors, other mechanisms of B-cell anergy 
are also postulated to exist (Rathmell et a l, 1996, Nemazee, 2000).
Although clonal deletion and anergy are the primary mechanisms of self-tolerance, it is 
believed that additional ‘fail-safe’ mechanisms must also exist. Much renewed interest 
is focused on regulatory T-cells with the ability to down-regulate the function of other 
autoreactive T-cells (Shevach, 2000). The molecular mechanisms by which suppressor 
T-cells recognize antigens and exert their suppressive effects have remained elusive 
(Shevach, 2000). There is some evidence that peripheral suppression of autoreactivity 
may be mediated, in part, by the regulated secretion of cytokines such as interleukin 
(IL)-10, transforming growth factor-p and IL-4 (Powrie et a l, 1996, Seddon and Mason,
1999). The behaviour and possible participation of regulatory T-cells in human 
autoimmune liver disease is the focus of ongoing studies (Longhi et a l , 2004).
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1.3 Breakdown of tolerance: mechanisms of autoimmunity
Although it would be attractive to explain all autoimmune diseases by a single 
mechanism, it is now clear that several different pathological processes could break 
tolerance, thus terminating a previously unresponsive state to autoantigens (Ohashi and 
DeFranco, 2002). More than one defect may be present in each disease, and the defects 
vary from one disorder to the other. It has been argued that the multilayered nature of 
self-tolerance is a ‘fail-safe’ mechanism: all or several control mechanisms must be 
infringed before disease develops (Ohashi and DeFranco, 2002). This approach may 
well explain several important principles regarding autoimmune disease: (1) it is usually 
multifactorial involving immunologic, genetic, and environmental factors interacting 
through complicated mechanisms that are incompletely understood (Ohashi and 
DeFranco, 2002); (2) it often has a slower progress than immune reactions to pathogens, 
suggesting that the control mechanism may continue to work up to a point; (3) it has a 
tendency to remit and relapse, indicating that control mechanisms may recover and at 
least temporarily restore tolerance (Kamradt and Mitchison, 2001, Ohashi and 
DeFranco, 2002).
The initiating mechanisms in autoimmunity can best be discussed in terms of those 
discussed for tolerance (Kamradt and Mitchison, 2001). While there is no convincing 
evidence of breakdown of central tolerance as a cause of autoimmunity, several 
mechanisms exist whereby failure of peripheral tolerance may contribute to the 
pathogenesis of autoimmune diseases (Kamradt and Mitchison, 2001, Ohashi and 
DeFranco, 2002). Most of these mechanisms have been deduced from in vitro work or 
animal model studies, since the evolution of human autoimmune disease can rarely be 
investigated from the onset (Kamradt and Mitchison, 2001, Ohashi and DeFranco,
2002). It appears that tolerance to self may be disrupted by several mechanisms such as: 
failure of T-cell anergy, activation-induced cell death and/or T-cell mediated 
suppression; polyclonal lymphocyte activation; release of sequestered antigens; 
exposure of ‘hidden’ or ‘cryptic’ self antigens; ‘epitope spreading’; ‘aberrant’ 
expression of class II MHC molecules; cytokine influence; and finally microbial/self 
molecular mimicry.
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1.3.1 Failure o f  T-cell anergy
Potentially autoreactive T-cells that escape clonal deletion are usually rendered anergic 
when they encounter self-antigens expressed on costimulator-deficient APC in the 
tissues (Kamradt and Mitchison, 2001, Ohashi and DeFranco, 2002). It follows that 
such T-cell anergy may be broken if these APC can be induced to express costimulatory 
molecules and to secrete cytokines that stimulate the generation of T helper cells type 1 
(Thl) (Mueller et al., 1989, Quill, 1996, Kamradt and Mitchison, 2001, Ohashi and 
DeFranco, 2002). Such induction may occur after infections with resultant tissue 
necrosis and local inflammation (Tough et al., 1997, Kamradt and Mitchison, 2001, 
Ohashi and DeFranco, 2002). Breakdown of B-cell anergy is also possible (Goodnow et 
al., 1991).
1.3.2 Failure o f activation-induced cell death
Persistent activation of potentially autoreactive lymphocytes may lead to their apoptosis 
(Refaeli et al., 1998, Rathmell and Thompson, 2002). It follows therefore that defects in 
apoptotic pathways may allow persistence and proliferation of autoreactive lymphocytes 
in the peripheral tissues (Strasser et al., 1991, Martinon and Tschopp, 2004, Opferman 
and Korsmeyer, 2003).
1.3.3 Failure o f  T-cell mediated suppression
The hypothesis that loss of regulatory or suppressor T-cells that can limit the function of 
autoreactive cells can lead to autoimmunity is quite attractive (Strasser et al., 1991). 
This notion has been difficult to prove, however, in large part because of the difficulty 
in the isolation and identification of antigen-specific regulatory T-cells.
1.3.4 Polyclonal lymphocyte activation
Autoimmunity may occur if self-reactive but anergic clones are stimulated by antigen- 
independent mechanisms. Several microorganisms and their products are capable of 
causing polyclonal (i.e., antigen nonspecific) activation of B-cells (Primi et al., 1977, 
Hang et al., 1985). Bacterial lipopolysaccharide (endotoxin), for example, can stimulate 
the production of anti-DNA, anti-thymocyte and anti-red cell antibodies in vitro 
(Murakami et al., 1997). Other bacterial products can also bind to and activate a large 
pool of CD4 T-cells in an antigen-independent manner. They do so by binding to class 
II MHC molecules on antigen-presenting cells and the beta chains of the T-cell receptor
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(TCR), outside the antigen-binding groove (Dellabona et al., 1990). Because they 
stimulate all T-cells that express a certain set or family of the Vbeta TCR, they are 
called ‘superantigens’ (Herman et al., 1991). It has been proposed that among the T- 
cells activated by superantigens, some may be reactive to self-antigens, leading to the 
induction of autoimmunity and indeed autoimmune disease, as it is for example the case 
for multiple sclerosis (Brocke et al., 1993).
1.3.5 Release o f sequestered antigens
Any self-antigen that is completely sequestered during development is likely to be 
viewed as foreign if introduced into the circulation (Kamradt and Mitchison, 2001). The 
mere release of these antigens is not sufficient to cause autoimmunity; the inflammation 
associated with the tissue injury is essential for up-regulation of costimulatory pathways 
that are critical for the induction of an immune response as it is the case of post- 
traumatic uveitis where an immune response is directed to sequestered ocular antigens 
(Caspi, 1999). Infections have been proposed to account for the release of sequestered 
autoantigens through tissue damage and the induction of inflammatory cytokines and 
costimulatory molecules (Horwitz et al., 1998, Kamradt and Mitchison, 2001)
1.3.6 Exposure o f  ‘hidden ’ or ‘cryptic ’ self antigens and ‘epitope spreading '
It is believed that a large number of intracellular self-determinants are not readily 
recognized by the immune system, and hence T-cells specific for such ‘cryptic’ self­
epitopes are not deleted (Lipham et al., 1991, Sercarz et al., 1993, Markovic-Plese et 
al., 1995). It follows that such T-cells could cause autoimmune diseases if the cryptic 
epitopes are somehow presented to them in an immunogenic form (Sercarz et al., 1993). 
Several factors could be responsible for rendering an epitope cryptic, including the 
available amount of the determinant itself, its ability to be processed by APC, and the 
availability of costimulatory factors (Sercarz et al., 1993). It has long being proposed 
that regardless of the initial trigger of an autoimmune response, the progression of the 
autoimmune response is maintained by recruitment of autoreactive T-cells that 
recognize normally cryptic self-determinants (Sercarz et al., 1993). The induction of 
such autoreactive T-cells is sometimes referred to as epitope spreading because the 
immune response ‘spreads’ to include determinants within the same molecule (intra­
molecular) or other molecules (inter-molecular) that were initially not recognized 
(Lehmann et al., 1992). There is compelling evidence for the role of epitope spreading
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in the pathogenesis of a murine model of multiple sclerosis, type 1 diabetes, and 
systemic lupus erythematosus (SLE) (Lehmann et al., 1998, McCluskey et al., 1998, 
Zechel et al., 1998, Miller et al., 1997).
1.3. 7 ‘Aberrant' expression o f  class II MHC molecules
Class II expression is the medium for communication between CD4 helper T 
lymphocytes and APC (Delves and Roitt, 2000a). Since this step is critical in initiating 
an immune response, class II expression is restricted to immune-cells such as 
professional APC and B lymphocytes (Delves and Roitt, 2000a). ‘Aberrant’ or 
‘inappropriate’ appearance of class II MHC molecules on cells that do not normally 
express them may be sufficient to incite an autoimmune response against that particular 
cell by CD4 T-cell lymphocytes as it has been shown, for example, on hepatocytes in 
autoimmune hepatitis and biliary epithelial cells in primary biliary cirrhosis (Ballardini 
et al., 1984, Lobo-Yeo et al., 1990).
1.3.8 Cytokine influence
Cytokines are soluble factors with pleiotropic effects that act both locally and 
systemically on cells of the immune system (Delves and Roitt, 2000b). Their role in the 
immune system is the recruitment of immunocompetent cells and modulation of their 
functions. In respect to their role in the induction of autoimmunity, cytokines can induce 
class II and enhance class I MHC expression on target cells that could eventually lead 
indirectly to the induction of autoimmune processes (bystander activation) (Cope, 1998, 
Hill and Sarvetnick, 2002, Tough et al., 1996). Other possible mechanisms include 
cytokine-mediated breakdown of immunological tolerance and a direct cytotoxic effect 
on target cells (Hill and Sarvetnick, 2002).
1.3.9 Molecular mimicry between microbial and self proteins
The concept of molecular mimicry, as it will be discussed in detail, is based on the 
observation that some infectious agents share antigenic determinants (epitopes) with 
self-antigens (Oldstone, 1987, Oldstone, 1998). An immune response against such 
microbes may then turn against the cross-reacting self-antigen initiating an autoimmune 
cascade that leads to host cell destruction and eventually to autoimmune disease 
(Oldstone, 1987, Oldstone, 1998).
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1.4 Breakdown of liver tolerance
Various mechanisms have been proposed to account for the initiation of an autoimmune 
liver response with no single initiating event being able to account for all instances of 
autoimmunity (Kita et al., 2001). Two general conditions, however, must prevail: self 
reactive B and T lymphocytes must exist in the immunological repertoire and 
autoantigens must be presented in conjunction with MHC class II molecules by APC 
(Kita et al., 2001, Mackay, 2002). The presence of lymphocytes in the liver is 
commonly considered to be associated with disease pathogenesis (Hata et al., 1990, 
Doherty and O’Farrelly, 2000, Mackay, 2002). Lymphocyte infiltration is well 
documented in inflammatory conditions such as autoimmune and viral liver diseases 
(Knolle and Gerken, 2000). The liver harbours lymphoid cells that subserve innate and 
adaptive immune responses and, like peripheral lymphoid tissues, is a site where naive 
T-cells can be activated by local antigen (Hata et al., 1990, Norris et al., 1998, Norris et 
al., 1999, Doherty et al., 1999, Doherty and O'Farrelly, 2000, Mehal et al., 2001). 
Hepatocytes or cholangiocytes can carry antigens perceived as foreign, and for which 
neither of the appropriate options, elimination or complete tolerance, has been achieved 
(Reynoso-Paz et al., 1999, Kita et al., 2001). Such antigens may be derivatives of 
hepatotropic viruses, drugs or xenobiotics, or the host itself, as it is the case in 
autoimmune liver diseases (Reynoso-Paz et al., 1999, Kita et al., 2001).
1.4.1 Infections and liver tolerance
Viral or other microbial infection of the liver induces an immune response to clear the 
pathogen, and the competence of the immune response determines whether chronic 
disease will develop or, as usually happens, clearance will occur (Knolle and Gerken,
2000). Hepatotropic viruses are generally non-cytopathic, and the host immune 
response is responsible for both viral clearance and the associated inflammatory cell 
injury (Chisari and Ferrari, 1995, Cemy and Chisari, 1999, Bertoletti and Ferrari, 2003). 
A misdirected immune response to hepatocellular or biliary ductular constituents 
released in the course of such injury is a postulated pathway for liver autoimmunity 
(Reynoso-Paz et al., 1999, Kita et al., 2001).
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1.4.2 Drugs and liver tolerance
The liver is the major site of drug metabolism. Drugs and their metabolites can be toxic 
if their degradation pathways are defective (Bissell et al., 2001, Liu and Kaplowitz,
2002). Thus, intracellular antigens may be released from the damaged cells (Robin et 
al., 1997). Presentation of protein adducts may eventually lead to an immune response, 
including the production of autoantibodies, inflammation and hepatocyte necrosis 
(Robin et al., 1997, Liu and Kaplowitz, 2002). In addition, the covalent binding of a 
drug metabolite to its enzyme may results in the modification of this enzyme and in the 
appearance of antibodies that recognise the alkylated form as a neo-antigen (Robin et 
al., 1997, Liu and Kaplowitz, 2002).
1.4.3 Apoptosis and liver tolerance
Apoptosis, as the basis for programmed cell death, is responsible for the normal regular 
turnover of hepatocytes and the elimination of liver cells in inflammatory pathologies 
(Patel, 2000, Kita et al., 2001, Crispe, 2003). Although less obvious in biliary 
epithelium, apoptosis is also present in autoimmune cholangiopathies (Reynoso-Paz et 
al., 1999). Aside from hepatocytes and their disposal, apoptosis is relevant to the 
breakdown and/or maintanance of liver tolerance (Patel, 2000, Kita et al., 2001, Crispe,
2003). First, death by apoptosis allows for non-inflammatory elimination of cell 
components in contrast to necrosis which is pro-inflammatory and potentially 
autoantigenic (Mackay, 2002). However, if apoptosis is overwhelming, apoptotic 
fragments can induce an autoimmune response and indeed autoimmune disease as it has 
been seen in the case of SLE (Cocca et al., 2002). Second, apoptosis is a mechanism 
used for the removal of autoreactive T and B lymphocytes, as it is illustrated by 
lymphoproliferative diseases due to deficiency of apoptotic genes (Vaishnaw et al.,
1999).
1.4.4 Autoimmune liver diseases
Autoimmune liver diseases represent a broad spectrum of disorders that can affect one 
or the other of the two anatomical components, in particular the hepatocytes in 
autoimmune hepatitis (AIH) types 1 and 2 and de novo AIH following transplantation 
and the cholangiocytes and bile ducts in primary biliary cirrhosis (PBC), and sclerosing 
cholangitis (SC) (Mackay, 2002). AIH-1 is characterised by seropositivity for 
antibodies to nuclear (ANA) and/or smooth muscle antibodies (SMA) and AIH type 2
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for anti-liver kidney microsomal type 1 antibodies (LKM1) (Alvarez et al., 1999). The 
serology of SC is similar to that of AIH-1 (Gregorio et al., 1997, Gregorio et al., 2001). 
The serological hallmark of PBC is the presence of high-titre anti-mitochondrial 
antibodies (AMA) (Neuberger, 1997). AIH and PBC represent the major autoimmune 
liver diseases; their main clinical, serological, and immunological characteristics as well 
as the current knowledge of their pathogenesis will be described later in detail.
1.5 Virus, liver and autoimmunity
Several viruses home to the liver (hepatotropic viruses) and cause hepatitis (Mackay,
2002). The liver can also be affected by viruses that primarily target other tissues such 
as herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and 
measles virus (Mackay, 2002). Among hepatotropic viruses, hepatitis B and C viruses 
(HBV, HCV) can take up permanent residence and cause serious chronic disease 
(Chisari and Ferrari, 1995, Cemy and Chisari, 1999). Hepatitis viruses have been found 
to induce aberrant autoantibodies which in the majority are non-organ specific and 
usually similar to those observed in AIH (Bogdanos et a l , 2000a, Obermayer-Straub 
and Manns, 2001). Autoimmunity is therefore a common feature of HBV and HCV 
infection with over 50% of the infected patients being positive for autoantibodies 
against nuclear antigens (ANA) and smooth muscle antigens (SMA) (Gregorio et al., 
1996, Gregorio et al., 1998, Lenzi et al., 1999, Abuaf et al., 1993, Cassani et al., 1997, 
Clifford et al., 1995, Bortolotti et al., 1996, Muratori et al., 2003b). As discussed later, 
LKM1 antibody is confined to patients with chronic HCV infection being found in up to 
10% of them while it is absent in chronic HBV infection (Lunel et al., 1992, Bortolotti 
et al., 1996, Gregorio et al., 1998, Cassani et al., 1997, Nishioka et al., 1997, Lenzi et 
al., 1999). Immunopathological manifestations in HBV and especially in HCV infection 
are not limited to autoantibody seropositivity but embrace the full spectrum of textbook 
autoimmune disorders, ranging from non-organ specific cryoglobulinaemia to the 
exquisitely organ specific autoimmune thyroiditis and include such conditions as 
rheumatoid arthritis, Sjogren’s syndrome, glomerulonephritis, lichen planus, 
polyarteritis nodosa, and type 1 diabetes (Czaja, 1997, Mehta et al., 2001). The 
mechanisms leading to immunopathological manifestations in viral hepatitis differ. 
Thus in cryoglobulinaemia from HCV and glomerulonephritis from HBV formation of 
immune complexes is involved in the pathological damage. Hepatitis C and B viral
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constituents are integral components of the immune complexes and interferon-(IFN)-a 
induced control of the viral infection is associated with an improvement in 
cryoglobulinaemia and glomerulonephritis (Czaja, 1997, Mehta et a l,  2001, Bogdanos 
et a l , 2000a, Obermayer-Straub and Manns, 2001). Interferon is also involved at the 
other end of the spectrum, but this time in unmasking or inducing de novo autoimmune 
thyroiditis (Dusheiko, 1997, Marcellin et a l , 1995). IFN-a may favour the development 
of Thl immune reaction and thereby contribute to the development of autoimmune 
disease (Foster, 1997). In addition, IFN-a inhibits the apoptosis of autoreactive B-cells 
leading to the overproduction of autoantibodies (Su and David, 1999).
That viruses and other microbial agents have the potential to trigger autoimmune 
responses ultimately resulting in autoimmune disease is an accepted notion indirectly 
supported by epidemiological studies (Kurtzke, 1993, Gamble, 1980), geographic 
distribution (Ebers and Sadovnick, 1993), migration surveys (Anand et a l , 1996) and 
concordance studies between monozygotic and dizygotic twins (Ebers et a l , 1986, 
Eastmond and Woodrow, 1977, James, 1996). Attempts to establish a direct 
epidemiological association between viral infections and autoimmune disorders have 
been hampered by the fact that, frequently, patients have experienced multiple viral 
infections by the time their disease is diagnosed (von Herrath, 2000). Moreover, 
immunologically mediated damage may occur years after the causative viral infection 
has been cleared by the host immune response, a ‘hit and run’ event, so that no viral 
footprints are detectable in the affected organ, thus removing our ability to identify the 
link (Oldstone, 1987, von Herrath, 2000). Type 1 diabetes, for example, is 100 times 
more frequent in individuals who had congenital rubella virus infection, compared to 
non-infected children (Menser et a l , 1978). However, pancreatic /?-cell destruction may 
become evident several years -up to the forth decade of life- after the exposure to the 
virus (Menser et a l , 1978, von Herrath, 2000).
The mechanism by which viruses could induce autoimmunity is under investigation 
(von Herrath et al., 2003, Wucherpfennig, 2001). First, viruses can selectively infect 
specialised target cells, such as the pancreatic /?-cells or the hepatocytes, leading directly 
to their destruction (von Herrath, 2000, von Herrath et a l , 2003, Wucherpfennig, 2001). 
In the case that all the cells are destroyed by a viral infection, the disease that occurs 
cannot be considered autoimmune in nature. This may happen in certain cases of 
hyperacute type 1 diabetes or in the case of fulminant hepatic failure related to viral 
hepatitis (von Herrath, 2000, von Herrath et a l , 2003, Wucherpfennig, 2001). On the
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other hand, if the viral infection destroys some but not all the target cells, disease may 
not result until years later (von Herrath, 2000, von Herrath et al., 2003, Wucherpfennig, 
2001).
Another scenario implicates activation of the target cells that leads to the secretion of 
immune mediators, among them cytokines such as IFN-y, tumor necrosis factor-a 
(TNF-a) or production of mediators such as nitric oxide that harm the surrounding cells 
(Wucherpfennig, 2001). This ‘bystander’ destruction of the cells could accompany 
inflammatory reactions in the liver (Knolle and Gerken, 2000, Diehl, 2000). The third 
possibility by which a virus can induce autoimmunity is molecular mimicry (Oldstone, 
1987, Oldstone, 1998, Wucherpfennig, 2001, von Herrath et al., 2003).
1.6 Viruses, molecular mimicry and autoimmunity
The hypothesis of molecular mimicry is based on the concept that an immunogenic 
determinant of an exogenous agent, such as a virus, incites formation of antibodies or 
effector T-cells, which in turn, react with homologous epitopes on a host protein 
(Oldstone, 1987, Oldstone, 1998). The sharing of a linear amino acid sequence or a 
conformation fit between a virus and a host ‘self determinant is the initial step of this 
process (Oldstone, 1987, Oldstone, 1998). Autoimmunity provoked by molecular 
mimicry should occur only when the viral and host determinants are similar enough to 
cross-react, yet different enough to break immunological tolerance (Oldstone, 1987, 
Oldstone, 1998). Antibodies or cytotoxic lymphocytes may then cross-react with a self­
protein, thereby causing cellular injury leading to cell destruction. Once the infectious 
agent initiates this process, it needs not to be present during the autoimmune destruction 
that follows. In this situation, the microbial agent may have been cleared, but elements 
of the immune response mounted against it would lead to tissue injury that, in turn, 
would release more self antigens, thereby inducing more antibodies, and so on 
(Oldstone, 1987, Oldstone, 1998). Therefore, although viruses may initiate disease, the 
likehood of their recovery from tissue sites is small (Oldstone, 1987, Oldstone, 1998, 
von Herrath, 2000).
There are numerous examples of antigenic determinants shared between viruses, 
bacteria or parasites, and host cell proteins (Oldstone, 1987, Oldstone, 1998, von 
Herrath, 2000). In an early study, more than 3% of over 600 monoclonal antibodies 
raised against different viral proteins, cross-reacted with normal tissue antigens
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(Srinivasappa et a l, 1986). Conversely, antibodies to self proteins such as hormones, 
cells of the nervous system or lymphocyte subsets may cross-react with viral 
polypeptides (Oldstone, 1987, Oldstone, 1998, von Herrath, 2000). The ability to find 
cross-reactive T-cells or antibodies which can recognise self-epitopes does not 
necessarily mean an autoimmune disease will develop (Oldstone, 1987, Oldstone, 1998, 
von Herrath, 2000). As it has been mentioned (see 1.2), regulation or suppression of 
self-reactive immune responses occurs when most of us encounter foreign antigenic 
mimics. This would explain why, although we are all commonly exposed to microbial 
mimics throughout our lives, autoimmunity is a relatively rare event. The transition 
from cross-reactive immune responses to autoimmune disease depends on numerous 
intrinsic and extrinsic factors such as the ability of host MHC molecules to bind and 
present antigens, the likelihood of a peptide being processed for binding to the MHC, 
the presence in the periphery of B or T-cells specific for self epitopes having escaped 
deletion, and the level of cytokines induced after an immune recognition event.
A long-standing paradigm in support of the molecular mimicry hypothesis is that 
proposed in the case of acute rheumatic fever (Cunningham et al., 1989, Cunningham, 
2000, Galvin et a l , 2002). Rheumatic fever involves autoimmune-mediated myocardial 
pathology that can arise following infection with group A streptococcus (Cunningham,
2000). At the molecular level, streptococcal surface M proteins share an amino acid 
sequence with cardiac myosin (Cunningham et a l , 1989, Cunningham, 2000, Galvin et 
a l , 2002). Serum antibodies from patients with acute rheumatic fever as well as 
monoclonal antibodies directed against a peptide of the streptococcal M protein cross- 
react with high-molecular weight cardiac and skeletal myosin (Cunningham et a l , 1989, 
Cunningham, 2000, Galvin et a l, 2002). Conversely, a monoclonal antibody raised to 
ventricular myosin binds the streptococcal M protein (Cunningham et a l, 1989, 
Cunningham, 2000, Galvin et a l, 2002). Help for pathogenic autoantibody development 
is provided by T-cell determinants that are stimulated by both streptococcal M peptides 
and mimics of cardiac myosin (Cunningham et a l, 1989, Cunningham, 2000, Galvin et 
a l, 2002). Multiple exposures to this pathogen in the susceptible host leads to 
progressive valvular damage mediated by cross-reactive antibodies (Cunningham et a l, 
1989, Cunningham, 2000, Galvin et a l, 2002).
The initial pathogenic insult does not need to be closely temporally related to the 
manifestation of autoimmune disease. This is well illustrated in Chagas’ disease caused
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by the Trypanosoma cruzi (Kierszenbaum, 1999). Acute infection with T. cruzi causes a 
transient myocarditis which resolves completely. Decades later, an autoimmune 
myocarditis, histologically characterised by mononuclear cell infiltration, in the absence 
of detectable parasites, develops in the susceptible host, leading eventually to dilated 
cardiomyopathy (Kierszenbaum, 1999). Molecular mimicry between the B13 antigen of 
T. cruzi and cardiac myocytes is thought to be responsible for the development of the 
autoimmune response (Cunha-Neto et a l , 1996). This system, illustrates the ‘hit and 
run’ model for the development of autoimmunity following infection (Oldstone, 1987, 
Oldstone, 1998, von Herrath, 2000).
Another striking example of molecular mimicry is a murine model of herpes simplex 
keratitis (HSK), a T-cell-mediated inflammatory disease of the cornea that is induced by 
local application of HSV (Zhao et a l,  1998). In humans, HSV1-induced destruction of 
corneal tissue represents a leading cause of blindness (Streilein et a l,  1997). In the 
mouse model, keratogenic T-cell clones produced following corneal application of the 
virus cross-react with a peptide from the HSV1 UL6  protein (Zhao et a l,  1998) . 
Viruses with a mutated UL6  gene or with a single amino acid substitution at the UL6  T- 
cell epitope are greatly impaired in their ability to induce HSK indicating that a viral 
infection can trigger T-cell-mediated autoimmunity by molecular mimicry (Zhao et a l, 
1998, Panoutsakopoulou et a l, 2001).
EBV infection has been implicated in the induction of anti-nuclear autoimmunity in 
SLE (James et a l, 2001b, James et a l, 2001a). A recurring proline-rich sequence 
-PPPGMRPP- is among the earliest antigenic sites to provoke a humoral autoimmune 
response against the B protein of the nuclear ribonucleoprotein (snRNP) autoantigenic 
complex (James and Harley, 1998). Immunisation of animal models with this peptide 
induces lupus-like autoimmunity, as does immunisation with the closely related 
sequence -  PPPGRRP - found in the EBV nuclear antigen-1 (EBNA-1) (James and 
Harley, 1998). Over time epitope spreading occurs from the single octapeptide, to other 
snRNP proteins as has been shown by the presence of autoantibodies that recognise 
various snRNP proteins including A, C, D and 70kDa antigens (James and Harley,
1998). Epidemiological support to this model comes from a study demonstrating that 
99% of young SLE patients have seroconverted against EBV compared to 70% of no- 
SLE normal controls (James et a l, 1997).
The majority of animal studies that have examined the issue of immunological cross­
reactivity have focused on B- and CD4 T-cells. More recently, the role of CD8  T-cells
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has also been investigated in a mouse model of inflammatory bowel disease using CD8 
T-cell clones that recognise both mycobacterial and murine heat shock protein 60 
(hsp60) (Steinhoff et al., 1999). Adoptive transfer of hsp60-specific T-cells into TCR/? 
null mice leads to massive infiltration of these T-cells into the small intestine and the 
liver (Steinhoff et al., 1999). Transfer of hsp60-specific T-cells into wild-type mice 
does not cause such pathology, possibly because in vivo expansion of these T-cells is 
limited in hosts that are not immunodeficient. Disease in this system is mediated by 
TCR recognition of the hsp60 self-antigen; a non-cross-reactive T-cell clone that only 
reacts with mycobacterial hsp60 does not cause disease (Steinhoff et al., 1999). These 
results establish TCR cross-reactivity between murine and bacterial hsp60 and indicate 
that molecular mimicry may also be relevant for CD8  T-cell populations (Steinhoff et 
a l , 1999).
1.7 Molecular mimicry in viral hepatitis
1.7.1 Hepatitis B virus and myelin basic protein
Interestingly, the concept of molecular mimicry was for the first time tested in a rabbit 
animal model using a hepatitis B virus DNA polymerase peptide with six amino acids 
identical to the encephalitogenic region of rabbit myelin basic protein (MBP), the major 
autoantigen of multiple sclerosis (MS) (Fujinami and Oldstone, 1985). T-cell reactivity 
to MBP was observed following immunization of rabbits with this peptide, and four of 
eleven animals showed histological signs of experimental autoimmune 
encephalomyelitis (EAE), the animal model of MS (Fujinami and Oldstone, 1985). This 
finding raised the important question of whether infection with viral or bacterial 
pathogens, rather than immunization with synthetic peptides, can also induce 
autoimmunity (Oldstone, 1998). As it will be discussed later (see Chapter 10), isolated 
cases of demyelinating disorders such as MS have been reported, although rarely, as a 
result of autoimmune adverse reactions following exposure to hepatitis B surface 
antigen through prophylactic HBV vaccination (Cohen and Shoenfeld, 1996).
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1.7.2 Hepatitis B and C viruses and non-organ specific autoantibodies
SMA and ANA are frequently found, and appear de novo, in the course of chronic HBV 
although their origin remains unclear (Gregorio et al., 1996). In an attempt to explain 
their production Gregorio et al. (1999) searched for putative cross-reactive epitopes in 
HBV and human smooth muscle and nuclear proteins. Six human proteins were 
identified with a high local sequence similarity with the HBV DNA polymerase: four 
nuclear proteins involved in structural and regulatory functions, namely MHC class II 
/rarts-activator (MHCIITA), nuclear pore complex protein (NPCP), nuclear mitotic 
apparatus (NuMA), and polyomyositis sclerosis antigen (PM-scl) and two smooth 
muscle proteins involved in muscle contraction, myosin and caldesmon (Figure 1.3 A) 
(Gregorio et al., 1999). When serum samples from HBV infected patients, pathological 
and healthy controls were tested for reactivity to synthetic peptides spanning the 
homologous sequences, viral/self mimicry was observed almost exclusively in HBV 
infected subjects (Gregorio et al., 1999). Antibody recognition of HBV-DNA 
polymerase/self peptide pairs was cross-reactive as shown by anti-peptide antibody 
competition experiments (Gregorio et al., 1999). Gregorio et al. (1999) further 
demonstrated cross-reactivity between homologous peptides and whole antigen with 
respect to myosin and caldesmon, and identified these proteins as autoantigens in 
chronic HBV infection by immunoblot (Gregorio et al., 1999).
More recently, the same group of investigators went on to study the role of molecular 
mimicry between HCV, nuclear and smooth muscle antigens (Gregorio et al., 2003). 
Using similar methodology, they found cross-reactive antibodies between a number of 
HCV antigens and human nuclear and smooth muscle mimics (Figure 1.3B). Myosin 
also appeared to be an important molecular target in HCV infection, although a different 
epitope to that found in HBV infection was involved (Gregorio et a l , 2003).
These studies document the usefulness of the application of molecular mimicry as a tool 
for the identification of unknown autoantigens cross-reactively recognised by viral 
agents, have provided an insight into how molecular mimicry and immunological cross­
reactivity may be involved in the induction of autoimmunity related to viral hepatitis, 
and have been the foundation on which this thesis is based (Gregorio et al., 1999, 
Gregorio et al., 2003).
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Protein Sequence
HBV DNA polymerase V G L L G F A A P F T Q C G
MHCIITA V G L L G R A A L D S P P G
HBV DNA polymerase S S T V P V F N P
NPCP S S T V P V S L P
HBV DNA polymerase G P L E E E L P R L A D
NuMA G s L E E E K R R A A D
HBV DNA polymerase N E K R R L K L
Pm-scl Q E K K R L K 1
i Myosin D E K R R L E
HBV DNA polymerase N E K R R L K
Caldesmon E E K R R L K
HCV polymerase L 1 S Q A E A A L E N L V
Matrin 3 L D Q E N E A A L E N G I
HCV polymerase A V s R T Q R R G
Histone H2A A V s R S Q R A G
HCV polymerase A L V A F K I M S G E
Replication protein A S L V A F K I M P L E
) HCV polymerase L A T K T F G S S G S S
Smoothelin M Q T K T F S S s S S S
HCV polymerase E G E V Q I V S T A T Q
Myosin E L E D T L D S T A T Q
HCV polymerase G V R V L E D G V N F A
Vimentin G V R L L Q D S V D F S
Figure 1.2 Amino acid sequence homology between: (A) the hepatitis B virus DNA 
polymerase and i) human nuclear proteins (MHCIITA, MHC class II trans-activator; 
NPCP, nuclear pore complex protein; NuMA, nuclear mitotic apparatus; Pm-scl; 
polyomyositis sclerosis antigen) and (ii) smooth muscle proteins; (B) the hepatitis C 
polyprotein and (i) nuclear antigens and (ii) smooth muscle proteins. Amino acids in 
standard single letter; Colon (:), identity; Full stop (), conservative substitution
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1.8 Hepatitis C and autoimmune hepatitis
AIH-2 is a severe form of autoimmune liver disease affecting mainly children that 
requires life-long immunosuppressive treatment (Gregorio et a l , 1997). Progression to 
cirrhosis and liver failure may occur in some patients despite therapeutic intervention 
and usually requires liver transplantation (Gregorio et al., 1997). Histologically, AIH-2 
is characterised by interface hepatitis where lymphocytes, plasma cells and 
macrophages from the portal tract infiltrate the adjacent parenchyma, and surround 
dying hepatocytes (Dienes et a l , 1989). Serologically, AIH-2 is characterised by 
elevated levels of immunoglobulin G (IgG) and high titres of LKM1 autoantibodies, the 
name deriving from the distinctive pattern that the antibody gives on rodent liver and 
kidney sections {see 2.2.2.1) (Alvarez et al., 1999). The molecular target of LKM1 has 
been identified as cytochrome P450 IID6  (CYP2D6), a 50 kDa microsomal enzyme 
involved in the metabolism of xenobiotics (Alvarez et a l , 1985, Gueguen et a l , 1989). 
LKM1 is also found in up to 10% of patients with chronic HCV infection but not in 
other viral hepatitides (Lunel et a l, 1992, Bortolotti et a l, 1996, Gregorio et a l, 1998, 
Cassani et a l, 1997, Nishioka et a l, 1997, Lenzi et a l, 1999). Early studies have also 
reported a minority of patients with AIH-2 to be infected with HCV, suggesting a causal 
link between this virus and AIH-2 (Lenzi et a l, 1990, Vergani and Mieli-Vergani, 
1993).
How cytochromes and in particular CYP2D6 become ‘self targets’ is not yet established 
(Manns and Obermayer-Straub, 1997, Bogdanos and McFarlane, 2003). It has long 
been thought that intracellular proteins are normally ‘hidden’ from immune recognition 
and therefore immunologically privileged {see 1.3.5). Antigen release following 
hepatocyte injury could provide the stimulus for an immune response towards ‘cryptic’ 
epitopes on CYP2D6 (Manns and Obermayer-Straub, 1997). This model of anti- 
CYP2D6 antibody production fails to provide a convincing explanation for the highly- 
specific nature of the observed anti-CYP2D6 immune response (Bogdanos and 
McFarlane, 2003). Firstly, not every form of liver damage is associated with an anti- 
CYP2D6 immune response: anti-CYP2D6 antibodies are undetectable in viral hepatitis 
A and B and in type 1 AIH (Bogdanos and McFarlane, 2003). Secondly, in those 
conditions where reactivity to cytochromes is present, distinctive profiles can be 
recognised. Anti-CYP2D6 antibodies are found in AIH-2 and in a proportion of HCV
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infected patients. In neither condition is it possible, however, to detect antibodies to 
cytochrome P450 1A2 (CYP1A2), the marker of the hepatitis associated with 
autoimmune polyendocrine syndrome type 1 (Clemente et al., 1998, Manns and 
Obermayer-Straub, 1997, Bogdanos and McFarlane, 2003). Moreover, despite a high 
level of amino acid homology between CYP2D6, CYP1A2 and CYP1A1, the latter does 
not act as target autoantigen (Clemente et al., 1998). These patterns indicate a specific, 
antigen-driven mechanism in the breakdown of immunological tolerance towards 
individual cytochromes (Bogdanos and McFarlane, 2003).
Kerkar et a l (2003) have identified the sequence CYP2D6193.212 as a major B-cell 
epitope recognised by sera from 93% of patients with AIH-2 and 50% of those with 
anti-LKMl positive HCV infection. They also found that there is extensive cross­
reactivity between immune responses directed to CYP2 D6193-212 and highly homologous 
regions within HCV and CMV antigens (Kerkar et al., 2003). Modelling studies located 
the CYP2 D6193-212 peptide to the surface of CYP2 D6 , making it accessible to antibody 
recognition in the context of the physiologically folded protein (Kerkar et al., 2003). 
Alanine substitution of the homologous HCV epitope confirmed that the homology 
shared by HCV, CMV and CYP2 D6193.212 was responsible for the observed cross­
reactivity (Kerkar et al., 2003). Furthermore, these Authors have shown that purified 
CYP2 D6193-212 specific autoantibodies are able to inhibit the activity of the native 
enzyme (Kerkar et al., 2003).
These findings provide suggestive evidence for molecular mimicry to be a mechanism 
for induction of anti-CYP2D6 autoantibodies and give support to the multi-hit theory of 
autoimmunity. Thus, multiple exposures to CMV, a common viral pathogen, may 
establish permissive immunological conditions, by priming a cross-reactive subset of 
autoreactive lymphocytes, in a genetically predisposed host (Kerkar et al., 2003). 
Chronic infection with HCV may then provide the final impetus for the generation of 
LKM1 autoantibodies through cross-reactive mechanisms (Kerkar et a l , 2003). 
Depending on the degree of immunological priming, the degree of genetic susceptibility 
(particularly at the HLA locus and coding regions for ‘innate’ components of 
immunity), and antigenic dose of the infecting pathogens, a minority of individuals may 
progress to autoimmune disease.
Others have also invoked cross-reactive mechanisms to explain the generation of LKM1 
antibodies on the basis that two sequences from the HCV polyprotein, one each from 
the envelope 1 (El) and the non structural 5B (NS5B) antigens, and one from the
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immediate early 175 KDa protein of HSV-1, share extensive homology with 
CYP2D6254-27i, the second most frequently recognised B-cell epitope of LKM1 in AIH- 
2 (Manns et a l, 1991). Although attractive, there was little experimental evidence to 
support this hypothesis and reactivity to the viral mimics had not been tested (Manns et 
al., 1991).
That reactivity to viral and self peptides, as indeed to the whole CYP2D6 protein, is of 
the IgG isotype thus suggesting the involvement of T-cell ‘help’ for B-cell 
immunoglobulin isotype class switching (Cebra et a l, 1984, Snapper and Mond, 1993). 
This notion is further supported by the presence of autoreactive T-cells in the blood and 
the liver of patients with AIH-2 and the results of immunohistochemical studies 
demonstrating that most infiltrating T-cells are positive for the CD4 helper/inducer 
phenotype, and a sizeable minority are positive for the CD8  cytotoxic/suppressor 
phenotype (Senaldi et a l, 1992, Vergani and Mieli-Vergani, 2003).
Taken together, these studies indicate that an autoimmune response to CYP2D6 is likely 
to follow the rules of any other autoimmune response, and involve CD4, CD8 , and B- 
lymphocytes, one of the components possibly prevailing at different stages of the 
pathological progress (Vergani and Mieli-Vergani, 2003, Bogdanos and McFarlane,
2003). Interestingly Cemy and Chisari (1999) have proposed a role for CD8  molecular 
mimicry in the causation of post-infectious autoimmunity making reference to HCV and 
AIH-2. They base their contention on the work of Kammer et al. (1999), showing 
induction of cytotoxic T-cells (CTL) reactive with a decamer (amino acids 8-17) of 
CYP2A6 and CYP2A7 after exposure to the homologous HCV core sequence (amino 
acids 178-187), the relevant peptides being totally unreactive at the B-cell level 
(Bogdanos et a l, 2000b). These authors proposed that liver cell damage mediated by 
HCV-specific CTL leads to the release of intracellular proteins like CYP2A6 and 
CYP2D6, uptake of these autoantigens by professional APCs, and autoantibody 
formation in the presence of autoreactive CD4 and CD8  T-cells (Kammer et a l,  1999). 
After viral clearance, the autoimmune disease would be upheld due to ongoing 
hepatocyte lysis by cross-reactive, HCV-induced CTL maintained by autoreactive 
helper T-cells (Kammer et a l, 1999). The interaction of HCV, autoreactive T-cells, and 
autoreactive CD8  and CD4 T-cells would thus be required for the induction of HCV- 
associated autoimmunity directed to cytochromes. The need of this complex interaction 
would explain the relatively low frequency of anti-CYP2D6 immune responses, and 
indeed of AIH, among HCV patients despite the high number of individuals with cross­
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reactive CTL (Bogdanos et al., 2000b). Kammer et a l (1999) findings demonstrate the 
potential of HCV to induce autoreactive CD8  CTL by a molecular mimicry mechanism 
involving viral/self mimics and therefore show a possible mechanism by which a virus 
can trigger AIH.
A feature of AIH-2 is the possible coexistence of other autoimmune diseases, in 
particular type 1 diabetes, Addison’s disease, hypoparathyroidism and autoimmune 
thyroiditis (Gregorio et a l , 1997). Choudhuri et al. (1998) have demonstrated cross­
reactive LKM1 antibody responses between CYP2 D632 1.351, the third most frequently 
recognised epitope of CYP2D6, and structurally similar regions of carboxypeptidase H, 
an autoantigen in type 1 diabetes, and 2 1 -hydroxylase, the major autoantigen in 
Addison’s disease. These Investigators proposed that autoimmunity once induced 
against one self-antigen may spread via molecular mimicry to other homologous self 
antigens, and, in genetically predisposed individuals, lead to overt autoimmune disease 
(Choudhuri et a l, 1998). Although intermolecular epitope spreading is a feature of other 
autoimmune disease such as type 1 diabetes and connective tissue disorders, the 
mechanistic explanation for this phenomenon has relied on molecular association or 
tissue colocalisation for the diversification of autoimmunity (James and Harley, 1998). 
The hypothesis of Choudhuri et a l (1998) although able in principle to explain the 
spread of autoimmunity to anatomically distant tissues through immunological cross­
reactivity, has not yet been confirmed.
It is now becoming clear that molecular mimicry studies have been based either on 
epidemiological association of infectious agents with specific autoimmune 
manifestations or experimental evidence demonstrating cross-reactivity between 
microbial and self antigens (Oldstone, 1998, von Herrath, 2000, von Herrath et a l ,
2003). In either case, the microbial trigger as well as the self target (or at least its origin) 
are known and an investigation is carried out to identify the microbial/self determinants 
that serve as targets of the cross-reactive immune responses (Oldstone, 1998). Several 
studies have provided knowledge of the fine specificity of immune responses towards 
specific antigenic regions (Oldstone, 1998, von Herrath, 2000, von Herrath et a l, 2003). 
These regions have been used through molecular mimicry studies as tools for the 
identification of mimicking microbial agents, which could be pathogenetically linked 
with the autoimmune disease (Oldstone, 1998, von Herrath, 2000, von Herrath et a l,
48
Chapter 1
2003). Primary biliary cirrhosis is one of these autoimmune diseases whereby 
molecular mimicry has been investigated in detail taking into account epidemiological 
considerations linking specific microbial agents with the disease, evidence of 
microbial/self cross-reactitivity but also identification of putative microbial mimics 
through search of homologies with the disease’s single immunodominant epitope (Van 
de Water et al., 2001).
1.9 Primary biliary cirrhosis
Primary biliary cirrhosis is an immune-mediated chronic cholestatic liver disease 
characterised by inflammatory destruction of the small intrahepatic bile ducts, 
progressing to cirrhosis and subsequent liver failure (Kaplan, 1996, Neuberger, 1997). 
The disease affects mainly middle-aged women, with most cases occurring between the 
ages of 40 and 60 years (Sherlock and Scheuer, 1973, Mahl et al., 1994). There is a 
wide variation in the recorded incidence between areas, ranging from 30 per 100,000 of 
the population in high prevalence areas like Northern England, rising to 1 in 1,500 in 
women over the age of 40 in the health district of Newcastle and North Tyneside, to less 
than 25 cases per million in Canada and Australia and almost no cases in sub-Saharan 
Africa or India (Witt-Sullivan et al., 1990, Watson et al., 1995, Kingham and Parker, 
1998, James et al., 1999, Metcalf and James, 1997). Two recent, large, epidemiological 
studies in UK and USA have indicated an upward trend of the prevalence rates of PBC, 
but it is not yet clear whether this increase is authentic and/or reflects greater awareness 
of the disease, in combination with an increased availability and better application of 
improved serological diagnostic tools (Kim et a l , 2000, Prince et al., 2001).
The clinical spectrum of PBC ranges from asymptomatic anicteric cholestasis with or 
without extrahepatic manifestations to severe cholestasis with cirrhosis and subsequent 
liver failure, the disease being along with chronic hepatitis C virus infection the 
commonest reasons for liver transplantation in the developed World (Neuberger, 1997). 
While ursodeoxycholic acid (UDCA) may slow progression, there is yet no curative 
therapy (Neuberger, 1997). Immunosuppressive therapy is relatively ineffective 
(Neuberger, 1997).
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1.9.1 Anti-mitochondrial antibody
The nature of PBC became clearer around the 1960s when first its apparent and then its 
unequivocal association with an antibody directed to mitochondrial antigens (AMA) 
was described (Mackay, 1958, Walker et a l, 1965). A milestone for the clinical 
hepatologist was the observation in 1965 by Walker, Doniach, Roitt and Sherlock that 
AMA was present in all their patients with PBC and in none of the controls which 
included patients with extra-hepatic bile duct obstruction, drug induced cholestasis and 
viral hepatitis (Doniach et a l, 1966). Ever since the description of this close association, 
AMA has acted as a powerful diagnostic tool since positivity for AMA was able to 
direct towards the correct diagnosis in the work up of cholestatic conditions, avoiding at 
times invasive procedures such as explorative laparotomy (Sherlock and Scheuer, 
1973). In addition to revealing a diagnostic marker, the paper by Walker et al. (1965) 
showed what anti-mitochondrial reactivity looks like under a fluorescent microscope 
and provided a straightforward technique for its detection. Almost forty years on, the 
detection of AMA is routinely done as originally described in the laboratory of 
Professor Deborah Doniach.
1.9.2 M2 antigens
In 1967 Berg et al. demonstrated that PBC sera reacted in vitro with isolated 
mitochondria. PBC specific AMA were shown to react with trypsin-sensitive antigens 
named mitochondrial type 2 (M2) to be differentiated from M l, the target antigen of 
anti-cardiolipin antibodies found in a proportion of patients with syphilis (Berg et al., 
1982). The M2 antigen was found to be closely associated with the inner surface of the 
inner membrane of all mitochondria tested, from human to fungal, and anti-M2 
antibodies were shown to cross-react with several bacteria, anti-mitochondrial activity, 
for example, being absorbed out of PBC sera by E. coli (Berg et al., 1967, Lindenbom- 
Fotinos et al., 1985, Teoh et al., 1994).
Cloning and identification of the autoantigenic targets of AMA represent a major step 
forward in the study of PBC. Reactivity against several mitochondrial antigens was 
noted in early studies, a 74 kDa protein present in mitochondrial preparations from a 
variety of species being the most frequently recognised antigen (Lindenbom-Fotinos et 
al., 1985, Frazer et a l, 1985). The precise molecular weight was species-, but not 
organ-specific (Baum and Berg, 1981). Less frequent was reactivity against antigens of 
56, 48, 41 and 36 kDa (Baum and Berg, 1981).
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The M2 antigens have been identified as components of the 2-oxo-acid dehydrogenase 
multienzyme complexes (OADC): pyruvate, 2-oxoglutarate and branched-chain 2-oxo 
acid dehydogenase complexes (PDC, OGDC and BCOADC, respectively) (Bassendine 
et al., 1997). Each of these three multifunctional complexes catalyses a set of linked 
reactions and occupies a key position in energy metabolism in a cell (Yeaman, 1989, 
Yeaman et a l, 2000). PDC links glycolysis to the Krebs cycle, OGDC is in the Krebs 
cycle itself and BCOADC is involved in the regulation of the oxidation of the branched- 
chain amino acids (Yeaman, 1989, Yeaman et al., 2000). Each complex consists of 
multiple copies of at least three enzymes (El, E2 and E3), which are encoded by genes 
in the nucleus and separately imported into mitochondria for assembly into high 
molecular weight multimers localised to the matrix aspect of the inner membrane 
(Yeaman, 1989, Yeaman et al., 2000). The structural core of these complexes is 
provided by E2, to which multiple copies of El and E3 are non-covalently bound 
(Yeaman, 1989, Yeaman et al., 2000). The E2 enzymes have a common structure, 
which consists of the N-terminal domain containing the lysine-bound lipoyl groups, 
which have a central role in the catalytic cycle; the peripheral subunit binding domain, 
responsible, at least in part, for binding the El and E3 components together; and the C- 
terminal inner core, which houses the active site responsible for the acyltransferase 
activity. E3 is common to all 3 complexes whereas El and E2 are unique to each 
complex. PDC contains a fourth polypeptide with a structural role, the E3 binding 
protein (E3BP), once termed protein X (De Marcucci and Lindsay, 1985).
It took a surprisingly long time after their original detection and characterisation for the 
molecular identities of the members of the M2 family to be established. The reason for 
the delay in realising that the major M2 antigen was a key mitochondrial constituent 
was primarily a trivial one. M2 co-purified with the inner mitochondrial membrane- 
albeit it was well known that it could readily be detached therefrom (Baum, 1995). In 
the mind-set of most investigators, PDC was a constituent of the matrix, and so its 
possible identity with M2 was never considered.
It was in 1987 that a cDNA for the 74 kDa mitochondrial autoantigen was cloned and 
sequenced leading to the identification of the E2 subunit of PDC-E2 as the major 
autoantigen in PBC (Gershwin et al., 1987, Van de Water et al., 1988b, Yeaman et al., 
1988). This significant development was accompanied by considerable efforts devoted 
to the characterization of the AMA responses by PBC sera. It was established that 
serum autoantibodies from more than 95% of patients with PBC react with PDC-E2 by
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immunoblotting or ELISA, whereas the frequency of reactivity against E2 subunit of 
OGDC and BCOADC is 50-70% (Leung et al., 1997). A few AMA seropositive 
patients react with PDC-E2 alone, while a majority also show reactivity against OGDC- 
E2 or BCOADC-E2 (Leung et al., 1997). Reactivity against BCOADC-E2 or OGDC- 
E2 alone is less common. As in the case of PDC, the predominant antibody reactivity to 
the BCOADC and OGDC enzyme complexes is against the E2 component (Yeaman et 
al., 2000). The E2 components of the OADC are evolutionarily highly conserved, both 
between species and between the different complexes (Baum, 1995, Yeaman et al., 
2000).
Of note, a single PBC serum can react with several mitochondrial autoantigens and each 
autoantigen seems to be recognised by a distinct population of autoantibodies, albeit 
there is some cross-reactivity between them (Baum, 1995, Leung et al., 1997). Major 
cross-reactivity occurs between PDC-E2 and PDC-E3BP: all PBC sera reactive with 
PDC-E2 also react with a peptide of 50-56 kDa, shown to be identical to the E3BP 
protein of PDC (Surh et al., 1989). That this is due to cross-reactivity, was documented 
by absorption studies where removal from PBC sera of reactivity to human PDC-E2 
with recombinant PDC-E2 also removed reactivity against the 56 kDa peptide (Surh et 
al., 1989). It is unclear whether the initial breakdown of self tolerance is to PDC-E2 
with epitope spreading to E3BP, to E3BP with spreading to E2, to both proteins 
simultaneously, or to either E2 or E3BP with immunologic cross-reactivity to the other 
(Dubel et al., 1999, Palmer et al., 1999).
Multiple bands on immunoblot could be due either to antibodies recognising different 
epitopes, each being characteristic for a different antigen or to the presence of a single 
cross-reactive epitope on different molecules. Through inhibition, biochemical and 
epitope mapping studies, it is now clear that more than 90% of PBC patients have 
antibodies to PDC-E2 and PDC-E3BP, but only 50% of patients have AMA that 
recognize all three oxo-acid complexes suggesting that epitopes in BCOADC and 
ODGDC are independent of the epitopes on PDC-E2 (Yeaman et al., 2000).
The use of oligopeptides and recombinant antigens has shown that the predominant 
epitope of PDC-E2 is located within the lipoyl domain of PDC-E2, but that at a 100- 
fold higher concentration, AMA can also react with the outer domain (Surh et al., 
1990). In view of the sequence similarity between inner and outer regions, this 
differential reactivity has been interpreted as the result of cross-reactivity between the
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two lipoyl binding domains, the priming immunogenic region being the inner lipoyl 
domain (Surh et al., 1990).
B-cell epitope mapping based on the use of truncated constructs of peptides has shown 
that AMA reactive with BCOADC-E2 and OGDC-E2 are each directed against a 
conformational epitope that includes the inner lipoyl domain (Leung et a l , 1995, 
Moteki et a l , 1996b). The highly conserved structure in the E2 subunit of 2 -0ADC and 
their lipoyl domains indicates that lipoic acid may be part of the immunodominant 
epitope. Studies investigating the contribution of lipoic acid to the autoantibody 
reactivity have, nonetheless, shown that AMA are capable of binding to both lipoylated 
and unlipoylated PDC-E2 (Flannery et a l , 1989, Fussey et a l , 1990, Leung et a l , 1990, 
Quinn et a l, 1993).
A notable characteristic of AMA in PBC sera is their capacity to block the catalytic 
function of the 2-0AD multienzyme complexes in vitro (Van de Water et a l,  1988a, 
Sundin, 1990). There is, however, no proof that any of these autoantibodies can 
interfere with PDC activity in vivo.
Autoantibodies to the 2-OADC enzymes are detected not only in serum, but also in 
body fluids into which serum immunoglobulins can be transferred. Interestingly, IgA 
AMA have been detected in the bile, saliva, and urine of patients with PBC, suggesting 
that AMA are secreted into the luminal fluid across bile ducts, salivary glands and 
uroepithelium of patients with PBC (Nishio et a l, 1997, Tanaka et a l, 2000, Reynoso- 
Paz et a l, 2000). Reactivity against a band on immunoblot characteristic for PDC-E2 
has been reported in the cerebrospinal fluid of a patient with PBC and a demyelinating 
disorder (Mackay et a l , 2000).
1.9.3 AMA as predictors o f  disease
Seropositivity for AMA is reported to be much higher than the prevalence of PBC in the 
general population, suggesting that AMA may precede the clinical onset of the disease 
(Metcalf and James, 1997). Evidence relating to the earliest events in the natural history 
of PBC has been derived from studies of patients with positive AMA, who were 
discovered accidentally when they were tested for an ‘autoantibody profile’ (Mitchison 
et al., 1986, Metcalf et al., 1996, Kisand et al., 2001). In 1986, Mitchison et al. (1986) 
of the Newcastle group, found liver histology diagnostic of or compatible with PBC in 
24 (83%) of 29 patients ‘accidentally’ found to be seropositive with an AMA titre of
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1/40 or greater, with normal conventional liver function tests and no symptoms of liver 
disease. Only two had normal liver histology (Mitchison et a l, 1986). When the same 
subjects were re-assessed some ten years later, three quarters of them had become 
clinically symptomatic with persistently cholestatic liver function tests (Metcalf et a l , 
1996). The median follow up in this cohort was 17.8 years, with one subject positive for 
AMA 23 years before the diagnosis of PBC was made (Metcalf et a l , 1996). 
Interestingly, none of the patients in this cohort had progressed to cirrhosis (Metcalf et 
a l , 1996). These findings indicate that, first, the progression of the disease can be very 
slow, second, identification of patients through an autoantibody screening of 
asymptomatic subjects may select particularly mild cases, third, AMA is a very 
powerful predictor of future development of PBC. A study by Kisand et a l (2001) 
provides support to the Newcastle experience reporting development of abnormal liver 
function tests, during a nine-year period of observation, in three of eight asymptomatic 
individuals positive for antibodies to PDC by ELISA.
AMA have also been investigated for their ability to predict disease progression 
(Christensen et a l , 1980, Roll et a l , 1983, Heseltine et a l, 1990, Kisand et a l,  1998). 
Heseltine et al. (1990) reported that IgG AMA titres correlated with histological stage 
of disease and with prognostic biochemical variables, including serum bilirubin and 
albumin levels. This report supports the earlier observation that IgG AMA titres, as 
assessed by immunofluorescence, increase with disease progression (Christensen et a l , 
1980, Roll et a l, 1983). An association between serum AMA titre and liver 
inflammatory activity has been reported in both untreated and UDCA treated PBC 
patients (Kisand et a l, 1998).
More recently, van Nostrand et a l (1997) have analysed the relationship between an 
established indicator of disease progression, such as the Mayo Risk Score, and levels of 
AMA measured by quantitative enzyme immunoassays, where recombinant OADC 
proteins served as substrate. The levels of AMA to 2-OADC proteins varied by more 
than 2 0 0 -fold between patients but remained relatively constant over time in individual 
patients. Despite being positively correlated with the Mayo Risk Score, the levels of 
AMA to 2-OADC proteins were not useful in predicting disease progression in the 
individual PBC patient (Van Norstrand et a l, 1997). In addition, these authors went on 
to show that there were no significant differences in the levels of autoantibodies to 2 - 
OADC proteins among patients at different histological stages of the disease (Van
54
Chapter 1
Norstrand et al., 1997). In view of the contrasting experimental evidence alluded to 
above, the role of AMA as predictor of disease progression remains to be clarified.
1.9.4 Detection o f  AMA
AMA are commonly detected by indirect immunofluorescence (IFL), immunoblotting, 
or ELISA and an important decision for diagnostic laboratories and clinicians is the 
choice of assay for the detection of AMA (Leung et al., 1997). IFL using rodent tissue 
sections or immobilized HEp-2 cells is by far the most commonly used serological test 
for AMA (Leung et al., 1997). This technique, especially when used on a composite 
substrate, i.e. a substrate composed of a combination of rodent tissues, enables the 
detection of a large variety of autoantibodies including SMA, ANA, and LKM1, all 
important in the diagnosis of autoimmune liver disease (Leung et al., 1997). AMA 
stains the distal renal tubuli and the gastric parietal cells of the stomach, and the dual 
renal-gastric positivity gives a clear, unmistakable immunofluorescent picture. The 
identification of AMA target antigens as subunits of the 2-OADC has led to the 
development of immunoblotting for the detection of specific mammalian mitochondrial 
antigens (Leung et al., 1997). Mitochondrial preparations derived from bovine or 
porcine heart, rat liver, human placenta, or other tissues are electrophoretically 
separated on SDS-polyacrylamide gel, tranferred onto nitrocellulose filters, and assayed 
with sera from patients with PBC and controls (Leung et al., 1997). AMA reactivity 
against these antigens is visualised by addition of an enzyme-labelled antihuman 
immunoglogulin and a chromogenic enzymatic substrate (Leung et al., 1997). The 
presence in the test serum of antibodies to any of the electrophoretically separated 
mitochondrial components results in bands identified by their molecular weight (Leung 
etal., 1997).
In addition to immunoblotting, which is time consuming, labour intensive, and 
requiring, as immunofluorescence, a degree of subjective interpretation, other 
approaches such as ELISA are gaining momentum since, at least for those ELISA kits 
produced commercially, the need for a skilled observer in the interpretation of the 
results is reduced to a minimum, making them ideal for use in non specialised centres 
(Van de Water et al., 1989, Moteki et al., 1996a, Miyakawa et al., 2001). Moreover, 
ELISA permit the evaluation of numerous sera in a single run. ELISA are widely used 
for the detection of antibodies to purified porcine or bovine M2 antigen or recombinant 
OADC proteins (Czaja and Homburger, 2001).
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1.9.5 AMA negative PBC
The pathognomonic connotation of AMA in the diagnosis of PBC started being 
questioned when Brunner and Klinge (1987) described four female patients with 
‘ immunocholangitis ’, a condition characterized by the typical biochemical and 
histological features of PBC, but with AMA seronegativity (Brunner and Klinge, 1987). 
A similar presentation characterised patients suffering from ‘primary autoimmune 
cholangitis’, ‘autoimmune cholangiopathy’, and ‘AMA-negative PBC’ (Goodman et al., 
1995, Taylor et al., 1994, Michieletti et al., 1994, Ben-Ari et al., 1993, Lacerda et al., 
1995, Sanchez-Pobre et al., 1996, Invemizzi et al., 1997). Though in one study AMA 
negativity has been reported in one third of PBC patients, a large series from the Mayo 
Clinic, shows only 6% AMA negativity amongst 597 cases of PBC analysed (Goodman 
et al., 1995, Lacerda et al., 1995). A similarly low proportion was noted in an earlier 
study by Berg et al (Berg et al., 1986).
The proportion of AMA negative PBC patients as ascertained by conventional 
immunofluorescence decreases when AMA is tested using more sensitive techniques 
(Nakanuma et al., 1997, Kitami et al., 1995, Kinoshita et al., 1999, Nakajima et al.,
1999).
Care must, therefore, be exercised when labelling patients as AMA negative, because 
AMA, and in particular the PBC-specific anti-M2, not detected by immunofluorescence, 
may be detectable by other means, such as ELISA or immunoblot using purified bovine 
or porcine heart mitochondria (Nakanuma et al., 1997, Kitami et al., 1995, Kinoshita et 
al., 1999, Nakajima et al., 1999). There is an increasing amount of evidence for this 
notion. Of 20 PBC patients AMA negative by immunofluorescence, 3 were found to 
have M2 specific antibodies by ELISA and immunoblot (Michieletti et al., 1994). 
Similarly, Invemizzi et al. (1997) reported a positive M2 specific band by 
immunoblotting in 6 of 25 (24%) IFL AMA-negative PBC patients. Muratori et al. 
noted that six out of 19 (32%) IFL-AMA negative patients recognised AMA-specific 
bands when tested by immunoblot against beef heart mithochondria. In other studies, up 
to 100% of patients AMA negative by immunofluorescence were found to be positive 
when tested by a variety of techniques including immunoblotting, ELISA using 
recombinant polypeptides spanning M2-related epitopic regions, and enzyme inhibition 
assays (Nakanuma et al., 1997, Kitami et al., 1995, Kinoshita et al., 1999, Nakajima et 
al., 1999).
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Of interest are the studies by the group of Gershwin who make use of cloned 
mitochondrial antigens, at times combined in hybrid recombinant molecules, as targets 
of AMA reactivity in ELISA and immunoblot (Moteki et al., 1996b, Miyakawa et a l,
2001). One of such molecules named rMIT-3 contains three key autoepitopes of M2, 
present on PDC-E2, BCOAD-E2, and OGDC-E2 (Miyakawa et al., 2001). In 1996, 
using these recombinant molecules they identified the presence of AMA in 67% of 
patients diagnosed as AMA negative by IFL (Moteki et al., 1996b). More recently, 
Miyakawa et al. (2001) from the same group, reported that, using an ELISA based on 
an advanced version of the recombinant mitochondrial preparation, 73% of IFL-AM A 
negative PBC patients were AMA-positive. When reactivity was investigated against 
the individual components of the trimeric recombinant molecule, it was found that 
antibodies to at least one of its components were present, by immunoblot, in 90% of 30 
IFL AMA-negative PBC patients (Miyakawa et al., 2001).
1.9.6 PBC-specific ANA
There are two main types of ANA in PBC: those that are not disease-specific, directed 
against targets such as centromere, Ro/SSA, La/SSB, Scl-70 and histones and those 
which are highly PBC-specific (Vergani and Bogdanos, 2003). The existence of ANA 
specific for PBC is in contrast to AIH-1, a disease also characterized by the presence of 
ANA (alone or in association with anti-smooth muscle antibody), but in which no 
specific ANA have yet been identified (Vergani and Bogdanos, 2003).
Two distinct immunofluorescence patterns characterise PBC-specific ANA, namely the 
perinuclear (rimlike) and the multiple nuclear dot (MND) patterns (Courvalin and 
Worman, 1997, Szostecki et al., 1997). Their molecular targets have been identified, 
with the antibodies responsible for the rimlike pattern recognising constituents of the 
nuclear envelope including gp210, a 210 kDa transmembrane glycoprotein of the 
nuclear pore complex (NPC), lamin B receptor, and nucleoporin p62, while those 
responsible for the MND pattern recognise the splOO and promyelocytic leukaemia 
proteins (Courvalin and Worman, 1997, Szostecki et al., 1997). These two latter auto­
antigens colocalize and the corresponding autoantibodies tend to occur together 
(Szostecki et al., 1997).
The PBC-specific ANA are not confined to AMA negative PBC, even though they are 
over-represented in this form of PBC (Vergani and Bogdanos, 2003). This over­
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representation is partially due to technical reasons since ANA positivity can be 
obscured by the confounding simultaneous presence of AMA (Vergani and Bogdanos,
2003). When analysed in immunofluorescence, ANA become more visible if AMA is 
absent or weak (Vergani and Bogdanos, 2003).
The potential of using observer-independent assays such as ELISA has been recently 
outlined (Muratori et al., 2003a). Measuring simultaneously reactivity to 3 PBC-specific 
ANA targets, namely anti-splOO, anti-gp210 and anti-lamin B receptor in PBC by 
ELISA, it was found that 85% of the AMA negative patients investigated were positive 
for one or more of the ANA specificities, suggesting that the clinicians provided with a 
panel of PBC specific ANA results may have at their disposal a ‘positive’ tool in the 
diagnosis of AMA negative PBC (Muratori et al., 2003a, Vergani and Bogdanos, 2003). 
The validity of these markers in the diagnosis of PBC in AMA negative patients needs 
confirmation in further studies.
Earlier immunofluoscence studies in which the majority or the totality of AMA negative 
PBC patients were found to be ANA positive, give support to the notion that PBC- 
specific ANAs may become an essential marker for AMA-negative PBC (Michieletti et 
a l , 1994, Lacerda et al., 1995). Of note is the observation that patients negative for 
MND or rimlike reactivity by immunofluorescence may be positive when tested by 
ELISA for reactivity to splOO and gp210 - their molecular equivalents (Muratori et al., 
2003a).
1.9.7 Pathogenicity o f AMA
Anti-M2 AMA are so disease-specific that it may be assumed that they are relevant to 
disease pathogenesis (Neuberger and Thomson, 1999). Most workers, however, have 
concluded that T-cells rather than the antibodies themselves are the direct cause of 
tissue damage (Gershwin and Mackay, 1991, Jones et al., 1995, Gershwin et al., 2000). 
For example, high titres of AMA can be raised in experimental animals, e.g. by 
immunization with recombinant human PDC-E2, with no evidence of liver damage 
even after a prolonged period, and there is no universal recurrence of PBC following 
liver transplantation, despite the persistence of AMA (Krams et al., 1989, Neuberger 
and Thomson, 1999). Anti-PDC-E2 AMA are able to inhibit in vitro the enzymatic 
activity of PDC-E2. However, there is no evidence that AMA interfere with PDC 
activity in vivo (Van de Water et al., 1988a, Sundin, 1990. The immunodominant 
antigenic regions recognised by T lymphocytes on PDC-E2 have been defined
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[Shimoda, 1995 #240, Shimoda e t a l., 1998, Kita e t a l., 2002, Shimoda e t a l., 1995). 
These comprise a region within the inner lipoyl-binding domain of the subunit, 
overlapping amino acid 212-226 (PDC-E2212-226) (Shimoda e t a l , 1995, Shimoda e t a l., 
1998, Kita e/ al., 2002) and targeted by both CD4 and CD8 T-cells. The same region is 
also the core target of the receptors of B-lymphocytes, which in their soluble form are 
antibodies (Van de Water e t a l , 1988b, Tuaillon e t a l ,  1992, Matsui e t  a l ,  1993). It is 
conceivable that helper T-cells, cytotoxic T-cells and B-cells act in concert in inflicting 
damage to the liver ductules in the pathogenic process of PBC (Gershwin e t a l ,  2000). 
In support of this view is the recent finding that soluble PDC-E2 complexed with a 
PDC-E2-specific human monoclonal antibody favours generation of PDC-E2-specific 
cytotoxic cells at a 100-fold lower concentration than otherwise required in the presence 
of the soluble antigen alone (Kita e t a l , 2002). Thus, AMA may play a pathogenic role 
in facilitating the development of a PDC-E2 specific CD8 T-cell immune response (Kita 
e t a l., 2002). That AMA may have pathogenic properties has been indirectly suggested 
by a recent clinical report where two infants, who received AMA transplacentally from 
their mothers, developed liver pathology that lasted as long as the autoantibody 
persisted in their serum (Hannam e t a l ,  2002).
1.9.8 P D C -E 2 212-226 is p h ys ica lly  ex p o sed  on the m o lecu le ’s  surface  
Determination of the three-dimensional structure of the inner lipoyl domain of human 
PDC-E2 has revealed that PDC-E2212-226 is physically exposed on the molecule’s 
surface which may partially explain its particular antigenicity (Howard e t a l., 1998). 
However, the mechanism by which this short sequence becomes the focus of PBC- 
specific anti-mitochondrial immune responses remains obscure.
Assuming that a concerted autoimmune attack is the ultimate mechanism of damage in 
PBC, the question as to what triggers this autoimmune attack remains without an 
answer (Baum, 1995). Many of the epidemiological, clinical and serological features of 
PBC are compatible with an environmental trigger (Jones, 2003).
1.9.9 Geographical clustering and PBC
An early study by Triger (1980) demonstrated that within the city of Sheffield in 
Northern England, 88% of the PBC patients received their water from the Revelin 
reservoir which accounts for 40% of the total water supply for the local population
59
Chapter 1
(Jones, 2003). Geographical clustering within a UK health administration of Northern- 
Eastern England has recently been demonstrated (Prince et al., 2001). Prince et al 
(2001) found that the risk for PBC was higher in the urban area of Tyneside than in the 
surrounding rural area. Within the rural area, there was significant clustering of cases.
•j
PBC occurred to a density of 10.7 cases/km in the highest risk areas (Prince et al., 
2001).
1.9.10 Familial clustering and PBC
Several studies have suggested that PBC cases tend to cluster within families, the 
prevalence of PBC being higher among family members of individuals with the disease 
(Bach and Schaffner, 1994, Brind et al., 1995, Tsuji et al., 1999, Agarwal et al., 2002, 
Abu-Mouch et al., 2003). In a study from the North-East of England the sibling relative 
risk for PBC was estimated at 10.5, suggesting a familial risk similar to that seen for 
other autoimmune diseases such as rheumatoid arthritis (Jones et al., 1999). 
Interestingly, when two members of the same family are affected, the disease tends to 
occur at the same time suggesting the existence of an external trigger (Neuberger and 
Thomson, 1999).
1.9.11 Migration studies and PBC
People migrating between different geographical regions seem to acquire the prevalence 
of the host population, thus while in the UK, the prevalence is about 150-240 per 
million, the prevalence among British immigrants to Australia is 47 per million and for 
the Australian community only 19 per million. Similarly, while PBC is almost absent in 
India, the prevalence of end stage PBC among first generation migrants to the UK from 
the Indian subcontinent is 14 per million (Watson et al., 1995, Anand et al., 1996)
One interpretation of these observations would be that the affected individuals within 
the same family or the same region are exposed to common environmental triggers 
(Jones, 2003). Environmental risk for a disease may be attributable either to infectious 
agents, for example viruses or bacteria, or non infectious agents such as chemicals and 
drugs. A number of putative infective organisms have been implicated in the 
pathogenesis of PBC, including Escherichia coli, mycobacteria and retroviral agent 
(Burroughs et al., 1984, Burroughs et al., 1992, Vilagut et al., 1994, Xu et al., 2003).
60
Chapter 1
1.10 PBC, bacterial infection and molecular mimicry
Hopf et al. (1989) reported an association between PBC and the presence of rough form 
mutants of E. coli in the patients’ faecal samples, whilst Butler et al. (1995) reported 
reactivity to PDC-E2 in 52% of sera from patients with chronic urinary tract infections 
(UTI). Conversely, patients with PBC have a higher incidence of recurrent UTI (Butler 
et al., 1995b). Recently, Mayo et al. (2000) reported that antibodies directed to an 18aa 
(177-194) sequence within the proteolytic subunit of the ATP-dependent Clp protease 
of E. coli are present in a third of sera from patients with PBC but in less than 1% of 
sera from patients with other autoimmune diseases. Further support to these reports was 
recently provided by Parikh-Patel et al. (2001) in the first controlled epidemiological 
analysis to show a positive association of PBC with UTI. These findings suggest an 
association between E. coli or other bacteria causing UTI and AMA responses (Hopf et 
a l, 1989, Burroughs et a l, 1992, Butler et a l, 1995a, Butler et a l,  1995b, Parikh-Patel 
et a l, 2001).
Granulomatous lesions identifiable either as aggregates of histiocytes or as non- 
caseating lesions adjacent to damaged bile ducts are frequently observed in the liver of 
patients with PBC, and the hypothesis that mycobacterial infection (able to induce 
granulomas) may be involved in the pathogenesis of PBC has been forwarded (Kaplan, 
1996). Early studies have reported AMA detection by ELISA and immunoblotting in up 
to 43% of patients with active pulmonary tuberculosis and in patients with leprosy 
(Klein et a l, 1993, Gilburd et al., 1994).
A study by Vilagut et al. (1994) showed that all of 19 sera from Spanish patients with 
PBC reacted specifically with an extract of Mycobacterium gordonae (MYCGO), 
consequently identified as the 65-kDa heat shock protein (hsp65) of MYCGO (Vilagut 
et al., 1997). There were no other reactions with nine other atypical mycobacteria 
(Vilagut et a l, 1994). Furthermore, they demonstrated that anti-hsp65 MYCGO 
antibodies, cross-reacted with PDC-E2 (Vilagut et a l, 1994). In fact, cross-reactivity of 
AMA against prokaryotic antigens has been reported for a number of microbes, 
including E. coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus aureus and 
Salmonella minnesota, although the target components of AMA in these bacteria have 
not been fully determined (Sayers and Baum, 1976, Fussey et a l, 1991, Baum, 1995). 
Several arguments have been proposed in support for a role of molecular mimicry in 
PBC (Van de Water et a l, 2001). Many suggestions are based on the observation that
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pyruvate dehydrogenase-E2 (PDC-E2), the major mitochondrial autoantigen recognized 
by both B- and T-cells from patients with PBC, is a well-conserved molecule among 
various species, including bacteria (Van de Water et al., 2001). Sera and T-cells from 
patients with PBC react with both human and Escherichia coli PDC-E2, and the epitope 
of E. coli PDC-E2 also maps to similar lipoyl domains (Fussey et al., 1991, Fussey et 
al., 1990, Shimoda et al., 1998). Further evidence of cross-reactivity is that antibodies 
raised in rabbits against rough mutants of bacteria (which have fragile cell walls) were 
reported to react with a typical M2 pattern on immunoblotting against mitochondria 
(Stemerowicz et al., 1988).
In support of the role of molecular mimicry and immunological cross-reactivity in PBC 
is the finding by Shimoda et a l (1997) that human PDC-E2 and E. coli PDC-E2 cross- 
react at the T-cell level. One T-cell clone, specific to the lipoyl domain of human PDC- 
E2 (GDLLAEIETDKATI) was shown to cross-react with the exogenous peptide 
derived from the lipoyl domain of E. coli PDC-E2 (EQSLITVEGDKASM) and the 
ExDK motif was found to be essential for the T-cell epitope recognition (Shimoda et 
al., 1998). The sequence ExDK is also found in E. coli PDC-E2 (Shimoda et al., 1998). 
In a recent study, the same group of investigators was able to cross-reactively activate 
PDC-E2 specific clones with 7 additional microbial mimics, all but one originated from 
OADC, such as Neurospora crassa PDC-E2, E. coli OGDC-E2, Neisseria meningitis 
outer membrane protein P64K, Acholeplasma laidlawii PDC-E2, Azotobacter vinelandii 
PDC-E2 and Pseudomonasputida PDC-E2 (Shimoda et al., 2000).
Taken together, these data suggest that the initial stimulus for an immune reaction 
directed specifically at the E2’s of the OADC, (and E3BP of PDC), may be a chronic 
exposure, in the context of costimulatory signals, and perhaps a particular genetic 
background, to microbial peptides that share strong sequence similarities with the 
lipoyl-binding peptides at the core of the dominant epitopes (Burroughs et ah, 1992, 
Van de Water et al., 2001). Expansion of reactivity and specificity to incorporate the 
entire domain, and then also to recognize El sub-units, would be by epitope-spreading 
{see 1.3.6). Because of the highly conserved nature of PDC-E2 among species, 
microbial mimics not of an OADC origin would be more convincing as playing a role in 
the pathogenesis of PBC. Such mimics had not been reported at the time the work 
described in this Thesis started.
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1.11 Hypothesis
The hypothesis of the present thesis is that molecular mimicry and immunological 
cross-reactivity play a key role in the development or maintenance of liver 
autoimmunity with a special focus on PBC.
1.12 Aims
1) Humoral and cellular micro-organism/self crossreactive responses will be 
studied in primary biliary cirrhosis, a liver disease considered to have an 
autoimmune pathogenesis and epidemiologically linked to micro-organism 
exposure.
2) The appearance and evolution of cross-reactive immune responses will be 
investigated in liver kidney microsomal-1 (LKM1) antibody positive hepatitis C 
virus (HCV) infected patients.
3) Molecular mimicry before and after exposure to a specific viral antigen 
(hepatitis B surface antigen-HBsAg) will be investigated in vaccinees before and 
after immunisation against HBsAg.
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Material and Methods
Chapter 2
2.1 MATERIALS
2.1.1 Commercially available chemicals, reagents, buffers and media
3H-thymidine
/?-mercaptoethanol (C2H6OS)
Acetic acid 
Acetonitrile
Bovine Serum Albumin (BSA) (Fraction V)
Brefeldin A
Bromophenol Blue 
Cytofix/Cytoperm
Diaminobenzidine (DAB) (C12H14N4 .4HC1) 
Dimethyl sulfoxide (DMSO) (C2H6SO) 
Fungizone
Glycerol (C3H80 3)
Heat inactivated foetal calf serum 
Heparin (preservative free)
Hydrogen peroxide (H2O2)
Lymphoprep (Ficoll)
Methanol (CH3OH)
Milk powder (fat free)
Amersham Pharmacia Biotech 
Limited, Little Chalfont, 
Buckinghamshire, UK
Bio-Rad Laboratories, 
Hertfordshire, UK
BDH, VWR International Ltd, 
Poole, Dorset, UK
BDH
Sigma Aldrich, Gillingham, Dorset, 
UK
Becton Dickinson, Franklin Lakes, 
New Jersey, USA 
Sigma Aldrich
Becton Dickinson
Sigma Aldrich
Sigma Aldrich
Invitrogen Life Technologies, 
Paisley, UK
BDH
Sigma Aldrich
Leo Laboratories Ltd., Princes 
Risborough, Leicestershire, UK
BDH
Axis-Shield, Oslo, Norway 
BDH
Nestle, Vevey, Switzerland
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Molecular weight rainbow coloured protein 
markers
o-Phenylenediamine dihydrochloride (OPD)
Penicillin/streptomycin
Phosphate Buffered Saline (PBS) tablets
Polyoxyethylene-sorbitan monolaurate 
(Tween20)
Recombinant human interleukin-2
Ready mini-gels (15% Tris-HCl) for 
immunoblotting
RPM I1640 medium with glutamine
Sodium azide (NaNa)
Sodium dodecyl sulphate (SDS) 
(Ci2H2504SNa)
Sodium perborate (0.03%) in phosphate 
citrate buffer (0.05 M, pH 5.0)
Streptavidin coated 96-well microplates
Sulfuric acid (H2SO4)
Tris (0.25M)/Glycine (1.92M)/SDS (1%)
Trypan-blue (0.4%)
Urea (CH4NO2)
2.1.2 Antigens, peptides
Biotinylated peptides
Cytochrome P450IID6 (CYP2D6) 
recombinant (baculovirus)
Herpes Simplex Virus-1 (HSV1) extract
Amersham Pharmacia Biotech 
Limited
Sigma Aldrich
Life Technologies
Sigma Aldrich
Sigma Aldrich
EuroCetus, Amsterdam, Netherlands 
Bio-Rad Laboratories
Life Technologies 
BDH
Bio-Rad Laboratories 
Sigma Aldrich
Mimotopes, Clayton, Victoria, 
Australia
BDH
National Diagnostics, Hessle Hulk, 
UK
Sigma Aldrich 
Bio-Rad Laboratories
Mimotopes
Pharmacia
Virusys, North Berwick, Maine, 
USA
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Pyruvate dehydrogenase complex (PDC) 
purified from porcine heart 
Small hepatitis B surface antigen (SHBsAg) 
recombinant (yeast)
2.1.3 Antibodies
FITC conjugated rabbit anti-human total IgG 
QRed conjugated anti-CD4 
PE conjugated anti-IFNy 
Peroxidase conjugated goat anti-human IgA
Peroxidase conjugated goat anti-human IgG
Peroxidase conjugated goat anti-human IgM
Peroxidase conjugated mouse anti-human 
IgGl, IgG2, IgG3, IgG4
Peroxidase conjugated rabbit anti-human IgA, 
IgG, IgM, k , X
2.1.4 Non-commercially available antigens
Periplasmic maltose E. coli
2.1.5 Plastics, consumables
Centrifuge tubes (50 ml; 15 ml)
Cryovials
Cryo 1°C Freezing Container
Sigma Aldrich
Research Diagnostics, Flanders NJ, USA
Dako, Ely, UK 
Sigma Aldrich
Dako
Southern Biotechnology Associates 
Inc., Birmingham, Alabama, USA
ibid
ibid
ibid
Dako
Professor Winfried Boos, Konstanz, 
Germany
Falcon, Becton Dickinson
Nunc, Roskilde, Denmark
Nalgene, Nalge Europe Ltd., 
Hereford, UK
Bibby Sterilin Limited., Store 
Staffs, UK
Disposable plastic pipettes
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FACScan tubes 
Filter and pipette tips 
Laboratory film ‘parafilm’
Microcentrifuge tubes
Pasteur pipettes
Precision weighing boats
Syringes
Test tube racks
Tissue culture plates; 96-, 48-, 24-well 
Trays
Universal containers 20 ml 
Whatman paper
2.1.6 Commercial assays
2.1.6.1 ELISA
Anti-cytomegalovirus (CMV) 
Anti-HSVl
AxA\-helicobacter pylori (HELPY)
Anti-liver kidney microsomal-1 (LKM1) 
(CYP2D6)
Anti-mitochondrial-2 (M2)
2.1.6.2 Immunoblot
Epstein-Barr virus (EBV)
HSV1
HELPY
Becton Dickinson
Starlab, Milton Keynes, UK
American National Can, Chicago, 
Illinois, USA
Thermo Life Sciences, Basingstoke, 
Hampshire, UK
Greiner Labortechnik Ltd., Darsley, 
Gloustershire, UK
Thermo Life Sciences
Becton Dickinson
Thermo Life Sciences
Nunc
Euroimmun 
Bibby Sterilin Limited 
Biorad Laboratories
Euroimmun, Montypool, UK
ibid
ibid
Pharmacia
Pharmacia
Euroimmun
ibid
ibid
68
Chapter 2
Liver (human) mitochondrial, microsomal ibid 
and cytosolic antigen
2.1.7 Instrumentation
Alarm timer
Autoclave (series 290)
Beta counter (model 1500)
Benchtop centrifuge (model Labofuge 
400R)
Cell harvester (model 200A/290)
Electronic calculator
ELISA microplate reader (model MRX)
ELISA washer (MRW model) 
Epifluorescence microscope (Aristoplan) 
FACScan flow cytometer
Finnpipettes
Gamma irradiator (model Gammacell-1000) 
Incubator (37 °C)
Incubator (CO2) (model MCO-17AIC) 
Laminar flow hood
Sharp Electronics,
Manchester, UK
Harvard LTE,
Greenfield, Oldham, UK
Canberra Packard Ltd.,
Pangboume, Berks, UK
Heraeus Instruments,
Osterode, Germany
Cambridge Technology Inc., 
Massachusetts, USA
Sharp Electronics
Dynex Technologies,
West Sussex, UK
Thermo Life Sciences
Leica, Germany
Becton Dickinson Immunochemistry 
Systems
San Jose, California, USA
Thermo Life Sceinces
AECL Industrial, Atomic Energy of 
Canada Ltd., Ontario, Canada
Jouan, Tring, Hertfordshire, UK
Sanyo, Jencons Scientific Ltd,
Bedfordshire, UK
Howorth
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Microcentrifuge (model IEC Centra-M)
Electrophoresis system (model MINI- 
PROTEAN II)
Neubauer counting chamber 
Pipette controller
Semi-dry electrophoretic transfer cell 
(model Trans-Blot SD)
Shaker
Spectrophotometer (model DU-62)
Thermometer 
Vortex (model Genie 2)
Water-bath
Famworth, Bolton, UK 
Heraeus Instruments 
Bio-Rad Laboratories
Weber Scientific International Ltd., 
London, UK
Starlab
Bio-Rad Laboratories
Dynex Technologies,
Beckman Instruments Ltd., High 
Wycombe, Buckinghamshire, UK
Themo Life Sciences
Scientific industries (Si), New York, 
USA
Grant Instruments Limited, Nerts, UK
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2.2 METHODS
2.2.1 Bioinformatics tools
2.2.1.1 PROTEININFO ‘advanced sequence search ’
Proteinlnfo (http://129.85.19.192/prowl/proteininfo.html) is a search engine from 
Proteometrics (www.proteometrics.com) that enables detection of sequences that match 
a particular sequence motif (Altschul, 1991). Fragments of sequence motifs can be 
entered and all of the sequences matching that pattern in a particular database are 
retrieved. Proteinfo provides the ability to choose a search among three databases, 
namely SWISS-PROT, NCBInr and dbEST. An entry in a database can be found by 
selecting keywords or sequence motifs after selecting a species or taxa (Altschul, 1991). 
Proteinfo’s ‘analysis amino acid sequence’ is a tool that gives the ability to perform a 
variety of analyses on an amino acid sequence or an entry in the database, including 
amino acid composition, hydrophobicity, disulfide maps and patterns of enzymatic 
digestion and mass spectrometric fragmentation (Altschul, 1991).
The PROTEININFO ‘advanced sequence search’ tool allows identification of sequence 
motifs with pre-selected amino acid substitutions in desirable positions of the sequence 
(Altschul, 1991). Instead of looking for entries in the database that contain the EITDKA 
sequence of human PDC-E2222-227, for example, it is possible to search for proteins that 
possess the ExTDK[STAG] motif where x, corresponds to any of the 20 amino acids; 
the [STAG] preference searches for entries with S or T or A or G amino acid at this 
position i.e. for motifs such as ExTDKS or ExTDKT or ExTDKA or ExTDKG. The 
PROTEININFO ‘advanced sequence search’ has also the ability to perform searches 
investigating entries with a partial identity (for example 70% or 82%) with the sequence 
under investigation. For example, it is possible to search for E. coli proteins with more 
than 85% identity with human PDC-E2 -EITDKA- i.e. E. coli sequences that have an 
identity of at least 5 amino acids of any possible 5 amino acid combination with 
EITDKA.
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2.2.1.2 BLAST
2.2.1.2.1 PSI-BLASTp
The Basic Local Alignment Search Tool (BLAST) provides a method for rapid 
searching of nucleotide (BLASTn) and protein (BLASTp) databases. Position Specific 
Iterative (PSI) BLAST refers to a feature of BLAST in which a profile table that lists 
the frequencies of each amino acid in each position of protein sequence is automatically 
constructed from a multiple alignment of the highest scoring hits in an initial BLAST 
search (Schaffer et al., 1999, Schaffer et al., 2001). PSI-BLAST calculates the number 
of different alignments that are expected to occur in a database search by chance. The 
lower the expected (E) value the more significant the score (Schaffer et a l,  1999, 
Schaffer et a l, 2001). PSI-BLASTp filters out those cases where the pattern occurrence 
is probably random and not indicative of homology and permits calculated expected 
(E)-values to take into account the amino acid composition of the individual database 
sequences involved, achieved with a scaling statistical procedure which provides a 
scoring system for each alignment (Schaffer et a l, 1999, Schaffer et a l,  2001). By 
applying this programme, alignments from different proteins with equal number of 
identities can receive different scores, based upon their amino acid composition 
(Schaffer et a l, 1999, Schaffer et a l,  2001).
2.2.1.2.2 BLASTp 2 sequences
‘BLASTp 2 sequences’ is an interactive tool that utilizes the BLAST engine for 
pairwise protein-protein sequence comparison based on the same algorithm and 
statistics of local alignments that have been described for PSI-BLAST (Tatusova and 
Madden, 1999).
Different scoring matrices are provided for protein-protein comparisons; each matrix is 
most sensitive at finding similarities at a specific evolutionary distance (Tatusova and 
Madden, 1999). The default matrix, BLOSUM62 is generally considered to be the best 
for a wide variety of distances; PAM70 is suitable for comparison of short sequences 
(Tatusova and Madden, 1999).
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2.1.2.3 Cn3D visualisation tool
Cn3D is a three-dimensional visualization tool for biomolecular structures, sequences, 
and sequence alignments (http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml). 
Cn3D displays structure-structure alignments along with their structure-based sequence 
alignments, to emphasize what regions of a group of related proteins which are most 
conserved in structure and sequence. Cn3D, version 4 is a complete multiple alignment 
editor giving the ability to create and even annotate multiple alignments. With the help 
of Cn3D, the three dimensional structure of short sequences, motifs or domains of a 
protein can be further analysed based on the structure of the whole protein deposited in 
the database (Figure 2.1).
Cn3D View menu contains items that control how the structure as a whole is displayed. 
The Show/Hide menu contains operations that allow certain substructures, chains, and 
domains to be shown or hidden. The choices in the Style menu affect the shape and 
colour of the different parts of the structure, for example, green for helices, orange for 
strands, and blue for coil.
Cn3D intentionally keeps colour separate from drawing style. The Style: 
Colouring/Shortcuts menu choices determine what properties are used to map different 
parts of the structure to different colours. Using the choices of the menu, it is for 
example easy to visualize a structure's NCBI-determined domain composition 
(Domain), or crystallographic temperatures (Temperature). Rendering Shortcuts choices 
determine the shape of the various parts of the structures, like Worms or Ball and Stick. 
When a single structure is loaded into Cn3D, the sequence viewer shows the sequences 
of all protein and nucleic acid chains in the structure. The colour of each residue is 
coordinated between the structure and sequence windows: each letter of the sequence 
represents a residue in the structure, and always adopts the colour of the backbone's 
alpha carbon, even if side chains are coloured differently from backbone in the structure 
window.
The most powerful application of the sequence window in Cn3D is to allow easy 
correlation of residues in the sequence with atoms in the structure. Thus, the user can 
quickly locate and highlight selected parts of the protein from the sequence window.
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Figure 2.1 A representative protein structure shown by Cn3D. This example is the 
WD40 domain, which is a multi-functional 7-fold beta propeller. Cn3D is showing a 
representative protein structure, the family alignment, and annotation panels with 
information about annotated features o f this protein family. Highlighted in both 
structure and sequence windows are the conserved residues in a pattern characteristic 
to this domain
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2.2.2 Detection of antibodies
2.2.2.1 Indirect Immunofluorescence
Tissue autoantibodies were detected by IIFL on 5-pm cryostat sections of rat liver, 
kidney and stomach (Smith et al., 1974). The cryostat sections were prepared as 
follows: segments of rat liver, kidney and stomach were juxtaposed to form a block of 
0.3 cm on a cryotome chuck and immersed in fumes of liquid nitrogen. After the 
cryostat sections were cut, they are fixed in air at room temperature for 30 min before 
use.
Fifty pi of patient sera were tested at the initial dilution of 1/10 in phosphate buffer 
saline (PBS, 0.15 M, pH 7.2). Tissue sections were incubated with the diluted sera for 
30 min at room temperature. Slides were then washed in PBS for 5 min. Fifty pi of 
fluorescein isothiocyanate (FITC)-conjugated anti-human IgG diluted 1/50 were added 
and the sections incubated for 30 min. Following washing in PBS for 5 min, the slides 
are mounted in 9:1 solution of glycerol and PBS. The sections were finally examined 
for flourescent staining by ultraviolet microscope. The end point of titration for sera 
tested was determined by double diluting the positive sera to extinction.
This technique enables the simultaneous detection of a large variety of autoantibodies 
including AMA, ANA, SMA, and LKM1, all important in the diagnosis of autoimmune 
liver diseases (Vergani et al., 2004). AMA stains the renal tubuli with a clear 
strengthening of the staining at the level of the distal, smaller, tubules (Vergani et al., 
2004). AMA also stains the gastric parietal cells of the stomach, and the dual renal- 
gastric positivity gives a clear, unmistakable immunofluorescent picture (Figure 2.2). 
Also LKM1 stains the renal tubuli with a pattern not immediately distinguishable from 
that of AMA, unless the kidney sections have been cut in such a way to give a good 
representation of both distal tubules, preferentially stained by AMA, and proximal 
tubules, preferentially stained by LKM1 (Figure 2.3). The presence of the liver in the 
composite substrate helps further in the differential diagnosis, since LKM1 gives a 
brilliant staining of the hepatocyte cytoplasm with contrastingly black, punched out 
nuclei, while AMA gives a much duller, granular cytoplasmic hue (Vergani et al.,
2004).
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Figure 2.2 Immunofluorescence appearance o f anti-mitochondrial antibodies. 
Substrate: rat kidney (left), rat stomach (right). AMA stains the renal tubuli with 
stronger staining o f the distal tubules (arrows). These are readily recognisable because 
smaller. The diagnosis is confirmed in the stomach, where AMA characteristically 
stains the gastric parietal cells
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Figure 2.3 Immunofluorescence appearance o f anti-mitochondrial (AMA) (left) and 
liver kidney microsomal antibody (LKM1) on rat kidney. The two autoantibodies are 
readily distinguishable here, since AMA shows a stronger staining o f the smaller, distal 
tubules. LKM1 and AMA are frequently misdiagnosed, especially when only the kidney 
substrate is used and the sections do not contain both proximal and distal tubules. The 
use o f other tissues such as stomach and liver is very important to facilitate the 
diagnosis, since they give different patterns characteristic for each o f the two 
autoantibodies (Vergani et al, 2004)
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2.2.2.2 Immunoblotting
Identification of antigen by immunoblotting requires the protein to be immobilized on a 
membrane, where it is identified by a specific antibody or human serum samples 
containing antibodies specific for this antigen. Following solubilization, the protein 
sample is separated by discontinuous sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) system (Laemmli, 1970). This system uses one- 
dimension polyacrylamide mini-gel electrophoresis to separate proteins under 
denaturing conditions, i.e., in the presence of 0.1% SDS. Blotting is performed in a 
tank of buffer with the gel completely submerged between two electrode panels. In this 
setting, proteins are separated only according to their molecular size as they move 
through a polyacrylamide gel matrix toward the anode. The unique combination of 
speed and high resolution is the foremost advantage of mini-gel electrophoresis.
A ready-made 2-well (one large for the protein sample and one smaller for the 
molecular weight marker) mini (7.0 cm height x 8.3 cm width 1.0 mm thickness) 15% 
gel was used for the separation of proteins with a molecular size up to 100 kDa; a 7% 
gel was used for the resolution of proteins with a molecular size ranging from 100 kDa 
to 200 kDa. The protein sample to be analysed was placed in sample buffer and boiled 
at 100 °C for 6 min. Ready-made mini gels are loaded with 25 pg/membrane of protein. 
The gels were run at 200 volt (V), using constant voltage mode for 45 min. Preliminary 
experiments using a series of different concentrations of antigen (5 -  50 pg/membrane) 
have been performed in the present study to define the optimal conditions o f the assay. 
A given amount of protein was chosen when it was immunofixed as a clear band by a 
positive serum, but was not detected by 7 serum samples from healthy controls and 12 
pathological controls. Biotinylated molecular weight standards ranging from 14.4 to 205 
kDa were used in adjacent wells to provide a reference against which to compare the 
proteins to be analysed. After electrophoresis, the stacking gel was removed and placed 
in transfer buffer. Blotting transfer buffer must allow effective elution from the gel 
matrix as well as effective binding of the proteins to the membrane. The commonly 
used buffer to transfer from SDS gels to nitrocellulose is 39 mM glycine, 48 mM Tris, 
pH 9.2 containing 0.0375% (w/v) SDS and 20% (v/v) methanol. This buffer maintains 
the negative charge of SDS-bound proteins, and the methanol increases the binding 
capacity of nitrocellulose. The proteins separated by SDS-PAGE were transferred on 
top of the nitrocellulose filter paper in a semi-dry electrophoretic transfer cell in transfer 
buffer at 13v constant voltage for 1 h. A transfer blotting sandwich was assembled as
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shown schematically in Figure 2.4. On one half of the transfer cassette, a scouring pad 
soaked in buffer was placed followed by two pieces of pre-wetted Whatman 540 paper 
cut to the same size of the gel. A transfer membrane also cut to the same size of the gel 
and pre-wetted with transfer buffer, was placed on the top of the filter, the gel being 
placed on the top of the membrane making sure there were no bubbles between the gel 
and the membrane (It is important not to trap bubbles at any stage as they block protein 
transfer). In the case of bubbles, these were removed by rolling a pipette smoothly 
across the surface. The sandwich was completed with the other two layers of Whatman 
paper and scouring pad, respectively (Figure 2.4). After transfer, the apparatus was 
dismantled and the transfer membrane was removed, noting the orientation of the blot 
by cutting off one comer of the membrane.
The part of the membrane which contained the molecular weight standards, was cut out 
and reacted with peroxidase-conjugated avidin to visualize the bands. The remaining 
membrane was incubated in blocking buffer for 1 h to absorb non-specific binding. The 
membrane was washed once for 15 min, and twice for 5 min, with fresh changes of 
washing buffer, at room temperature, on a rocking platform. The washed membrane was 
cut into strips and incubated with serum samples from patients and controls at dilutions 
ranging between 1/200 and 1/5,000 for 2 h at room temperature. The strips were 
washed as previously described and incubated for 90 minutes with the labelled 
peroxidase-conjugated anti-human total Ig or IgG or individual IgG subclasses antisera, 
respectively diluted 1/1000 -  1/4000 in blocking buffer according to the manufacturer’s 
guidelines.
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Figure 2.4 Material specifications for ready precast gels (A-B) and schematic 
representation o f the blotting sandwich (C). I f  the same protein sample is to be probed 
with multiple serum samples, a 2-well mini gel consisting o f a large well for the protein 
sample and a smaller one for the molecular weight standard can be used as indicated 
by the type o f comb o f the ready precast gel (A). Migrations are based on the leading 
dye front being run to the bottom o f a gel (B). Single-percentage gels produce the 
greatest resolution between any 2 bands that are close in molecular weight, whereas a 
linear gradient gel allows both high and low molecular weight bands to be visualized 
on the same gel (B). A blotting membrane (nitrocellulose) and 2 sheets o f thick filter 
paper were preassembled into a blotting membrane/filter paper sandwich, to fit  the 
ready Gel/Mini-PROTEAN-size gels (C)
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2.2.2.S ELISA
Biotinylated synthetic peptides were constructed by 9-fluorenylmethyloxycarbonyl (f- 
moc) chemistry (Weiner et al., 1992, Rodda and Tribbick, 1996). Biotin was linked to 
the peptides through a spacer with alternating serine (S) and glycine (G) residues to 
avoid steric hindrance and reduce hydrophobicity (Rodda and Tribbick, 1996). Peptides 
conformed to the following format: biotin-SGSG-peptide-amide, where SGSG is the 
spacer. Peptides encoding a scrambled 15-, 18-, or 20-meric randomly generated 
sequence of amino acids, biotin-SGSGHEDYVNQSLRPTPLEISVRA-amide (van ’t 
Hof et al., 1993, Choudhuri et al., 1998, Gregorio et al., 1999, Gregorio et al., 2003, 
Kerkar et al., 2003), was used as the negative control peptides. All peptides were more 
than 90% pure after reverse-phase high performance liquid chromatography (HPLC). 
The identity of each peptide was confirmed by mass spectrometry. Peptides have been 
dissolved in 200-600 pi of 40% acetonitrile and divided in aliquots kept at -70° C until 
use. The reactivity of anti-peptide positive serum was tested by ELISA (Choudhuri et 
al., 1998, Gregorio et al., 1999, Gregorio et a l, 2003, Kerkar et al., 2003).
A total of 200 ml/well of 2% BSA/PBS was added for 1 h at 20°C to a 96-well 
polysterene plate pre-coated with 5 mg/ml streptavidin to prevent non-specific binding. 
The optimum concentrations of reagents at various steps of each immunoassay were 
determined in preliminary experiments by checkerboard titration. Two serum samples 
giving high anti-peptide readings were tested at dilutions of 1/100, 1/200, 1/300, 1/500, 
1/1000 to define the dilution giving the lowest background noise and the optimal anti­
peptide binding value using different concentrations of peptide (2, 5, 15, 30 pg/ml) 
(Kerkar et al., 2003). After addition to each well of 100 ml of biotinylated peptide 
diluted to 1/1000 in PBS containing 0.1% sodium azide and 0.1% BSA, the plate was 
mildly agitated in a shaker for 1 h at 20°C. One hundred pi of patient serum diluted to 
1/200 (except otherwise indicated) in 2% BSA/PBS containing 0.1% sodium azide were 
added to each well and incubated under mild agitation at 20°C for 90 minutes. After 90 
minutes incubation, plates were incubated with 100 pl/well of serum diluted in 2% 
BSA/PBS containing 0.1% sodium azide. After each of the above steps, the plates were 
washed five times with PBS containing 0.1% Tween 20. After washing, 100 pl/well of 
horseradish peroxidase (HRP)-conjugated rabbit anti-total human Ig, or goat IgG, or 
mouse anti-human IgG subclasses (GI, G2, G3, G4) (Santiago et al., 1997) diluted in 
2% BSA/PBS were added. The reaction was detected by the addition of 100 pl/well of
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freshly-prepared o-phenylenediamine (OPD) solution containing 0.4 mg/ml of 3% 
hydrogen peroxide in citrate phosphate buffer terminated with 100 pl/well of 4N 
sulfuric acid. Absorbance (optical density, OD) was read in a microplate reader at 490 
nm. In each plate, one well was used as blank, in which serum and peptide were 
omitted, and two additional wells were used for a positive and a negative control. The 
positive control consisted of an LKM1-positive serum (titre 1/5120), which in 
preliminary experiments was shown to react with CYP2 D6253-272, that is a well-defined 
immunodominant epitope on CYP2D6 (Kerkar et al., 2003). Randomly generated 
scrambled control peptides incubated with serum from a healthy individual were used as 
negative control. Each serum tested against experimental peptides was also tested 
against the control peptide. Reaction for a given peptide was considered positive when 
ODtest/ OD00"*™1 peptide was >2, this cut off representing values higher than mean ±5 
SD of anti-peptide readings of serum samples from up to 11 healthy subjects against 7 
randomly selected peptides, the number of serum samples and peptides tested 
depending on the condition of the experiment and the total number of peptides and 
serum samples under investigation (Choudhuri et a l , 1998, Gregorio et al., 1999, 
Gregorio et al., 2003, Kerkar et a l , 2003).
All experiments were performed in triplicate. Repeated experiments gave variations 
< 10%.
2.2.2.4 Inhibition studies
2.2.2.4.1 Liquid phase
To investigate whether the reactivity to microbial and homologous self peptides was 
due to cross-reactivity, competition ELISA were performed coating the plate with a 
microbial or self homologue and using the relevant microbial and self peptides and 
antigens, a control peptide and a control antigen as competitors in liquid phase 
(Choudhuri et a l , 1998, Gregorio et a l, 1999, Gregorio et a l, 2003, Kerkar et al., 
2003). A predetermined diluted serum was mixed with peptide solutions to give final 
peptide concentrations of 1000, 500, 250, 100, 65, 30, 15, 7.5, 3.8 pg/ml, respectively 
(except otherwise indicated). The solutions were incubated at room temperature for 90 
minutes and then tested for residual anti-peptide antibody reactivity by ELISA.
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2.2.2.4.2 Solid phase
Inhibition studies were also done using solid phase inhibitors (peptides or antigens). 
Briefly, 200pl of a test serum diluted in a predetermined dilution were added to the first 
well of an 8-well row pre-coated with either the test peptide or antigen, or control 
peptide or antigen. After 15 minutes incubation at 20°C on a shaker, the serum was 
sequentially transferred to wells 2-8, with a 15-minute incubation in each well. One 
hundred pi of absorbed serum were then tested for anti-peptide antigen and compared 
with antibody reactivity before absorption. Antibody detection was carried out under 
identical conditions to those described in ELISA.
2.2.2.5 Relative affinity o f  anti-peptide antibody
The relative affinity of antibody binding to microbial and self homologues was tested 
according to Quinn et al (1993) with slight modifications such as urea being used as a 
chaotropic agent instead of potassium thiocyanate (KSCN) (Hedman et al., 1991). 
Microplate wells were coated with 100 pi of peptides in final concentrations as for the 
determination of anti-peptide antibody binding (Quinn et a l , 1993). After blocking for 
an hour and washing, wells were incubated with serum samples at a dilution o f 1/1000 
or 1/10000 (except otherwise indicated) for 2 hours at room temperature. Sera positive 
and negative for individual anti-peptide reactivities where used as controls. After 
washing, graded concentrations of urea (1M- 8M) were added to each well for 3 
minutes to inhibit antigen-antibody interactions (Hedman et al., 1991). After washing, 
the substrate solution was added and the reaction was stopped as previously described. 
Absorbance values in the absence and presence of urea were used to calculate the 
percentage (%) of inhibition of anti-peptide antibody binding by different 
concentrations of urea (Hedman et al., 1991, Quinn et al., 1993). Results were 
expressed as the mean ±SD of three experiments using individual serum samples.
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2.2.3 Cellular studies
2.2.3.1 Separation o f  peripheral blood mononuclear cells
Ten to 40 ml of peripheral blood were obtained by venepuncture, and mixed with 
preservative-free heparin in a sterile syringe, to a final concentration of 10 U/ml 
(Plebanski, 2000). Aliquots of whole blood were layered on the top of an equal volume 
of Lymphoprep (Ficoll) density gradient solution of density 1.077 g/ml in a 20 or 40 ml 
sterile tube and centrifuged at 800g for 20 min at 20 °C, without brake (Plebanski,
2000). The milky-white layer of PBMC at the interface between the Ficoll (transparent) 
and the remaining plasma (yellow) was collected by aspirating it gently from the top 
with a sterile pipette to a fresh tube and washed at 300g for 7 min with RPMI 1640 
medium without glutamine (Plebanski, 2000). In the presence of red cells, the flicked 
pellet of cell preparation was mixed gently with 10 ml of red blood cell lysis solution 
(ACK buffer containing 0.15 M NH4CI, 1 mM KHCO3, 0.1 mM Na2 EDTA; pH 7.2 and 
left at room temperature). After 5 minutes, the solution was diluted with 25 ml of RPMI 
and 2 ml of foetal calf serum (FCS) to underlay the cells in the red blood cell lysis 
solution and centrifuged at 600g for 7 minutes at room temperature (Plebanski, 2000). 
After discarding the supernatant (including the FCS), the pellet was flicked and 
resuspended in 5 ml RPMI and washed by centrifuging at 600g for 7 minutes at room 
temperature. After discarding the supernatant, the flicked cells, clean of red cells (white 
pellet of cells), were washed again in RPMI and resuspended in the appropriate medium 
at the required cell concentration for further cell culture studies or diluted in frozen 
buffer (90% heat inactivated FCS and 10% DMSO) and stored in cryovials for 48 h at - 
70 °C and then transferred to a liquid nitrogen tank (Plebanski, 2000).
2.2.3.2 Thawing cryopreserved cells
Cryopreserved cells were thawed from the nitrogen tank by first transferring the vials to 
-70 °C for 48 h (Plebanski, 2000). Cells were then quickly thawed by immersion and 
gentle shaking of the vials in a 37 °C water bath (Plebanski, 2000). Cells were 
transferred from the vial to a 15 ml sterile Universal tube; initially slowly with gentle 
shaking (0.5 ml/min for the first 2 min), followed by 2 ml/min for the next 2 min and 
then topped up with 7 ml RPMI with glutamine (Plebanski, 2000). After centrifugation 
at 600g for 7 min at room temperature with brake, the supernatant was discarded and 12 
ml of RPMI with glutamine were added for a final spin, as before (Plebanski, 2000). A
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cell count was performed using a haemocytometer and lymphocyte viability was 
determined at the same time by Trypan-blue exclusion (Plebanski, 2000). Equal 
volumes of Trypan-blue solution and lymphocyte suspension were mixed, then put into 
a haemocytometer chamber and examined under a light microscope. The cell viability 
was consistently over 90% (Plebanski, 2000).
2.2.33 T-cell proliferation assay
The T-cell proliferation assay is based on the principle that engagement of the TCR by 
the HLA-antigen complex on the surface of autologous APC, together with the second 
signal results in T-cell activation, cytokine secretion, and cell division (Lenschow et al., 
1996). The level of antigen-induced T-cell proliferation, which is quantified by the 
incorporation or radiolabelled thymidine, gives a measure of the in vivo priming of T- 
cells specific for that antigen (Vyakamam et al., 2000). Since PBMC contain 
professional APC as well as T-cells, these cells can be used in proliferation assays 
without separation or further addition (Vyakamam et al., 2000). 1 x 106/ml 
cryopreserved or fresh PBMC were diluted in RPMI-1640 medium supplemented with 
10% heat-inactivated FCS, 2 mM L-glutamine, 25 mM HEPES, 100 U/ml 
benzylpenicillin and 0.1 mg/ml streptomycin, 2.5 pg/ml amphotericin B (Fungizone) 
(complete culture medium), without IL-2 and 100 pl/well were added in a 96-well round 
bottom plate in the presence of peptide, full-length antigen or non-antigen specific 
stimuli (Vyakamam et al., 2000, Plebanski, 2000). After a 7-day culture at 37 °C in a 
humidified 5% CO2 atmosphere, the microcultures were pulsed with 0.5 pCi/well of 
3H-thymidine for 18 h and harvested onto glass-fibre filter papers using a multichannel 
harvester (Vyakamam et al., 2000). Filters were discharged automatically into 
scintillation vials, allowed to air-dry, 1 ml scintillant added and the amount of 
incorporated 3H-thymidine was determined by liquid scintillation spectroscopy 
(Vyakamam et al., 2000). In each experiment, 5-8 wells containing PBMC, but no 
antigen served as negative controls (Vyakamam et al., 2000). Each peptide or full- 
length antigen was tested in triplicate (Vyakamam et al., 2000). Results were expressed 
as the stimulation index (SI) which is the ratio of the mean counts per min (cpm) from 
triplicate determinations in the presence of antigen to the mean cpm obtained in the 
absence of antigen. The wells exhibiting an SI >3 were considered positive in T-cell
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proliferation experiments (Shimoda et al., 1995, Shimoda et al., 1998, Shimoda et al., 
2000, Vyakamam et al., 2000).
2.2.3.4 Intracellular cytokine staining
Flow cytometry is a powerful analytical technique in which individual cells can be 
simultaneously analysed for several parameters, including size and granularity, as well 
as the expression of surface and intracellular markers defined by fluorochrome labelled 
antibodies (see 2.1.3) (Prussin and Metcalfe, 1995, Openshaw et al., 1995, Carter and 
Swain, 1997). Fluorescent anti-cytokine monoclonal antibodies have become very 
useful for the intracellular staining and multiparameter flow cytometric analysis of 
individual cytokine-producing cells within mixed cell populations (Jung et al., 1993, 
Vikingsson et a l, 1994, Prussin and Metcalfe, 1995). Multicolour immunofluorescent 
staining with antibodies against intracellular cytokines and cell surface markers 
provides a high resolution method to identify the nature and frequency of cells which 
express a particular cytokine(s) (Jung et al., 1993, Vikingsson et a l,  1994, Prussin and 
Metcalfe, 1995, Openshaw et al., 1995, Nicholson et al., 1996, Picker et al., 1995). For 
example, multicolour immunofluorescent staining of an individual cell surface antigen 
and two cytoplasmic cytokines has been used to identify and enumerate cell types which 
express cytokines in either a restricted (e.g., Thl- versus Th2-like cells) or unrestricted 
(e.g., ThO-like cells) pattern (Prussin and Metcalfe, 1995, Openshaw et al., 1995, 
Nicholson et al., 1996, Austrup et al., 1997). In addition to enabling highly specific and 
sensitive measurements of several parameters for individual cells simultaneously, this 
method has the capacity for rapid analysis of large numbers of cells which are required 
for making statistically significant measurements (Roederer et al., 1997, Herzenberg et 
al., 2002).
Staining of intracellular cytokines depends on the identification of cytokine specific 
monoclonal antibodies which are compatible with a fixation-permeabilization procedure 
(Sander et al., 1991). Optimal intracellular cytokine staining has been reported using a 
combination of fixation with paraformaldehyde and subsequent permeabilization of cell 
membranes with the detergent saponin. Paraformaldehyde fixation allows preservation 
of cell morphology and intracellular antigenicity, while also enabling the cells to 
withstand permeabilization by detergent (Sander et al., 1991). Membrane 
permeabilization by saponin allows the cytokine-specific monoclonal antibody to
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penetrate the cell membrane, cytosol, and membranes of the endoplasmic reticulum and 
Golgi apparatus (Sander et a l , 1991).
A direct two-colour immunofluorescent staining method was used in the present study 
to characterise T lymphocytes. Piars of different fluorochrome-conjugated antibodies 
able to bind to distinct cell surface determinants were used. Two lymphocyte markers 
could therefore be determined at one time. 0.5 x 106 cells/ml were incubated for 6 hours 
at 37°C in 10% FCS in RPMI, with the relevant peptides, in the presence of 20 pg/mL 
Brefeldin A, after the first 1 hour (Maini et al., 1999, Maini et a l , 2000, Lopes et a l , 
2003). Brefeldin A is used to block cytokine secretion and to induce intracellular 
accumulation (Yewdell and Bennink, 1989). Incubation without antigen was used as 
negative control. After incubation, cells were transferred to fluorescence activated cell 
sorter (FACS) tubes in the presence of 400 pi of PBS 1% FCS. After a centrifugation at 
600g for 5 minutes at room temperature, the supernatant was removed and cells were 
gently vortexed. Cells were then stained with QRed-conjugated anti-CD4 antibody 
(1/100) and incubated for 20 minutes in 4 °C (Maini et a l , 1999, Maini et a l , 2000, 
Lopes et a l , 2003). After centrifugation, removal of the medium and vortexing as 
previously described, 100 pi of Cytofix/Cytoperm were added to permeabilize and fix 
the cell membranes, for 20 minutes at 4 °C. After centrifugation and removal of the 
medium, cells were stained with PE-conjugated anti-IFNy in 100 pi of 0.1 saponin in 
PBS and incubated for 30 minutes in 4 °C. Following two 5 min washes with pre-cooled 
0.1% FCS phosphate-buffered saline at pH 7.2, the cell pellet was resuspended in 400 pi 
of fixation buffer and analyzed by flow cytometry. Lymphocytes were identified by 
their characteristic forward and 90° light scatter properties and a gate is set to exclude 
debris. Fluorescence signal overlap was subtracted by electronic compensation using 
lymphocytes stained with a single fluorochrome. A minimum of 5,000 events was 
acquired for each sample and analyzed using the FACScan Research software (Becton 
Dickinson). Quadrant markers were set using preparations of lymphocytes stained with 
mAbs conjugated with either QRed or PE alone or in combination, such that cells in 
quadrant 1 stain with PE-conjugated antibody alone, in quadrant 2 with both 
fluorochromes, in quadrant 3 with neither and in quadrant 4 with QRed-conjugated 
antibody alone. After washing, cells were analyzed by flow cytometry.
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2.2.4 T-cell ‘help*for B-cell antibody production
For the study of ClpX specific T-cell ‘help’ in the production of anti-ClpP antibodies in 
patients with PBC, 1 x 106/ml cryopreserved or fresh PBMC were stimulated with PDC 
antigen (15pg/ml) in complete medium with IL-2 (10 U/ml) in the presence of 0.5-1 x 
106 irradiated (3,000 rad) autologous PBMC (feeder cells) as APC (Stevens et al., 1988, 
Mosmann and Coffinan, 1989, Mahon et al., 1995). Ionising radiation was used to 
abolish selectively the functions of radiosensitive subpopulations of immunocompetent 
cells. Irradiation prevents replication of feeder cells and antigen presenting cells. 
Ionising radiations are quantitated in Gray (Gy) or rads. One Gy is equal to 100 rads. 
A Gammacell-1,000 irradiator was used in this study. The gamma irradiation source 
used was caesium 137, which has a half-life of 30.2 years.
Every 3 days, 0.5 ml/ well of the cell-free supernatants were aspirated and the cultures 
replenished with fresh complete medium for 2 weeks in the presence of IL-2. At day 14, 
cells were washed and 1 x 106/ml PBMC were cultured for 72 hours in 24-well plates 
with individual human PDC-E2212-226, ClpX ECOLI, ClpP ECOLI, ClpP human 
peptides (15pg/ml) in complete medium without IL-2 and in the presence of 0.5 x 
106/ml irradiated autologous PBMC. At the end of the culture, the cell-free supernatant 
was collected and tested by ELISA (see 2.2.2.3) for anti-peptide antibody reactivity 
while the cells were washed and subjected to intracellular cytokine staining.
2.2.5 Patients
Details of patients, pathological and normal controls studied in the present Thesis are 
given in individual Chapters. All subjects consented to participate in the study. The 
Local Ethical Committees approved the study protocol.
2.2.6 Statistical analysis
Occasionally results are expressed as individual numerical values and are given in a 
tabulated form. More commonly and when data conform to a normal distribution, 
results are expressed as means and their variability around the mean is illustrated by the 
standard deviation (SD) of the mean. Standard error of the mean is given instead when 
this notation is necessary for further statistical computation eg Student’s t test. The 
unpaired Student’s t test is employed to assess differences between means of the two
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samples while the paired t test is used to ascertain differences between the means of 
paired observations. The correlation between two variables is analysed by the use of the 
Pearson coefficient of correlation (r), while the distribution of discrete variables in two 
sets of data are compared with the Chi square (%2) with the Yates’s correction. When 
dealing with small numbers, the Fisher’s exact test was used instead.
Data were also analysed using non-parametric statistical computations equivalent to the 
parametric ones. The non-parametric analysis applies equally well to date non-normally 
distributed as to those following a Gaussian distribution. In normally distributed sets of 
data, however, parametric tests tend to be more powerful discriminations than their non- 
parametric counterparts. For this reason, results of non-parametric tests (such as the 
Wilcoxon’s rank sum test and the (R) Spearman’s coefficient of correlation) are given 
only in those cases in which data cannot be reconciled with a normal distribution. In 
such cases the average value is given as the median, while the extent of variation in data 
distribution is indicated by the range. P values less than 0.05 are considered significant. 
Statistical analyses were performed using the SPSS (SPSS inc., Chicago, Illinois, USA) 
statistical package.
The candidate has performed all the experiments described in this Thesis, the only 
exception being the IIFL for autoantibody detection performed by Dr Edward T Davies, 
Immunology Department, Rayne Institute, King’s College.
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Mycobacteria and PBC
Chapter 3
3.1 BACKGROUND
PBC-specific AMA have been shown to cross-react with PDC-E2 of a variety of micro­
organisms (Sayers and Baum, 1976, Fussey et al., 1991, Baum, 1995). A study by 
Vilagut et al. (1994) showed that sera from Spanish patients with PBC reacted 
specifically with an extract of Mycobacterium gordonae (MYCGO). This reactivity was 
restricted to PBC, being absent in pathological controls including patients with HBV, 
HCV, AIH and normal controls (Vilagut et al., 1994). Furthermore, these investigators 
demonstrated that this reactivity reflected antibodies directed to the 65-kDa heat shock 
protein (hsp65) of MYCGO, that cross-reacts with PDC-E2 (Vilagut et al.9 1997). 
Vilagut et al. (1997) went on to suggest the existence of a shared epitope between 
MYCGO hsp65 and human mitochondrial antigens as the reason for the observed cross­
reaction. Following a protein database search showing that there is an excellent and 
almost unique match between part of the dominant B-and T-cell epitope of PDC-E2 and 
a peptide sequence in MYCGO and other mycobacterial hsp65s, the present study 
investigated whether the peptides showing such molecular mimicry are, firstly, targets 
of a PBC-specific humoral immune response and, secondly whether they are also targets 
of a cross-reactive immune response. A third aim was to compare such immune 
responses in Spanish and in British PBC populations in view of the different PBC- 
specificity of reactivity against MYCGO reported in a previous study (O'Donohue et al., 
1994).
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3.2 METHODS
3.2.1 Subjects
Serum samples were obtained from 90 patients with PBC: 40 followed up at the Liver 
Unit, Hospital Clinic, Barcelona, Spain (38 female, mean age 55.3 years±12SD), all but 
one AMA positive by IIFL (median titer: 1/400, range 1/50 -  1/800), mean duration of 
disease 83 months (range 5 -221) and 50 attending the out-patient clinic of the Liver 
Transplantation and Hepatobiliary Medicine Unit, Royal Free Hospital, London, United 
Kingdom (44 female, mean age 54.9 years±llSD), all but two AMA positive by IIFL 
(median titre: 1/640, range 1/40 -  1/10240), mean duration of disease 49 months (range 
1-180). Demographic, biochemical and clinical characteristics of the patients are given 
in Table 3.1. Ten of 40 sera from Spain were aliquots stored at -70°C from the original 
study by Vilagut et a l (1994). All sera were tested under code.
Eighty-four chronic HCV infected subjects, all HCV RNA positive, 44 from Spain (16 
female, mean age 39±13.2SD) and 40 from UK (28 female, mean age 47±11SD), all 
AMA negative, were tested as pathological controls.
3.2.2 Detection o f AMA
For the present study, AMA was retested by conventional IIFL (see 2.2.2.1) and was 
further evaluated by immunoblotting (see 2.2.22) and by ELISA (see 2.2.2.3) using as 
antigen purified PDC from porcine heart mitochondria (see 2.1.2).
3.2.3 Protein database search and analysis
Identification of MYCGO hsp65 sequences homologous to human PDC-E2 was carried 
out through two complementary approaches. First, the complete 120 aa MYCGO hsp65 
protein fragment was serially divided into 6 aa segments, each overlapping the 
preceding segment by 1 aa. The resulting set of 115 hexamers was used to scan for 
sequence-sharing motifs between MYCGO hsp65 and the 614 aa human PDC-E2 
protein using the ‘Proteinlnfo’ computer-assisted programme (see 2.2.1.1). A similar 
investigation was carried out by dissecting the MYCGO hsp65 protein fragment into 5 
and 4 aa motifs that were used as sequence probes for comparison to human PDC-E2. 
Second, the resulting homologies were further evaluated by comparing the MYCGO
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hsp65 and human PDC-E2 using the computer-assisted protein-protein sequence 
comparison programme 4BLASTp 2 sequences' (see 2.2.1.2.2).
3.2.4 Peptide synthesis
Six biotinylated (see 2.2.23) 15-mer regions containing the relevant sequences: 
MYCGO hsp659o-io4 (-DQSIGDLIAEAMDKV-), human PDC-E2208-222 (-
KVGEKLSEGDLLAEI -), PDC-E22i2-226 (-KLSEGDLLAEIETDK-), PDC-E22i6.230 (- 
GDLLAEIETDKATIG-), and PDC-E2220.234 (-AEIETDKATIGFEVQ-), human 
hsp60i79-i93 (-DKEIGNIISDAMKKV-) and an irrelevant 15-mer control peptide were 
synthesized (see 2.2.23).
3.2.5 ELISA
Antibody binding to the peptides was determined by ELISA (see 2.2.23). The final 
peptide concentration was 15 pg/ml and the dilution of serum samples was 1/200 (see 
2.2.23).
3.2.6 Inhibition studies
To investigate whether the simultaneous reactivity to MYCGO hsp659o-io4 and PDC- 
E22i2.226 was due to cross-reactivity, competition ELISA were performed (see 2.2.2.4.1) 
measuring residual anti-MYCGO hsp659o-io4 antibody reactivity after incubation with 
MYCGO hsp659o-io4, and PDC-E22i2.226, PDC antigen, control peptide and control 
antigen (cytochrome P4502D6) as liquid phase competitors (final concentrations: 1000, 
500, 250,100, 65, 30,15, 7.5, 3.75 pg/ml).
3.2.7Anti-peptide antibody affinity
The relative affinity of antibody binding to MYCGO hsp659o-io4 and PDC-E22i2.226 was 
also investigated (see 22.2.5).
3.2.8 IgG subclass o f anti-PDC-E2 antibodies
IgG subclasses of PDC-E2 specific autoantibodies were determined by immunoblotting 
(see 2.2.22) in serum samples from 30 PBC patients including 10 MYCGO hsp659o-io4 
reactive Spanish cases and 20 MYCGO hsp659o-io4 unreactive cases (10 Spanish and 10 
British), all reactive with PDC-E2 antigen and peptide.
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3 3  RESULTS
3.3.1 Protein database search and analysis
Amino acid comparison revealed a 7/8 (88%) aa similarity (6 identities, 1 conservative 
substitution) between MYCGO hsp6592-99 (SIGDL/AE) and human PDC-E2214-221 
(SEGDLZAE) (identities in bold, conservative substitutions in italic). No other penta- 
or tetrameric sequences are shared in common between MYCGO hsp65 and human 
PDC-E2. Database searches confirmed that, in bacteria, the motif SxGDL[IL]AE is 
virtually unique to mycobacterial hsps (SIGDLIAE), the only exception being 
SEGDLVAE in P galactosidase of Lactobacillus delbrueckii (see 4..3.1). The only 
human sequence containing that motif is the inner lipoyl domain of PDC-E2.
In summary, there is an excellent and almost unique match between sequences of the 
dominant epitope of PDC-E2 and of mycobacterial hsp65.
3.3.2 ELISA
To delineate the most antigenically relevant sequence within PDC-E2208-234, - the core 
sequence of the inner lipoyl domain surrounding the key lysine residue (K226), site of 
attachment of lipoic acid (Yeaman et al., 2000) -,14 randomly selected PBC sera were 
tested against four 15-mer peptides overlapping by 11 aa spanning the full PDC-E2208- 
234. Reactivity to PDC-E2208-222> PDC-E2212-226? PDC-E2216-230? and PDC-E2220-234 was 
present in 3, 14, 6 and 7 of the 14 PBC patients, respectively, absorbance values being 
highest against PDC-E2212-226 in 11 of the 14 cases. Thereafter, studies focused on the 
PDC-E2212-226 sequence.
3.3.2.1 Single anti-peptide antibody reactivity
Table 3.1 summarises demographic, clinical, immunological and peptide antibody 
binding details of the 40 Spanish and 50 British patients with PBC.
Reactivity to MYCGO hsp659o-io4 was found in 20 (50%) of the 40 Spanish PBC 
patients and in 2 (4%) of the British PBC patients (p=0.000002). None of the HCV 
infected subjects reacted with MYCGO hsp659o-io4.
Reactivity to the human PDC-E2212-226 was found in 38 (95%) of 40 Spanish PBC 
patients and in 48 (96%) of 50 British PBC patients. None of the Spanish or British 
HCV infected subjects reacted with PDC-E2212-226-
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3.3.2.2 Double anti-peptide antibody reactivity
Double reactivity to the MYCGO hsp659o-io4/human PDC-E2212-226 pair was present in 
19 (47.5%) Spanish PBC patients and in 2 (4%) of the 50 British PBC patients 
(p=0.000004). No sera were found to react with human hsp60i79-i93.
Among the 10 serum samples from the original study of Vilagut et al. with an evident 
anti-MYCGO hsp65 antibody reactivity, 9 (90%) were MYCGO hsp6 5 9 o-i04/human 
PDC-E2 2 12-226 double reactive.
There were no differences in anti-PDC antibody titres or other clinical, biochemical or 
histological parameters between the Spanish PBC patients with or without MYCGO 
hsp659o-io4/human PDC-E2212-226 double reactivity, as well as between the Spanish 
(double reactive or unreactive) and British PBC patients
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Table 3.1 Demographic, immunological features and anti-peptide reactivity details of 
the 40 Spanish and the 50 British PBC patients
Spanish PBC 
(n=40)
British PBC 
(n=50)
P
Female/Male 38/2 44/6 ns
Age (years) 55.3±1.27 54.9±1.6 ns
Duration of disease (months) 83.3±7.5 79.3±5.8 ns
AMA IIFL (pos/neg) 39/1 48/2 ns
AMA IIFL titres, median 1/400 1/640 ns
(range) (1/50-1/800) (1/40-1/5120)
AMA ELISA titres (U/ml) 84.4± 6.1 78.3±3.14 ns
Anti-M Y CGO90-104 20/40 (50%) 2/50 (4%) 0.000002
(Mean *ODlesl/conlrol±SEM) 3.4±0.37
Human PDC-E2212-226 38/40 (95%) 48/50 (96%) ns
(Mean ODlesl/“ "tro1 ±SEM) 3.34±0.18 3.44±0.19 ns
MY CGO90-104/PDC-E2212-226 19/40 (47.5%) 2/50 (4%) 0.000004
PBC, primary biliary cirrhosis; AMA, anti-mitochondrial antibody; IIFL, indirect 
immunofluorescence; MYCGO, Mycobacterium gordonae; PDC-E2, pyruvate 
dehydrogenase complex-E2 subunit; *, absorbance values are expressed as optical 
density (OD)test/contro1 an(j  considered positive >2 (see 2.2.2.3); SEM, standard error
o f the mean; n, number; ns, not significant
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3.3.3 Inhibition studies
3.3.3.1 Inhibition o f  anti-MYCGO antibody reactivity
Inhibition of anti-MYCGO hsp659o-io4 antibody binding by pre-incubation with relevant 
and control peptides/antigens are given in Table 3.2 and Figure 2.1.
Antibody binding to MYCGO hsp659o-io4 was inhibited by pre-incubation with the 
MYCGO hsp659o-io4 by 67.8-85.2% in all 10 MYCGO hsp659o-104/PDC-E2 2 12-226 
double-reactive cases where competition experiments were performed (Table 3.2). 
Among these, in cases 9, 10, 16, 17 (Figure 3.1 A), and 35 of Spanish and case 11 of 
British serum samples (Figure 3.IB) antibody binding to MYCGO hsp659o-io4 was 
inhibited 68-77% by pre-incubation with human PDC-E2212-226 and 65-78.1% by pre­
incubation with PDC antigen (Table 3.2).
In cases 21, 34 and 36 of Spanish and 23 of British serum samples anti-MYCGO 
hsp6 5 9 o-io4 antibody binding was not inhibited much beyond what was observed with 
control antigen or peptide, by pre-incubation with human PDC-E2212-226 (12-23.6% 
inhibition) or PDC antigen (13.4-19.4% inhibition) (Table 3.2).
The level of inhibition in case 23 of the British serum samples reached 60.7% when
62.5 pg/ml of PDC antigen was used as liquid phase competitor; the inhibition 
decreasing thereafter when up to 1000 pg/ml PDC antigen was used for competition 
(Table 3.2).
3.3.3.2 Inhibition o f  anti-PDC-E2 antibody reactivity
The inhibition experiments were also performed in reverse. Anti-PDC-E2 2 12-226 
antibody reactivity was tested after pre-incubation of individual serum samples from the 
6 microbial/self cross-reactive cases with relevant and control peptides/antigens. In all 
cases (9, 10, 16, 17, 35 of Spanish and 11 of British serum samples) (Table 3.2B and 
Figure 3.1C-D), antibody binding to human PDC-E2212-226 was inhibited up to 78.1%, 
77% and 77% by pre-incubation with PDC-E2212-226, MYCGO hsp659o-i04, and the PDC 
antigen respectively.
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Table 3.2 Inhibition of anti-MYCGO hsp6590.io4 (A) and anti-PDC-E22i2-226 (B) 
antibody reactivity by pre-incubation with relevant and control peptides and antigens of 
MYCGO hsp659o-io4/PDC-E22i2-226 double reactive PBC cases
Case Origin 
#
Maximum
Inhibition
(%)
A.
MYCGO Human PDC Control Control
hsp659o.io4 PDC-E2212-226 antigen antigen peptide
9 Spanish 76.2 77 72.5 11.2 6.7
10 Spanish 72.3 69.2 72 7.8 11.2
16 Spanish 79.1 72.1 78.1 13 8.2
17* Spanish 82.8 71.2 77.2 14.2 9.2
21 Spanish 69 17 14.2 15.1 4.5
35 Spanish 79.9 69.2 65 13.2 11.2
34 Spanish 84.9 12 13.4 11.2 9.2
36 Spanish 75.1 21.2 19.4 11.9 5.9
11** British 85.2 68 67 13.8 9.2
23 British 67.8 23.6 60.7*** 7.2 4.5
B.
Human MYCGO PDC Control Control
PDC-E22i2- hsp659o-io4 antigen antigen peptide
226
9 Spanish 76 75.2 77 4.2 3.1
10 Spanish 73.9 73 71.3 8.2 7.1
16 Spanish 78.1 69.8 72 8 3
17* Spanish 72 77 77 6 4
35 Spanish 67.7 72.8 69.1 10.1 2.8
11** British 70 72 71 11 2
* See Figure 3.1A-B; ** See Figure 3.1C-D; *** Inhibition observed with
62.5pg/ml o f PDC antigen as liquid phase competitor. This declined to 23% when
1000 pg/ml was used; MYCGO, Mycobacterium gordonae; hsp, heat shock protein 
PDC, pyruvate dehydrogenase complex; PBC, primary biliary cirrhosis
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Figure 3,1 A-D: Inhibition o f  antibody binding against MYCGO hsp6590-104 (A-B) and 
PDC-E2212-226 (C-D) by pre-incubation with MYCGO hsp6590-104 (♦ ), human PDC- 
E2 212-226 (®), porcine PDC antigen (A), control antigen (o) and control peptide (*) o f  
Spanish case 17 (A,C), and British case 11 (B,D). Antibody binding is represented as a 
percentage o f  inhibition o f  binding to the peptide MYCGO hsp65 90-104 in the presence o f  
competitor peptide at different concentrations; MYCGO, Mycobacterium gordonae; 
hsp, heat shock protein; PDC, pyruvate dehydrogenase complex; ab, antibody
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3.3,4 Affinity o f anti-peptide antibody
The relative affinity of antibody binding to MYCGO hsp659o-io4 and PDC-E2 2 12-226 for 
Spanish case 9 and British case 11 is illustrated in Figure 3.2 demonstrating in each case 
higher relative antibody affinity to MYCGO hsp659o-io4 compared to PDC-E22 12-226, the 
avidity indices being 0.66 vs 0.47 and 1.1 vs 0.53 mol/L, respectively (Figure 3.2A-B).
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Figure 3.2 A-B. Affinity profile o f  anti-peptide antibody. ELISA microplate wells were 
coated with Mycobacterium gordonae heat shock protein (hsp)6590-104 and human 
pyruvate dehydrogenase complex (PDC)-E2212-226- After incubation with individual 
serum samples o f  Spanish case 9 (A) and British case 53 (B) at a dilution o f  1/10,000, 
urea was added at various concentrations and allowed to inhibit antibody-antigen 
interaction for 15 minutes. Absorbance values were plotted as the percentage o f  initial 
absorbance against urea concentration (mean ± SD). Each point is the average o f  3 
observations. From this the relative affinity index, defined as the concentration o f  urea 
that elutes 50% o f the antibody reactivity, fo r both MYCGO hsp6590-10 (°) and human 
PDC-E2212-226 ( •)  can be extrapolated (-— -). OD, optical density
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3.3.5 IgG subclass o f  anti-PDC-E2 autoantibodies
Anti-PDC-E2 reactivity was predominantly of the IgG3 subclass alone or in 
combination with either IgGl or to a lesser extent IgG2 subclass, in each of the 3 groups 
(Table 3.3). No significant differences were found between the 10 MYCGO hsp659o-io4 
reactive Spanish PBC cases and the 10 MYCGO hsp659o-io4 unreactive Spanish or the 
10 MYCGO hsp659o-io4 unreactive British cases. No reactivity to PDC-E2 of the IgG4 
subclass was present.
Table 3.3 Patterns of anti-PDC-E2 antibody IgG subclass specific reactivity in: (A) 
MYCGO hsp659o-io4 reactive Spanish PBC cases; (B) MYCGO hsp659o-io4 unreactive 
Spanish PBC cases; (C) MYCGO hsp659o.io4 unreactive British PBC cases. All serum 
samples were reactive for PDC-E2212-226
Pattern IgG3 IgGl/IgG3 IgG2/IgG3
A 10 Spanish 
MYCGO hsp659(M04 
reactivive PBC cases
7/10 2/10 1/10
B 10 Spanish 
MYCGO hsp659o.io4 
unreactivive PBC cases
6/10 3/10 1/10
C 10 British 
MYCGO hsp659o.io4 
reactivive PBC cases
7/10 2/10 1/10
PDC-E2, pyruvate dehydrogenase complex-E2 subunit; MYCGO, Mycobacterium 
gordonae; hsp65, heat shock protein 65 kDa; PBC, primary biliary cirrhosis
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3.4 DISCUSSION
In this section of the thesis, an attempt was made to see whether there is molecular 
mimicry at the level of mimicking peptidyl epitopes, for the previously described cross­
reactivity between MYCGO hsp65 and human PDC-E2, the major target antigen of 
antimitochondrial immune response in patients with PBC (Vilagut et a l , 1994, Vilagut 
et a l , 1997, Yeaman et al., 2000). The Spanish investigators found a species-specific 
reaction of sera from patients with PBC with membranes from MYCGO. In a 
subsequent study the same group was able to recognize MYCGO hsp65 as a target of 
PBC-specific cross-reactive antibodies (Vilagut et a l , 1994, Vilagut et a l , 1997). The 
authors suggested a shared epitope between MYCGO hsp65 and human mitochondrial 
antigens as the reason for the observed cross-reaction (Vilagut et a l , 1997). Starting 
from this point, the present study has identified a striking aa similarity between 
MYCGO hsp659o-io4 and human PDC-E2 2 12-226, the unique peptide sequence shared by 
the respective dominant epitopes of AMA and PDC-E2 specific CD4 and CD8 cells 
(Van de Water et al., 1988, Tuaillon et a l,  1992, Matsui et a l, 1993, Shimoda et a l, 
1995, Shimoda et a l,  1998, Kita et a l,  2002).
Anti-PDC-E2 antibody response is polyclonal and includes a wide range of specificities, 
targeting, to a greater or lesser extent, the sequence 212-226 on PDC-E2 and various 
flanking sequences extending out to include almost the entire inner-lipoyl domain of 
PDC-E2 (Van de Water et a l, 1988, Tuaillon et a l, 1992, Matsui et a l,  1993). The 
focus of autoantibody reactivity can be a linear sequence, the critical residues being 
contiguous, located on a short segment of the antigenic protein (Geysen et a l,  1985, 
Dyrberg et a l, 1990, Novotny, 1991, Wucherpfennig et a l, 1997, Craig et a l,  1998). 
Three-dimensional studies show PDC-E2212-226 to be physically exposed on the 
molecule’s surface making it a potential target of microbial/self cross-reactive humoral 
responses (Howard et a l,  1998).
The PDC-E2212-226 mimicking motif SxGDL(IL)AE is virtually unique to mycobacterial 
hsps, being expressed in practically all mycobacterial hsp65s, including those of M 
tuberculosis and M. leprae. In man the only full match of SxGDLIAE is the inner lipoyl 
domain of PDC-E2, while human hsp60, the evolutionary equivalent of hsp65, has only 
2 identities at the corresponding sequence (ExGNIISD). Hence, an excellent and almost
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unique match between this part of the E2 epitope and mycobacterial hsp has been 
identified.
The present work, involving the construction of the corresponding peptides, and testing 
their reactivity on relevant sera by ELISA, has led to three major findings. Firstly, 50% 
of the Spanish PBC patients reacted with MYCGO hsp659o-io4, this recognition being 
virtually absent among British PBC patients, even though the groups were equally 
reactive against PDC-E2212-226- Second, within the Spanish serum samples, anti- 
MYCGO hsp659<M04 reactivity was restricted to PBC, not being found in any of the 44 
Spanish HCV infected controls. Thirdly, double-reactivity against MYCGO hsp659o-io4 
and PDC-E2 2 12-226 usually reflected cross-reactivity, as demonstrated by inhibition 
studies.
These results agree with those of O’Donohue et al. (1994) in finding no difference in 
anti-hsp65 mycobacterial reactivity in UK between PBC patients and controls. The 
question then arises as to why differential reactivity to hsp659o-io4 is limited to Spanish 
patients with PBC. Is this because exposure to mycobacteria in general, or to a specific, 
atypical mycobacterium is particularly elevated in Spain? Distribution of atypical 
mycobacteria varies between different geographic regions; interestingly, Catalonia, the 
region from where the Spanish cohort originates, has one of the highest colonisation 
rates in Spain for atypical mycobacteria (Falkinham, 1996, Le Dantec et al., 2002, de 
March Ayuela, 2000, Martin Casabona and Rossello Urgell, 2000). In support to an 
epidemiological link is the observation that reactivity to hsp659o-io4 is present in 9 of the 
10 serum samples conserved from the 1993-1994 Vilagut study, a percentage close to 
the 100% originally reported for reactivity to full-length hsp65, while this is only 37% 
for the more recent sera suggesting a shift in the epidemiology over time. Thus, the 
differential responses to hsp659o-io4 in the two European countries may be due to 
different epidemiological patterns (Falkinham, 1996, Le Dantec et a l,  2002, de March 
Ayuela, 2000, Martin Casabona and Rossello Urgell, 2000). The assumption, however, 
that anti-hsp659o-io4 reactivity in Spanish PBC patients simply reflects a widespread 
exposure to mycobacteria in the Iberian country is questioned by the finding that none 
of 44 HCV infected patients, originating from the same region, have antibodies to 
hsp659o-io4-
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In analysing the response to microbial and self sequences, it is evident that reactivity to 
PDC-E22i2-226> present in practically all the PBC patients studied, does not equate with 
reactivity to the highly homologous hsp659o-io4, this being confined to a set of patients 
within a geographically-defined subgroup. This indicates that molecular mimicry does 
not automatically coincide with antigenic mimicry (Oldstone, 1987, Quaratino et al., 
1995, Bogdanos et al., 2000). In those patients who were simultaneously reactive to 
PDC-E2 2 12-226 and hsp659o-io4, double reactivity was shown to be in most cases cross­
reactive, by inhibition studies.
Moreover, the antibody affinity to hsp659<M04 was higher than that to PDC-E2212-226, 
suggesting that the response to the mycobacterial sequence may precede that to PDC-E2 
(Figure 3.2) (Quinn et al., 1993).
A pathogenic scenario may then be proposed where exposure to a PDC-E2 2 12-226 
mimicking microbial sequence, such as that contained in various mycobacterial hsp65, 
primes a potentially cross-reactive lymphocyte population (Oldstone, 1998, Liang and 
Mamula, 2000, von Herrath et al., 2003). This view is consistent with the findings that 
sera from patients with infectious diseases such as tuberculosis and leprosy, in which 
immune responses to mycobacterial stress proteins have been demonstrated, present 
antibodies that recognise the main mitochondrial autoantigen of PBC (Klein et al., 
1993, Gilburd et al., 1994). Exposure to identical or very similar sequences present in 
other microbes could further expand this cross-reactive population, thus resulting in 
emergence of autoimmunity in genetically predisposed individuals (Kerkar et al., 2003). 
If this is the case, insignificant differences in prevalence of PBC between different 
countries such as UK and Spain may be the result of complex but significant differences 
of the immunogenetic background and exposure to distinct microbial mimics (such as 
MYCGO in Spain and E. coli in UK) (Vilagut et al., 1997, Butler et al., 1995).
These observations do not prove the role of mycobacteria as the cause of PBC but rather 
favour the concept that infectious agents can act as co-factors for the precipitation of an 
immune-mediated response (Baum, 1995, von Herrath, 2000, von Herrath et al., 2003). 
They also provide the impetus for extensive investigation of PDC-E2212-226- mimicking 
sequences of microbial origin that could serve as targets of PBC-specific cross-reactive 
responses, similar to what has been found for the mycobacterial hsp65 mimic.
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Lactobacilli and PBC
Chapter 4
4.1 BACKGROUND
The findings of the previous Chapter (see Chapter 3) suggested that the motif 
SxGDL[IL]AE shared by the immunodominant mitochondrial autoepitope on PDC-E2 
(PDC-E2212-226) and mycobacterial hsps is the focus of cross-reactive responses in patients 
with PBC. It was also found that among other microbial proteins this same motif is present 
only in p  galactosidase (lactase) of Lactobacillus delbrueckii (BGAL LACDE), subsp. 
bulgaricus. Of interest, the corresponding mimic of human PDC-E2212-226 in E. coli, 
(ECOLI PDC-E2231-245) which has been repeatedly suggested to be involved in the 
induction of human PDC-E2 autoimmunity, does not contain this motif (see Figure 4.1) 
(Shimoda et al., 1998, Shimoda et al., 2000, Van de Water et al., 2001).
In an attempt to investigate whether the microbial BGAL LACDE and ECOLI PDC-E2 
mimics are targets of antibody responses and cross-react with human PDC-E2, the 
homologous peptidyl sequences were constructed and tested by ELISA for reactivity and 
competitive cross-reactivity using sera from patients with PBC, - with or without PDC-E2 
autoantibodies -, pathological and normal controls.
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4.2 METHODS
4.2.1 Subjects
4.2.1.1 PBC patients
4.2.1.1.1 AMA positive PBC patients
Antibody responses to microbial/self mimics were tested in the group of 50 British patients 
with PBC enrolled in the study of mycobacterial/self cross-reactive responses (see Chapter 
3). Histology was compatible with PBC in all 30 cases in whom a biopsy had been 
performed; 7 of these were at stage I, 5 at stage II, 9 at stage III and 9 at stage IV. In the 
remaining 20 patients biopsy was not performed due to the early clinical stage or 
conversely, to the end stage of the disease. At the time of serum collection, 41 of the 50 
patients were symptomatic with a mean duration of disease of 47.2 months (range 1-179). 
Overall, 22 patients were classified as early stage or intermediate stage and 28 as advanced 
or end stage disease.
4.2.1.2 AMA negative PBC patients
Twenty-three patients with biopsy-proven PBC (20 female, 45.7 years, range 24-69) 
consistently negative for AMA by conventional IIFL, and for anti-PDC-E2 antibodies by 
ELISA and western blot, using as antigen purified PDC, were also studied. At the time of 
serum collection, 19 patients were symptomatic with a mean duration of disease of 32.1 
months (range 17-97); 7 were at stage II, 9 at stage III and 7 at stage IV.
4.2.1.3 Pathological controls
As pathological controls, 157 sera (all AMA negative) from patients with other liver and 
non-liver related disorders were tested including 41 patients with chronic HBV infection 
(37 female, 50.2±13 years), all HBV DNA positive; 52 patients with chronic HCV infection 
(48 female, 53 years±ll), all HCV RNA positive; 28 patients with autoimmune thyroid 
dysfunction (26 female, 47.2±15 years), all anti-thyroid peroxidase antibody positive; and 
36 patients with Crohn’s disease (34 female, 42±9).
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4.2.1.4 Normal controls
Thirty-three healthy volunteer members of staff (30 female, 49.2±9.2 years), all AMA 
negative, were tested as normal controls.
4.2.2 Detection o f AMA
AMA was retested by conventional IIFL (see 2.2.2.1), immunoblotting (see 2.22.2), and by 
ELISA (see 2.1.6.1).
4.2.3 Protein database search and analysis
Microbial mimics of human PDC-E2212-226 (excluding those of mycobacterial hsp65), 
containing the SxGDL[ILV]AE motif were identified by scanning the SWISSPROT protein 
database using the Advanced Proteinlnfo programme (see 2.2.1.1). The resulting 
similarities were further evaluated using the protein-protein sequence comparison ‘BLASTp 
2 sequences' programme (see 2.2.1.2.2) and compared with the previously described 
similarity shared by human PDC-E2212-226 and the corresponding ECOLI PDC-E2231-245 
mimic.
4.2.4 Peptide synthesis
Four 15-mer biotinylated peptides containing the homologous LACDE BGAL266-280 
(RDSEGDLVAEKLGPI), ECOLI PDC-E223i-245 (KVAAEQSLITVEGDK), human PDC- 
E2212-226 (KLSEGDLLAEIETDK) sequences and an irrelevant 15 aa control peptide were 
constructed (see 2.22.3).
4.2.5 ELISA
Antibody binding to the peptides was determined by ELISA (see 2.22.3). The final peptide 
concentration was 15pg/ml and the dilution of serum samples was 1/200 (see 2.22.3).
4.2.6 Inhibition studies
To investigate whether the simultaneous reactivity to LACDE BGAL266-280 and human 
PDC-E2 2 12-226 was due to cross-reactivity, competition ELISA was performed (see
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2.2.2.4.1), measuring residual anti-LACDE BGAL266-280 or anti-PDC-E2212-226 reactivity 
after pre-incubation respectively with LACDE BGAL266-280, PDC-E2212-226, PDC antigen, 
control peptide and control antigen (CYP2D6, see 2.1.6.1) as liquid phase competitors 
(final concentrations: 5, 10, 25, 50, 100, 250, 500, 1000 pg/ml). Inhibition of anti-ECOLI 
PDC-E2231-245 reactivity was measured under conditions similar to those described for 
LACDE BGAL266-280 (see 2.2.2A).
4.2.7Anti-peptide antibody affinity
The relative affinity of anti-peptide antibody binding (see 2.2.2.5) was tested in one serum 
reactive to LACDE BGAL266-280/ECOLI PDC-E2231-245/human PDC-E2212-226 and in 3 
LACDE BGAL266-280/ human PDC-E2212-226 double reactive sera .
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4.3 RESULTS
4.3.1 Protein database search and analysis
LACDE BGAL266-280 is the only non-hsp65 mycobacterial microbial sequence sharing the 
motif SxGDL[ILV]AE with human PDC-E2212-226. LACDE BGAL266-280 shares 8 aa in a 
row (7 identities) and has a total of 10/15 (67%) similarity with human PDC-E2212-226 
(Figure 4.1).
The corresponding B G A L 2 4 6 - 2 6 0  of Lactococcus lactis has 7/15 ( 47% )  similarity (2 
identities) with human PDC-E2 2 1 2 -2 2 6 ; the corresponding B G A L 2 6 6 - 2 8 0  of Lactococcus sakei 
has 5/15 ( 33% )  similarity (2 identities); and the Lactococcus acidophilus B G A L 2 6 8 - 2 8 2  
(EDViVGS^/LEQDVPL) has 7/15 ( 47% )  similarity (2 identities) (Figure 4 . 1) .
The corresponding ECOLI PDC-E2231-245 sequence (KK4AE0SL/TFEGDK), shares 11/15 
(73%) similarity (5 identities) with human PDC-E2212-226 (KLSEGDLL/1E/E7DK) 
(identities in b o l d ,  conservative substitutions in italic) (Figure 4 . 1) ,  while LACDE 
BGAL266-280 CKDSEGDLFAEKLGPI) and ECOLI PDC-E2231-245 sequence 
(ATVylAE^SL/rVEGDK) share 6/15 ( 40% )  similarity (1 identity).
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Species Protein Sequence aa position Identities Similarity (%)
E. co li K V A A E Q s L I T V E G D K (aa 231-245) 5 11/15(73%)
Human PDC-E2 K L S E G D L L A E I E T D K (aa 212-226)
L actobacillus d elbrueckii subsp. bulgaricus BGAL R D S E G D L V A E K L G P I (aa 266-280) 7 10/15 (67%)
L actococcus la c tis subsp. la c tis BGAL L Y D D E Q L I G E C H G F D (aa 246-260) 2 7/15 (47%)
Lactobacillus sa kei BGAL R D Q H Q I I L T A D L T S G (aa 266-280) 2 5/15(33%)
Lactobacillus acidophilus BGAL E D V N G s A I L E Q D V P L (aa 268-282) 2 7/15(47%)
FIGURE 4.1 Sequence alignment o f  the immunodominant autoepitope on human E2 subunit ofpyruvate dehydrogenase complex (PDC- 
E22n-226)> and mimics o f  E. coli PDC-2 and Lactobacillus f-galactosidase (BGAL) mimics. Amino acids in standard single letter code; 
Colon (:) and bold letters, Identical residues; Full stop, (.) and italic, Conservative substitutions; aa, amino acid
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4.3.2 ELISA
Percentages of anti-peptide reactivity in PBC patients, pathological and healthy controls are 
given in Table 4.1.
4.3.2.1 Single anti-peptide antibody reactivity
4.3.2.1.1 IgG class anti-peptide reactivity
IgG class antibody reactivity to the human PDC-E2 2 12-226 was found in 48 (96%) of 50 
AMA positive PBC patients (mean OD“sl/co"tro1 3.24±1.26), in 1 (4%) of 23 AMA negative 
PBC, 5 (3%) of 157 pathological controls, among which were 1 HBV infected woman, 3 
HCV infected patients (2 female) and 1 woman with Crohn’s disease (p<0.05 for all), all 
AMA negative by IIFL, ELISA or Western blot. None of the 33 healthy controls reacted 
with human PDC-E2 2 12-226*
IgG class antibody reactivity to LACDE BGAL266-280 was found in 15 (30%) AMA positive 
PBC patients (mean OD,est/con,ro' 3.13±1.18), in 1 (4%, p=0.03) AMA negative PBC, 19 (12 
%, p-0.006) pathological controls (mean ODtest/control 3.07±1.1) including 3 with HBV 
(/?=0.01); 5 with HCV (/t=0.09), 2 with autoimmune thyroid disease (p=0.04), 6 with 
Crohn’s disease (17%, p=0.24), and in 3 of the normal controls (p=0.15).
IgG class antibody reactivity to ECOLI PDC-E2231-245 was present in 2 (4%) AMA positive 
PBC patients, in none AMA negative PBC and in 1 (0.4%) of the controls - an AMA 
negative chronic HCV infected woman (p>0.05 for all).
4.3.2.1.2 IgG subclass anti-peptide reactivity
Among the 48 anti-human PDC-E22i2-226 reactive AMA positive PBC patients, 42 (87.5%) 
had IgG antibody reactivity predominantly of the IgG3 subclass including all 15 cases 
reacting with LACDE BGAL266-280* Anti-PDC-E2212-226 reactivity of the AMA negative 
PBC case was of the IgG 1 and IgG3 subclass.
Among the 15 LACDE BGAL266-280 reactive AMA positive PBC cases, all but one had IgG 
antibody reactivity predominantly of the IgG3 subclass; the single AMA negative PBC case 
with reactivity to LACDE BGAL266-280 was of the IgG 1,3,4 subclasses.
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Among the 19 pathological controls and the 3 healthy subjects reactive with LACDE 
BGAL266-280, antibody binding was of the IgG4 (19 cases) or the IgG2 subclass (2 cases) 
and the IgG 1,2,3 in one case (an HCV infected woman with IgG3 anti-PDC-E2 2 12-226 
reactivity).
Overall, 14 (28%) of the 50 AMA positive PBC cases had IgG3 anti-LACDE BGAL266-280 
antibody reactivity compared to none of the AMA negative, 1 (0.6%,/k0.0001) of the 157 
pathological controls and none of the 33 healthy controls (p<0.05 for all) (Table 4.1). 
Among the 2 ECOLI PDC-E2231-246 reactive AMA positive PBC cases, anti-ECOLI PDC- 
E2231-246 antibody reactivity was of the IgG 1,3 isotype in one and IgG 1,2,3,4 in the other.
4.3.2.2 Double anti-peptide antibody reactivity
IgG class antibody reactivity to the LACDE BGAL266-280/ PDC-E2212-226 pair was found in 
15 (30%) PBC patients (7 at early or intermediate stage and 8 at advanced or end stage 
disease), none in anti-PDC-E2 negative PBC, 1 (1%) amongst pathological controls (a 53- 
year-old AMA negative HCV infected woman), and in none of the healthy controls (p<0.01 
for all).
PBC patients with double LACDE BGAL266-280/PDC-E2 2 12-226 tended to be younger 
compared to unreactive patients (50.6±2.8 vs 56.5±1.95,p=0.065).
There was no significant correlation between double reactivity and clinical stage or other 
clinical and experimental data.
Double ECOLI PDC-E2231 .2 4 5 /  PDC-E2212-226 reactivity was found in one AMA positive 
patient, reactive also with LACDE BGAL266-280-
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Table 4.1 Antibody reactivity to human pyruvate dehydrogenase complex E2 subunit (PDC-E2)212-226, and its microbial mimics E. coli (ECOLI) 
PDC-E2231-245, and ft galactosidase (BGAL)266-280 of Lactobacillus delbrueckii (LACDE) expressed in absolute numbers and percentages (%), in 
50 anti-mitochondrial antibody (AMA) positive patients with PBC, 23 AMA negative PBC patients, 157 pathological controls including 41 
with chronic hepatitis B virus (HBV) infection, 52 with chronic hepatitis C virus (HCV) infection, 28 with autoimmune thyroiditis, 36 patients 
with Crohn’s disease and 33 healthy controls
Single Reactivity
PDC-E2212-226 ECOLI PDC-E2231-245 LACDE BGAL2 66-280
Total IgG IgG3 Total IgG Total IgG IgG3
AMA positive PBC (n=50) 48/50 (96%) 42/50(84%) 2f/50 (4%) 15/50 (30%) 14/50(28%)
AMA negative PBC (n=23) 1/23 (4%)§§ 0§§ 0* 1/23(4%)' O'
Pathological controls (n=157) 5/157 (3%)§§ 1/157 (1%)§§ 1 (1%)* 19/157(12%)" 1/157(1%)§§
Chronic HBV 1/41 (2%)§§ 0§§ 0* 3/41 (7%)' 0§
Chronic HCV 3/52 (6%)§§ 1/52 (2%)§§ 0* 5/52 (10%)* 1/52 (2%)§
Autoimmune thyroiditis 0§§ 0§§ 0* 2/28 (7%)' 0 "
Crohn’s disease 1/36 (3%)§§ 0§§ 0* 6/36 (17%)* 0 "
Healthy Controls (n=33) 0§§ 0§§ 0* 3/33 (9%)* 0"
Comparisons of cmti-peptide reactivity are between AMA positive PBC and AMA negative PBC, pathological or healthy control groups; * p>0.05; % 
p<0.05; p<0.01; §, p<0.01; §§, p<0.001; f, one case hadIgGl,3 and one IgGl,2,3,4
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FIGURE 4.2 Distribution o f  IgG subclass antibody binding against anti-fi galactosidase 
(BGAL)266-280 o f Lactobacillus delbrueckii (LACDE) in 8 representative PBC cases (A) and 
8 controls (B) including 2 normal (N) subjects, 1 with autoimmune thyroid disease (AITD), 
2 with Crohn’s disease (CD), 2 with hepatitis C virus infection (HCV) and one with 
hepatitis B virus (HBV) infection. Anti-LACDE BGAL266-28O antibody reactivity is expressed 
as a percentage o f IgG subclass (see 2.2.2.3)
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4.3.3 Comparison o f  antibody binding to LACDE and ECOLI mimics
Of the 15/15 AMA positive sera reacting with LACDE BGAL266-280 at a dilution of 1/200, 
13/15 (87%) reacted at 1/500 and 10/15 (66%) at 1/1 O'3 dilutions. At 1/10"4 dilution, there 
were still 3/15 (20%) sera which were reactive to LACDE BGAL266-280 (Table 4.2). Of the 
2 PBC sera reacting with ECOLI PDC-E2231-245 at 1/200, none was reactive at a dilution of 
1/500.
Table 4.2 Antibody reactivity against Lactobacillus delbrueckii (LACDE) /? galactosidase 
(BGAL)266-280 and E. coli (ECOLI) ECOLI pyruvate dehydrogenase complex E2 subunit 
(PDC-E2231-245) in serial dilutions of serum samples of patients with primary biliary 
cirrhosis. At 1/200 dilution reactivity to LACDE BGAL266-280 and ECOLI PDC-E2231-245 
was present in 15 and 2 cases, respectively
Total number o f  reactive cases
Serum sample 
dilution
1/200 1/500 (%) 1/103 (%) 1/104 (%)
LACDE BGAL266-280 15 13/15 (87%) 10/15 (66%) 3/15 (20%)
ECOLI PDC“E2231 -245 2 0 0 0
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4.3.4 Inhibition studies
Inhibition results of anti-peptide binding by pre-incubation with relevant and control 
peptides and antigens are given in detail in Table 4.3. A representative case is presented in 
Figure 4. 3.
IgG3 subclass antibody binding to LACDE BGAL266-280 was inhibited by 67-79.6% after 
pre-incubation with the LACDE BGAL266-280; by 62-75.7% after pre-incubation with 
human PDC-E2212-226 and by 65-78.2% after pre-incubation with PDC, in all 4 cases tested 
(Table 4.3). Insignificant inhibition was observed by pre-incubation with the irrelevant 
control peptide and antigen (Figure 4. 3A) (see 2.2.2.4).
Antibody binding to human PDC-E2212-226 was also significantly inhibited after pre­
incubation with the PDC-E2212-226, LACDE BGAL266-280 and the PDC antigen (Table 4.3 
and Figure 4.3B).
Inhibition studies of the human PDC-E2212-226/ECOLIPDC-E2231-245/LACDE BGAL266-280 
reactive serum revealed inability of ECOLI PDC-E2231-245 to inhibit significantly the 
antibody binding to human PDC-E2212-226 while the reverse was possible (Table 4.3 C-D). 
ECOLI PDC-E2231-245 and LACDE BGAL266-280 were unable to inhibit reactivity to each 
other (maximum inhibition <20%).
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Table 4.3 A-B. Percentage inhibition of anti-LACDE BGAL266-28o (A) and anti-human PDC-E22i2-226 (B) antibody reactivity by pre-incubation with relevant 
and control peptides and antigens in four LACDE BGAL266-28o/PDC-E22i2.226 double reactive PBC cases; C-D. Inhibition of anti-ECOLI PDC-E2 231.245 (C) and 
anti-human PDC-E2212-226 (D) antibody reactivity by pre-incubation with relevant mimics and control peptides and antigens
Case Maximum Inhibition %
A
LACDE BGAL266.280 Human PDC-E2212-226 PDC antigen Control antigen Control peptide
1 75.8 75.7 73.1 11.7 9.3
2 67 65.1 66.8 7.3 8.2
3 77.7 62 65 10.4 6.2
4* 79.6 73.5 78.2 7.3 5.2
B
Human PDC-E2212-226 LACDE BGAL266-280 PDC antigen Control antigen Control peptide
1 72.8 75 75.9 7.2 3.1
2 81.5 83.2 81.2 8 7.1
3 75 78.3 73.4 10.1 6.3
4* 78.9 67 79.8 7.6 5.7
C
ECOLI PDC-E2231-245 Human PDC-E2212-226 LACDE BGAL266-280 PDC antigen Control antigen Control peptide
63.2 81.1 34.2 86.3 10.1 9.2
D
Human PDC-E2212-226 ECOLI P DC*E2231.245 LACDE BGAL266-280 PDC antigen Control antigen Control peptide
73.1 23.4 79.2 78.4 12.3 11.4
*See Figure 4.3 A-B; LACDE, Lactobacillus delbrueckii; BGAL, j3galactosidase; PDC-E2, pyruvate dehydrogenase complex E2; ECOLI, E. coli
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FIGURE 4. 3 Inhibition o f  antibody (ab) binding against LACDE BGAL266-28O (A) or human PDC-E2212-226 (B) o f  a representative serum sample 
by pre-incubation with LACDE BGAL266-28O (♦), human PDC-E2212-226 (A), PDC antigen (■), control peptide (%) and control protein (o), in 
the presence o f competitor peptide at different concentrations, 0; 5; 10; 15; 25; 50; LOO; 250; 500; 1000 pg/ml. LACDE, Lactobacillus 
delbrueckii; BGAL, p  galactosidase (lactase); PDC, pyruvate dehydrogenase complex; ab, antibody
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4.3,5 Affinity o f  anti-peptide antibody
The relative affinity index (rAI) representing the concentration of the chaotropic reagent 
(urea) that elutes 50% of the anti-peptide antibody binding {see 222 .5)  for the one case 
reactive with human PDC-E22 12-226, ECOLI PDC-E2 231-245,LACDE BGAL266-28o mimics 
and three LACDE BGAL266-28o/human PDC-E22i2.226 double reactive cases is illustrated in 
Figure 4.4. In each case, higher antibody rAI was found for LACDE BGAL266-280 compared 
to human PDC-E22i2.226- In the multiple-reactive case, the lowest antibody rAI was that to 
ECOLI PDC-E223j-245 (Figure 4.4).
Human PDC-E2/ECOLIPDC-E2/LACDE BGAL 
mutiple reactive PBC case
Human PDC-E2/LACDE BGAL 
Double reactive PBC cases (n=3)
rAI
ECOLI
PDC-E223i_245
Human 
PDC-E22! 2.226
LACDE
BGAL266.28o
Human
PDC-E2212-226
LACDE
BGAL266_280
Figure 4.4 Relative affinity indices (rAI) o f anti-peptide antibody binding in a multiple 
human PDC-E2 212-22^ ECOLI PDC-E2231-245/  LACDE BGAL26&280 reactive case (leftpanel) 
and three double human PDC-E2212-226/LA CDE BGAL266-280 reactive cases (mean+SD). 
Each point is the average o f  3 observations (see 2.2.2.5). ECOLI, E. coli; PDC-E2, 
pyruvate dehydrogenase complex E2 subunit; LACDE, Lactobacillus delbrueckii, BGAL, f3 
galactosidase
120
92
Chapter 4
4.4 DISCUSSION
This section has found that almost one third of patients with primary biliary cirrhosis have 
an IgG3 subclass antibody response against a lactobacillus sequence that shares the motif 
SxGDL[IL]AE with the major mitochondrial PDC-E2212-226 autoepitope. Reactivity is 
virtually absent to ECOLI PDC-E2231-245, a human PDC-E2212-226 mimic which does not 
contain the SxGDL[IL]AE motif (Burroughs et a l, 1992, Shimoda et a l, 1998). IgG3 anti- 
LACDE BGAL266-280 antibody reactivity is highly PBC specific, being found only in one 
case of a large number of pathological and healthy controls.
Not only is the IgG3 anti-LACDE BGAL266-280/PDC-E2212-226 antibody reactivity specific 
for PBC but it is also cross-reactive, since its binding to the microbial sequence LACDE 
BGAL266-280 is inhibited by pre-incubation with human PDC-E2 2 12-226 and vice versa. 
Importantly, the binding to the LACDE sequence is also inhibited by the purified PDC 
mitochondrial antigen, demonstrating that the cross-reactive microbial/self recognition 
targets the naturally occurring autoantigen (see Table 4.3 and Figure 4.3). These findings 
are in sharp contrast to those obtained for the ECOLI P D C -E 2231-245, which has proved a 
poor inhibitor of anti-human PDC-E2212-226 reactivity (see Table 4.3).
Anti-LACDE BGAL266-280 antibody reactivity was present, though significantly less 
frequently, in conditions other than PBC: remarkably this was always of the IgG4 and/or 
IgG2 subclasses and was never associated with reactivity to the self-epitope PDC-E2212-226. 
This indicates that only in the case of PBC do the anti-BGAL antibodies also recognise a 
conformation of a relevant sequence that matches that of the PDC-E2 peptide.
It is unlikely that these findings reflect an epiphenomenon, restricted to IgG3 antibodies, 
arising from LACDE BGAL266-280/PDC-E2212-226 amino acid similarity. If this were the 
case then all anti-PDC-E2212-226 positive cases would be expected to react with LACDE 
BGAL266-280. Moreover, there would then be expected to be the same frequency of non­
cross-reactive, non-IgG3, anti-LACDE BGAL266-280 reactivity in PBC subjects as observed 
in controls. Conversely, the anti- LACDE BGAL266-280 antibody present in controls would 
be expected to react with the PDC-E2212-226 mimic. But this is not the case. Further support 
for the potential biological significance of the observed anti-LACDE BGAL266-280 reactivity 
has been provided by the fact that anti-LACDE BGAL266-280 reactivity was significantly
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more frequent and tended to persist even in a 1/104 dilution compared to that against 
ECOLI PDC-E2 231-245 which disappeared at 1/500 serum dilution (see Table 4.2). The fact 
that anti-PDC-E2 antibody negative patients with PBC do not have anti-LACDE BGAL266- 
280 antibodies strengthens the significance of the observed reactivity and its potential 
relation to the appearance of anti-PDC-E2 antibodies. Notably, IgG3 anti-BGAL266-280 
LACDE reactivity was present in AMA positive patients with PBC regardless of disease 
severity, equally present at early as well as at late stages of its natural history.
What the link is between the PBC specificity of a microbe-self cross-reactive response and 
its belonging to the IgG3 isotype remains to be clarified. Lactobacillus delbrueckii subsp. 
bulgaricus is essential to starter cultures and for yoghurt production (Borchers et al., 2002). 
Of potential relevance is the fact that whilst there are Lactobacillus strains able to promote 
peripheral tolerance to self proteins, there exist others that, depending on the 
immunological state of the host, can induce T-cells to overproduce IFN-y (Solis Pereyra 
and Lemonnier, 1991, Solis-Pereyra et al., 1997, Maassen et al., 2000, Borchers et al., 
2002, Perdigon et al., 2002, Christensen et al., 2002, Aattour et al., 2002, Maassen et al., 
2003). This cytokine is known to promote production of antibodies of the IgG3 isotype and 
to limit that of IgG4 antibodies, through its inhibitory activity of Th2 cell programmes 
(Stevens et a l , 1988, Snapper and Mond, 1993, Snapper et al., 1997). Of interest in terms 
of pathogenicity is the singular ability of IgG3 antibodies to recruit the major effectors of 
tissue damage, such as complement and Fc receptorbearing cells involved in antibody- 
dependent cell-mediated cytotoxicity (ADCC) (Anderson and Looney, 1987, Wiener et a l, 
1988, Jefferis, 1990). Thus, in theory, IgG3 anti-BGAL266-280 LACDE antibodies may 
engage effectors of damage against target cells over-expressing PDC-E22i2.226, - or an as- 
yet unidentified mimic thereof - the physically exposed peptidyl sequence representing the 
dominant AMA epitope. The fact that the antibody affinity to the LACDE BGAL sequence 
was higher than that to PDC-E2 of human or E. coli origin suggests that the response to the 
lactobacillus mimic may precede that to PDC-E2 (Figure 4.4).
In conclusion, the present findings indicate a clear, disease-specific occurrence of IgG3 
antibodies cross-reacting against a peptide of BGAL LACDE and the dominant epitope of 
PDC-E2 in a significant sub-set of PBC patients. Since BGAL LACDE is a major enzyme 
of an organism widely used in food production, its possible role as an environmental trigger
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in the pathogenesis of PBC must now seriously be considered. However, whether LACDE 
containing fermented products accelerate PBC specific autoimmunity in genetically 
susceptible individuals or in contrast induce tolerance and hence offer an approach to 
therapeutic interventions in patients with PBC, remains to be clarified (Faria and Weiner, 
1999, Borchers et a l , 2002, Christensen et al., 2002, Maassen et al., 2003). Nevertheless, 
these findings provide the stimulus for continuous search for other microbial mimics 
originated from infectious agents, particularly those epidemiologically linked to PBC that 
could serve as targets of cross-reactive immune responses.
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E. coli and PBC
Chapter 5
5.1 BACKGROUND
The mechanism by which PDC-E2212-226, the immunodominant mitochondrial 
autoepitope, becomes the focus of PBC-specific anti-mitochondrial immune responses 
remains obscure (Baum, 1995, Gershwin et a l, 2000).
Several infectious agents have been postulated to trigger AMA production, and common 
bacteria such as mycobacteria and Lactobacilli may fall into this category, as has been 
indicated by the results obtained in Chapter 3 & 4 of the present Thesis (Van de Water 
et al., 2001, Baum, 1995). There is some experimental and epidemiological evidence to 
suggest, however, that recurrent urinary tract infection (UTI) caused by Escherichia coli 
(ECOLI) may also be pathogenetically linked to PBC (Stemerowicz et al., 1988, Hopf et 
a l, 1989, Burroughs et al., 1992, Butler et al., 1995a, Butler et a l, 1995b, Shimoda et 
al., 1998, Shimoda et al., 2000, Parikh-Patel et al., 2001, Butler et al., 1993). Hopf et al. 
(1989) reported a high incidence of rough form mutants of ECOLI, in faecal samples 
from patients with PBC. In 52% of patients with recurrent UTI, Butler et al. (1995a) 
found antibodies reacting with PDC-E2. Conversely, patients with PBC reportedly have 
a higher incidence of recurrent UTI (Butler et al., 1993, Butler et al., 1995b).
The fact that PDC-E2 proteins from a number of microbial OADC proteins and 
in particular those of ECOLI demonstrate PBC-specific antibody and T-cell cross­
reactivity with human PDC-E2, lends support to ECOLI infection having a role in the 
induction of AMA, through a mechanism of molecular mimicry (Fussey et a l,  1991, 
Baum, 1995, Shimoda et al., 1998, Shimoda et al., 2000). Others have challenged this 
view arguing that cross-reactive immunity can readily be predicted, taking into account 
the highly conserved nature of PDC-E2 among species, and in particular of the inner 
lipoyl domain (Van de Water et al., 2001).
If microbial mimicry is implicated in breaking immunological tolerance to PDC-E2, 
there is the alternative possibility that short microbial sequences totally unrelated to 
OADC but still good mimics of the immunodominant PDC-E2 epitope are involved. 
This has been proven to be the case for the mycobacterial hsp659o-io4 sequence (Chapter 
3) and p galactosidase (lactase) of Lactobacillus delbrueckii (Chapter 4) and may well 
be true for other non-OADC ECOLI or other microbial mimics of the human PDC- 
E 2 2 12-226.
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Interrogating protein databases, sequences with high degree of similarity to PDC-E2212- 
226 were found (see below) in proteins of ECOLI, Helicobacter pylori (HELPY), 
Pseudomonas aerigunosa (PSEAE), human CMV (HCMV), and Haemophilus 
influenzae (HAEIN). Intriguingly, these sequences had a greater similarity to human 
PDC-E2212-226 than did ECOLI PDC-E2 itself (see below). The present study 
investigated whether these sequences are targets of antibody responses and PDC-E2212- 
226 cross-reactive immunity both at peptide and full protein level in 55 AMA-positive 
PBC and 23 AMA-negative PBC patients and compared the results with those of a large 
number of normal and pathological controls including women with recurrent UTI and 
without liver disease.
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5.2 METHODS
5.2.1 Subjects
5.2.1.1 PBC patients
Serum samples were obtained from 55 patients with PBC (median age 56±13 years; 46 
female), all AMA-positive (1/40 -  1/10480), median duration of disease 38 months 
(range 1-184) attending the out-patient clinic of Liver Transplantation and Hepatobiliary 
Medicine Unit, Royal Free Hospital. Demographic, biochemical, immunological and 
clinical characteristics of these patients, are given in detail in Chapters 3 & 4. Twenty- 
nine of them underwent screening tests for significant bacteruria (see below), and 
recorded data were available, 19 being positive and 10 negative for recurrent UTI. In the 
remaining 26 patients urine tests were not performed.
Twenty-three women with PBC consistently negative for AMA by conventional IIFL, 
and for anti-PDC-E2 antibodies by ELISA and western blot were also studied (see 
4.2.1.2).
5.2.1.2 Pathological and normal controls
Pathological controls included 170 patients with other liver (27 chronic HBV infection; 
42 chronic HCV infection; 17 alcoholic liver disease; 15 AIH-1 and 12 with AIH-2) and 
non-liver disorders (38 autoimmune thyroid disease; 10 polyomyositis; 9 systemic lupus 
erythematosus). Twenty women (median age 53 years, range 24-85) attending a UTI 
out-patient clinic were also tested; these subjects were part of a larger group of 50 
women and were included in the present study on the basis that unthawed aliquots of 
serum samples were available from them (Burroughs et al., 1984, Butler et a l,  1993, 
Butler et a l, 1995a, Butler et al., 1995b). All had a history of long-standing recurrent 
episodes of significant bacteruria and all were receiving prophylactic antibiotics at the 
time the serum was taken. Significant bacteruria was defined as the presence of 105 
organisms per ml or more growing in pure culture, regardless of the presence of 
symptoms or pyuria (Burroughs et a l,  1984, Butler et al., 1993, Butler et al., 1995a, 
Butler et al., 1995b). All but two women were infected by ECOLI (Burroughs et al., 
1984). None of the patients had clinical or biochemical evidence of liver disease. Ten of 
these were diagnosed as AMA-positive by immunoblot, showing OADC (M2) specific
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bands, and/or ELISA, though not by IIFL (see, 2.1.2, 2.1.6 and 2.2.2.2). The prevalence 
of AMA seropositivity in this group of women was similar to that (52%) previously 
reported by Butler et al. (1993, 1995a).
Twenty-eight healthy, volunteer members of staff (median age 33 years, range 22-68, 23 
female), were tested as normal controls.
5.2.2 Detection o f AMA
AMA was retested by conventional IIFL (see 2.2.2.1), immunoblotting (see 22.2.2), and 
by ELISA (see 2.1.6.1).
5.2.3 Protein database search and analysis
Microbial homologues to human PDC-E2212-226 were identified by scanning the 
SwissProt protein database using the Proteinlnfo programme (see 2.2.1.1). The resulting 
sequences were further evaluated using the PSI-BLAST programme (see 2.2.1.2.1). Ten 
non-PDC-E2 related microbial sequences giving the highest percentage of homology 
and the best score were synthesized.
5.2.4 Peptide synthesis
Eleven 15-mer biotinylated peptides containing the relevant human PDC-E2 and 
microbial sequences and an irrelevant 15 aa control peptide (see 2.2.23) were 
constructed.
5.2.5 ELISA
Antibody binding to the peptides was determined by ELISA (see 2.2.22). The final 
peptide concentration was 15pg/ml and the dilution of serum samples was 1/200.
5.2.6 Inhibition studies
To investigate whether the simultaneous reactivity to ECOLI maltose E (MALE)95-io9 
and human PDC-E2 2 12-226 was due to cross-reactivity, competition ELISA were 
performed (see 2.2.2.4.1), measuring residual anti-ECOLI MALE95-109 or anti-PDC- 
E2212-226 reactivity after incubation respectively with ECOLI MALE95-109, PDC-E2212-226, 
purified MALE ECOLI protein (see 2.1.4), PDC antigen (see 2.1.2), control peptide and 
antigen (CYP2D6, see 2.1.2) as liquid phase competitors. Inhibition of anti-ECOLI
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ATP-dependent helicase hrpA (HRPA) 153.1 & reactivity was measured under conditions 
similar to those described for ECOLI MALE95.109.
5.2.7Anti-peptide antibody affinity
The relative affinity of antibody binding (see 2 2 2 .5 )  to ECOLI MALE95.109 and PDC- 
E2212-226 was carried out in 2  ECOLI MALE95-109/PDC-E2212-226 double reactive cases.
5.2.8 Three-dimensional modelling
Three-dimensional modelling of the ECOLI MALE95.109 was carried out by analysing 
the structure of MALE ECOLI with the Cn3D visualization tool (see 2.1.2.3).
5.3 RESULTS
5.3.1 Protein database search and analysis
The 10 non-0ADC-related microbial sequences sharing extensive homology with 
human PDC-E2212-226 are shown in Figure 5.1. Six are from ECOLI proteins, and one 
each from HELPY, PSEAE, HCMV, and HAEIN. ClpX is the ATP-binding subunit of 
the caseinolytic protease (Clp) complex, the ClpP, proteolytic, subunit of which is 
autoantibody target in PBC (Wang et a l,  1997, Singh et al., 2000, Mayo et al., 2000). 
ECOLI MALE is a soluble periplasmic protein and therefore potentially accessible to 
antibody (Boos and Shuman, 1998). HELPY UREB is a known antibody target in 
HELPY infection and PSEAE DCDA355.363 is a CD8 epitope cross-recognised with 
PDC-E2212-220 (Futagami et al., 1998, Kita et al., 2002). Human PDC-E2212-226 
(KLSEGDLLAE/E7DK) shares 11/15 (73%) similarity (5 identities) with the 
corresponding ECOLI PDC-E2 2 3 1-245 sequence (KF/4AEQSL/TFEGDK, identities in 
bold, conservative substitutions in italic). According to the PSI-BLAST scoring system 
(see 2.2.1.2.1), ECOLI CLPX280-294 ranks first in homology with human PDC-E2212-226, 
among the non-OADC-related sequences of all species in the protein database, while all 
other 9 microbial mimics rank in a better position than does the ECOLI PDC-E2231-245.
To investigate whether this over-representation of ECOLI homologues is 
accidental, due to the large number of ECOLI proteins in the database, or is biologically 
meaningful, a search for ECOLI mimics of CYP2D6257-27i,the immunodominant epitope
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of LKM1 in AIH-2 has been performed (Alvarez et al., 1999, Manns et al., 1991). 
CYP2D6257-27i was selected in view of its analogy with PDC-E2 in relation to PBC: 1) it 
is the major autoantigen of an autoimmune liver disease (Alvarez et al., 1999, Manns et 
al., 1991); 2) an intracellular enzyme exposed on a cell membrane (Robin et al., 1997, 
Muratori et al., 2000, Sugimura et al., 2002); 3) LKM-1 antibodies are able to inhibit 
the enzymatic activity of CYP2D6 (Manns et al., 1990, Manns and Obermayer-Straub, 
1997, Kerkar et al., 2003); 4) molecular mimicry has been proposed to account for 
immunological features of AIH-2 (Manns et al., 1991).
In the database no ECOLI proteins were found to share 6-mers in common with 
CYP2 D6257-271; a 15-mer from maltodextrin phosphorylase shared 40% identity.
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Sequence aa position ID Protein species Identities Similarity (%)
K N A E 0 S L  /  T V E G  D K (231-245) PDC-E2 Pyruvate dehydrogenase complex-E2 E.coli 5 11/15(73)
K L S  E G D L L A E I E T D K (212-226) PDC-E2 Pyruvate dehydrogenase complex-E2 Human
K A S E G E L L A Q V E P E D (280-294) CLPX ATP-dependent clp X E.coli 8 14/15(93)
L  M T  D  G I L L A E I Q  Q D R (153-167) HRPA ATP-dependent helicase hrpA E.coli 7 12/15(80)
G Y A g S G L L A E I T P  D K (95-109) MALE Periplasmic maltose-binding protein E.coli 7 11/15(73)
D A A V E D L L A E  F S Q P  K (605-619) FADP Fatty acid oxidation complex alpha E.coli 6 9/15 (60)
L A T L D D L L A E I G L G N (517-531) SPOT (P)ppGpp synthetase II E.coli 6 9/15 (60)
G Q A  M F D L L A E Y E K V G (81-95) NARW Nitrate reductase 2 E.coli 6 8/15(53)
R L G D T D L I A E F E H D Y (22-36) UREB Urease beta subunit Helicobacter pylori 7 13/15(87)
A L A E G D L L A V R S A G A (355-369) DCDA Diaminopimelate decarboxylase Pseudomonas aeruginosa 7 9/15 (60)
V T  P Y F D L L  A E I M A R S (663-677) V120 Capsid assembly protein UL47 Human cytomegalovirus 5 10/15 (67)
Q N S  E G D L L E L Y C G Y G (205-219) TRMA tRNA (uracil-5-)-methyltranferase Haemophilus influenzae 6 8/15(53)
Figure 5. 1. Sequence alignment between human E2 subunit o f  human pyruvate dehydrogenase complex (PDC-E2)212-226, and microbial mimics. 
Amino acids in standard single-letter code. Identities in bold; Conservative substitutions in italic; aa, amino acid; ID, identification code
131
Chapter 5
5.3.2 ELISA
Anti-peptide antibody binding details for patients with PBC, pathological and healthy 
controls are given in Table 5.1 A-B, 5. 2 and 5.3.
5.3.2.1 Single anti-peptide antibody reactivity
Reactivity to human PDC-E2212-226 was found in 52 (94.5%) of 55 AMA-positive PBC 
patients, in 1 (4%) of 23 AMA-negative PBC, in 16 (8.4%) of 190 pathological controls, 
among whom there were 10 women with recurrent UTI, all but one positive for AMA by 
ELISA and/or immunoblot; 1 HBV infected, 52 year old, male subject (AMA-negative); 
2 HCV infected patients (a 67 year old female, anti-PDC-E2 positive by immunoblotting 
with a liver histology not compatible with PBC and a 37 year old male subject AMA- 
negative); 2 women (42 and 76 year old) with autoimmune thyroiditis (both AMA- 
negative); and a 36 year old female with SLE (high-titre AMA-positive by IFL with 
normal liver function tests) without history of liver disease. Among the 28 healthy 
controls, 1 (3.6%) reacted with PDC-E2212-226 [a 62 year old male, AMA-positive at 
low-titre (1/40) by IFL with repeatedly normal liver function tests and without clinical 
signs of liver disease].
Reactivity to at least one of the 10 PDC-E2212-226 microbial mimics was found in 39 
(70.9%) AMA-positive PBC patients (among whom 3 did not react with any of the 6 
ECOLI peptides); in 2 (9%) AMA-negative PBC patients (p<0.0001) (one reacted with 
ECOLI SPOT517-531 and one with ECOLI HRPA153.167), in 28 (14.7%) of the 
pathological controls including 11 (55%, p=0.2) with recurrent UTI; 2 with HBV; 5 
with HCV; 5 with autoimmune thyroiditis; 1 with polyomyositis, 1 with SLE, 2 with 
AIH-1; and 1 with AIH-2, and 2 normal controls (p<0.05, for all).
Among the 3 PBC patients non reactive to PDC-E2212-226, one reacted with ECOLI 
SPOT517-531 alone, one with ECOLI SPOT517.531 and ECOLI HRPA153-167, and one with 
ECOLI MALE95.109 and ECOLI FADP605-6i9.
5.3.2.2 Double anti-peptide antibody reactivity
Double reactivity to at least one PDC-E2212-226/microbial pair was found in 36 (65.4%) 
AMA-positive PBC patients, 1 (4%) AMA-negative PBC (p<0.0001) and in 13 (6.8%,
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p<0.01) pathological controls, 9 with recurrent UTI, 1 with HCV, 2 with autoimmune 
thyroiditis, 1 with SLE, and in one healthy control (p<0.01).
Among the 36 PBC cases reacting with at least one PDC-E2/microbial pair, 33 (91.7%) 
were reactive with at least one ECOLI peptide among which 3 (9.1 %) were reactive 
with ClpX28o-294; 15 (45.5%) with HRPA153.167; 16 (48.5%) with MALE95.109; 11 
(33.3%) with FADP6o5-6 i9; 1 0  (30.3%) with SPOT517-531 and 6 (18.2%) with NARW8i.95. 
Other reactivities jointly with PDC-E2212-226 included 1 (3%) with HEPLY UREB22-36; 2 
(6%) with PSEAE DCDA355-369; 2 (6%) with HCMV V120663-677; and 3 (9.1%) with 
HAEIN TRMA205-219.
Double reactivity to at least one PDC-E2212-226/ECOLI pair was found in 17 of 19 
(89.5%) PBC patients with recurrent UTI, in 2 of 10 (20%) PBC patients with no history 
of recurrent UTI (p<0.01 vs PBC with recurrent UTI) and in 14 of 26 (53.8%) PBC 
patients with no urine tests (p=0.01 vs PBC with recurrent UTI). Of the 9 UTI patients 
without PBC who reacted with human PDC-E2212-226, all reacted with at least one 
ECOLI peptide, 8 were AMA-positive by ELISA and/or immunoblot. There was no 
significant correlation between double reactivity and other experimental and clinical 
data.
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Table 5.1A Antibody binding to human PDC-E22i2-226 and ECOLI mimics in 55 
AMA-positive PBC patients
PDC-E2212-226
human
CLPX HRPA MALE
ECOLI
FADP SPOT NARW * Recurrent
UTI
1 3.7 neg 3.4 2.7 neg 2.1 neg 3 pos
2 7.1 neg 3.4 6.8 2.7 neg neg 3 pos
3 4.3 neg neg 5.3 neg neg neg 1 pos
4 2 neg 2.3 3.2 2.3 neg neg 3 pos
5 2.3 neg neg 2.3 neg neg neg 1 pos
6 4.3 neg 2 neg neg 3.4 neg 2 pos
7 4 neg neg neg 2.7 neg 2 2 pos
8 3 neg 2 2.1 neg neg 2.1 3 pos
9 2 neg 3.4 neg neg neg 2.5 2 pos
10 5.6 neg neg 2 neg 3.9 neg 2 pos
11 2.3 neg neg neg neg neg neg 0 pos
12 3 neg 3.4 neg neg 2.3 neg 2 pos
13 2.1 3.6 2 2.5 2.6 neg neg 4 pos
14 2 neg neg neg 2.3 4.3 neg 2 pos
15 2.7 2.3 neg 3.2 neg neg 3.4 3 pos
16 neg neg neg neg neg 2.5 neg 1 pos
17 4.6 neg neg 2.3 neg neg neg 1 pos
18 3.4 neg 3.4 neg 2.9 2.7 2.3 4 pos
19 6.7 neg 5.6 neg 3.5 6 neg 3 pos
20 4.9 neg neg neg neg neg neg 0 neg
21 2.8 neg neg neg neg neg neg 0 neg
22 2.2 neg neg 2.2 neg neg neg 1 neg
23 2 neg neg neg neg neg neg 0 neg
24 2 neg neg neg neg neg neg 0 neg
25 2.9 neg neg neg neg neg neg 0 neg
26 4 neg neg neg neg neg neg 0 neg
27 5.6 neg neg neg 2.3 neg neg 1 neg
28 2.3 neg neg neg neg neg neg 0 neg
29 7.1 neg neg neg neg neg neg 0 neg
30 2.1 neg neg neg neg 2 neg 1 nt
31 3.8 neg neg 4.5 neg neg neg 1 nt
32 3.4 neg neg neg neg neg neg 0 nt
33 2.3 neg neg neg neg neg neg 0 nt
34 2.9 neg neg neg neg neg neg 0 nt
35 3.4 neg 2.3 neg neg neg neg 1 nt
36 2 neg neg neg neg neg neg 0 nt
37 2.6 neg neg neg neg neg neg 0 nt
38 neg neg 6.7 neg neg 2.9 neg 2 nt
39 2.3 neg neg neg neg neg neg 0 nt
40 5 neg neg neg neg neg neg 0 nt
41 2.3 neg 3 3.2 neg neg neg 2 nt
42 3.3 neg 4.6 neg neg neg neg 1 nt
43 3.8 neg neg neg neg neg neg 0 nt
44 2 neg 2.5 neg neg neg neg 1 nt
45 2.7 neg neg neg 2.6 neg 2 2 nt
46 5 neg neg neg neg neg neg 0 nt
47 2.7 2.3 neg neg neg neg neg 1 nt
48 2.9 neg neg 2.7 neg neg neg 1 nt
49 4 neg neg neg 2 2 neg 2 nt
50 2.4 neg neg neg 3.6 neg neg 1 nt
51 3 neg 2.3 neg neg 2.9 neg 2 nt
52 3 neg neg 2.1 neg neg neg 1 nt
53 2.7 neg neg 3.2 neg neg neg 1 nt
54 2.9 neg neg neg neg neg neg 0 nt
55 neg neg neg 2.3 2.9 neg neg 2 nt
*** 52 3 16 17 12 12 6 36
% (94.5) (5-4) (29.1) (30.9) (21.8) (21.8) (10.9) (65.4)
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Table 5.IB A ntibody binding to human PDC-E2 2 12-226 and non-ECOLI microbial 
mimics in 55 AMA-positive PBC patients
PDC-E22I2-226 UREB DCDA V120 TRMA **
human HELPY PSEU HCMV HAEIN
1 3.7 neg neg neg 3.2 4
2 7.1 neg neg neg neg 3
3 4.3 neg neg neg neg 1
4 2 neg neg neg neg 3
5 2.3 neg neg neg neg 1
6 4.3 neg neg neg neg 2
7 4 neg neg neg 4.9 3
8 3 neg 2.3 2.3 neg 5
9 2 neg neg neg neg 2
10 5.6 neg neg neg neg 2
11 2.3 neg neg neg neg 0
12 3 neg neg neg neg 2
13 2.1 neg neg neg neg 4
14 2 neg neg neg neg 2
15 2.7 neg neg neg neg 3
16 neg neg neg neg neg 1
17 4.6 neg neg neg neg 1
18 3.4 neg neg neg neg 4
19 6.7 neg neg neg neg 3
20 4.9 neg neg neg neg 0
21 2.8 neg neg neg neg 0
22 2.2 neg neg neg neg 1
23 2 2.3 neg neg neg 1
24 2 neg neg neg neg 0
25 2.9 neg neg neg neg 0
26 4 neg neg neg neg 0
27 5.6 neg neg neg neg 1
28 2.3 neg neg 3.2 neg 1
29 7.1 neg neg neg neg 0
30 2.1 neg neg neg neg 1
31 3.8 neg neg neg 2.5 2
32 3.4 neg neg neg neg 0
33 2.3 neg 2.7 neg neg 1
34 2.9 neg neg neg neg 0
35 3.4 neg neg neg neg 1
36 2 neg neg neg neg 0
37 2.6 neg neg neg neg 0
38 neg neg neg neg neg 2
39 2.3 neg neg neg neg 0
40 5 neg neg neg neg 0
41 2.3 neg neg neg neg 2
42 3.3 neg neg neg neg 1
43 3.8 neg neg neg neg 0
144 2 neg neg neg neg
45 2.7 neg neg neg neg 2
46 5 neg neg neg neg 0
47 2.7 neg neg neg neg 1
48 2.9 neg neg neg neg 1
49 4 neg neg neg neg 2
150 2.4 neg neg neg neg
51 3 neg neg neg neg 2
52 3 neg neg neg neg 1
53 2.7 neg neg neg neg 1
54 2.9 neg neg neg neg 0
55 neg neg neg neg neg 2
*** 52 1 2 2 3 39
% (945)_ . (1.8) (3.6) (3-6) . (5-4) (70.9)
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Footnote to Table 5,1A-B
Absorbance values are expressed as Q j f est/ Q i f ontro1 peptide and considered negative 
(neg) when <2; pos, positive; nt, no urine test; total number o f  * ECOLI or ** 
microbial peptides recognized by an individual patient; ***, total number (%) o f  
patients recognizing a peptide; UTI, urinary tract infection; AMA, anti-mitochondrial 
antibody; PDC-E2, pyruvate dehydrogenase complex-E2; ECOLI, Escherichia coli; 
ClpX, caseinolytic protease X; HRPA, ATP-dependent helicase hrpA; MALE, maltose 
E; FADP, fatty acid oxidation complex alpha subunit; SPOT, (P) ppGpp synthetase II; 
NARW, nitrate reductase 2; HELPY, Helicobacter pylori; UREB, urease beta subunit; 
PSEU, Pseudomonas aeruginosa; DCDA, diaminopimelate decarboxylase; HCMV, 
human cytomegalovirus; VI20, capsid assembly protein UL47; HAEIN, Haemophilus 
influenzae; TRMA, tRNA (uracil-5-)-methyltranferase
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Table 5.2 Single and double reactivity to self and microbial peptides expressed in absolute numbers and percentages (%), in 55 anti- 
mitochondrial antibody (AMA) positive patients with primary biliary cirrhosis (PBC), including 19 with recurrent urinary tract infection (UTI), 
10 without UTI and 26 with no urine test, and 23 AMA-negative PBC patients
AMA-positive PBC 
Total 
n=55
with UTI 
n=19
AMA-positive PBC 
without UTI no urine test 
n=10 n=26
AMA-negative PBC 
n=23
PDC-E2212-226 52 (94.5) 18(95) 10(100) 24 (92.3) 1(4)
ECOLI CLPX280-294 3 (5.4) 2(10.5) 0 1 (3.8) 0
ECOLI HRPAj 53.167 16(29.1) 10(52.6) 0 6(23.1) 1(4)
ECOLI MALE95.109 17(30.9) 10(52.6) 1 ( 10) 6(23.1) 0
ECOLI FADP605^ i9 1 2 (2 1 .8) 7 (36.8) 1 ( 10) 4(15.3) 0
ECOLI SPOT517-53i 1 2 (2 1 .8) 8(42.1) 0 4(15.3) 1(4)
ECOLI NARWgi.95 6(10.9) 5 (26.3) 0 1 (3.8) 0
ECOLI (at least 1 peptide) 36 (65.5) 18(94.7) 2 (2 0 ) 16(61.5) 2 (8)
HELPY UREB22-36 1 ( 1.8) 0 1 ( 10) 0 0
PSEAE DCDA355-369 2(3.6) 1 (5.3) 0 1 (3.8) 0
HCMVV120663-677 2(3.6) 1 (5.3) 1 ( 10) 0 0
HAEIN TRMA205-219 2(3.6) 2(10.5) 0 1 (3.8) 0
PDC-E2212W  ECOLI CLPX28o-294 3 (5.4) 2(10.5) 0 1 (3.8) 0
PDC-E2212-226/ ECOLI HRPAi53_i67 15(27.3) 10(52.6) 0 5 (19.2) 1(4)
PDC-E2212-226/ ECOLI MALE95.109 16(29.1) 10(52.6) 1 ( 10) 5 (19.2) 0
PDC-E22,2-226/ ECOLI FADP605-619 1 1 (2 0 ) 7 (36.8) 1 ( 10) 3(11.5) 0
PDC-E2212W  ECOLI SPOT517-531 10(18.2) 7 (36.8) 0 3(11.5) 0
PDC-E2212-226/ ECOLI NARWsi-95 6 (10.9) 5 (26.3) 0 1 (3.8) 0
PDC-E22,2-226/ HELPY UREB22-36 1 (1.8) 0 1(10) 0 0
PDC-E2212-226/ PSEAE DCDA355.369 2(3.6) 1 (5.3) 0 1(10) 0
PDC-E22l2-226/ V120 HCMV663-677 2(3.6) 1 (5.3) 1(10) 0 0
PDC-E2212-226/ HAEIN TRMA205-2i9 3 (5.4) 2(10.5) 0 1(10) 0
PDC-E22i2-226/ ECOLI (at least lpair) 33 (60) 17(89.5) 2(20) 14(53.8) 1(4)
137
Table 5.3 Single and double reactivity to self and microbial peptides expressed in absolute numbers and percentages (%), in 190 pathological 
controls and 28 healthy subjects
U T I
n=20
H B V
n=27
H C V
n=42
A L D
n=17
A IT D
n=38
P M
n=10
SL E
n=9
A IH -1
n=15
A IH -2
n=12
H ealth y
n=28
P D C -E 2212-226 10(50) 1 (3.7) 2 (4.8) 0 2 (5.2) 0 1(11) 0 0 1 (3.6)
EC O LI C L P X 28o-294 0 0 1 (2.4) 0 0 1(10) 0 0 1 (8.3) 0
E C O L I H R P A 153-i67 3  (15) 1 (3.7) 1 i 2 A ) 0 1 (2.6) 0 0 0 0 ! 8 - 8
EC O L I M A L E 95-109 4(20) 0 2 (4.8) 0 4(10.5) 0 1(11) 1 (6.6) 0 1 (3.6)
E C O L I F A D P 605-6i9 0 0 0 0 0 0 0 0 0 0
E C O L I S P O T 517-531 5(25) 1 (3.7) 0 0 1 (2.6) 0 0 0 1 (8.3) 0
E C O L I N A R W 8i .95 2(10) 0 0 0 0 1(10) 0 1 (6.6) 0 0
E C O L I (at least 1 p ep tid e) 11(55) 2 (7.4) 4 (9.5) 0 5 (13.2) 1(10) 1(11) 2(13.2) 1 (8.3) 2 (7.2)
H E L P Y  U R E B 22-36 3(15) 0 1 (2.4) 0 1 (2.6) 0 0 2 (13.2) 0 0
P S E A E  D C D A 355.369 1(5) 0 0 0 1 (2.6) 0 0 0 0 0
H C M V  V 1 2 0 663-677 1(5) 0 1 (2.4) 0 0 0 0 0 0 0
H A E IN  T R M A 205-219 4(20) 1 (3.7) 1 (2.4) 0 0 0 1(11) 0 0 0
P D C -E 22i2-226/ E C O LI C L P X 28o-294 0 0 0 0 0 0 0 0 0 0
P D C -E 2212-226/ E C O L I H R P A I53-167 1(5) 0 0 0 0 0 0 0 0 0
PDC-E2212-226/ EC O LI M A L E 95-109 4(20) 1 0 0 2 (5.2) 0 1(11) 0 0 1 (3.6)
P D C -E 2212-226/ EC O LI FADP605-619 0 0 0 0 0 0 0 0 0 0
PDC-E2212-226/ E C O L I S P O T 517-531 3(15) 0 0 0 0 0 0 0 0 0
PDC-E2212-226/ E C O LI N A R W si-95 2 ( 1 0 ) 0 0 0 0 0 0 0 0 0
PDC-E2212-226/ H E L P Y  U R E B 22-36 2 ( 1 0 ) 0 1 (2.4) 0 0 0 0 0 0 0
PDC-E2212-226/  P S E A E  D C D A 355-369 H 5 } 0 1 (2.4) 0 0 0 0 0 0 0
PDC-E2212-226/ V 1 2 0  HCMV663-677 1(5) 0 0 0 0 0 0 0 0
P D C -E 22 12-226/  H A E IN  T R M A 205-219 3(15) 0 0 0 0 1 ( 1 1 ) 0 0 0
P D C -E 2212-226/  EC O LI (at least lp a ir) 9(45) 0 0 0 2 (5.2) 0 1 ( 1 1 ) 0 0 1 (3.6)
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Footnote to Tables 5.2 & 5.3
PBC, primary biliary cirrhosis; UTI, urinary tract infection; HBV, hepatitis B virus; 
HCV, hepatitis C virus; ALD, alcoholic liver disease; AITD, autoimmune thyroid 
disease; PM, polyomyositis; SLE, systemic lupus erythematosus; AIH, autoimmune 
hepatitis; n, number; PDC-E2; pyruvate dehydrogenase complex-E2; ECOLI, 
Escherichia coli; HELPY, Helicobacter pylori; PSEAE, Pseudomonas aeruginosa; 
HCMV, Human cytomegalovirus; HAEIN, Haemophilus influenzae
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5.3.3 Inhibition studies
Inhibition of reactivity to microbial/self mimics by pre-incubation with relevant and 
control antigens is detailed in Table 5.4 and Figure 5.2.
Antibody binding to ECOLI MALE95-109 (Table 5.4A) was inhibited by 66.7-79.6% after 
pre-incubation with the ECOLI MALE95-109 in the seven cases tested. Among these, in 
cases 31, 53 (see Figure 5.2A-B), 3, 5 and 48 antibody binding was inhibited by 68.3- 
70.1% after pre-incubation with human PDC-E2212-226 and by 67-73.2% after pre­
incubation with PDC antigen (Table 5.4A). Inhibition ranged from 52-78% after pre­
incubation with the full MALE protein in the 3 cases tested.
In cases 31 and 53 (Figure 5.2C-D), antibody binding to human PDC-E2 2 12-226 was 
significantly inhibited after pre-incubation with the PDC-E2212-226, ECOLI MALE95.109, 
PDC antigen and with the full ECOLI MALE protein.
A s can be seen in Figure 5.2 and Table 5.4 the E C O L I M A L E 95-109 was a better inhibitor 
of binding to both itself and P D C -E 2 2 12-226 than PDC-E2212-226*
Similar sets of results were obtained when competition experiments were performed 
measuring anti-ECOLI H R P A 153-167 antibody binding (Table 5.4C).
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Case 31 Case 53
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40
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B. 80
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Competitor peptide concentrations (pg/ml)
Figure 5. 2. A-D: Inhibition o f  antibody (ab) binding against ECOLI MALE95.109 (A,B) 
and human PDC-E2212-226 (D,E). Pre-incubation with ECOLI MALE95.109 (♦), human 
PDC-E2 212-226 (u) ,  fu ll ECOLI MALE protein (0 ), PDC antigen (A), control antigen (o) 
and control peptide (-#-) o f  serum 31 (A,C) and 53 (B, D). On the vertical axis is the 
percentage o f  inhibition o f  antibody binding to the peptide in the presence o f  competitor 
peptide or antigen at different concentrations: 0; 15; 50; 100; 250; 500; 1000 jug/ml. 
ECOLI, E. coli; MALE, maltose E; PDC, pyruvate dehydrogenase complex
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T a b le  5 .4  Inh ib ition  o f  anti-E C O L I M A L E 9 5 .1 0 9  (A ) or an ti-P D C -E 2 2 1 2 -2 2 6  (B ) or anti-E C O L I H R P A 153 -1 6 7  
incubation  w ith  relevant p ep tid es and an tigens.
(C ) antibody reactiv ity  b y  pre-
Case Maximum Inhibition %
A. ECOLI MALE9 5 .1 0 9  ECOLI MALE protein PDC-E2212-226 PDC antigen Control antigen Control peptide
31a 73.8 68.5 69.2 67 1 2 9.1
53b 75.5 52 69.7 72.3 5.2 3.4
15 79.6 78 2 2 18 13.8 8.3
3 69.1 69.7 73.2 11.3 5.4
5 71.2 70.1 6 8 .2 8 .8 8.9
41 66.7 1 2 .1 14.7 1 1 .8 5.4
48 72.2 68.3 6 8 .1 12.9 1 1 .1
B. PDC-E2212-226 ECOLI MALE9 5 . 1 0 9 ECOLI MALE PDC antigen Control antigen Control peptide
protein
31c 87.9 78.8 82.2 93.4 14 3.4
53d 77.5 79 78.1 79.2 1 1 .2 7.9
ECOLI HRPA153-i67 PDC-E2212-226 PDC antigen Control antigen Control peptide
42 72.1 62.7 60.4 13.9 9.3
18 77.6 76.3 75 5.2 1.3
12 79.6 18.5 2 2 . 6 4.5 8.3
1 72.8 73.2 77 9.2 9.1
2 82.1 12.7 1 1 . 1 14.2 1 1 .2
9 65 20.7 19.5 18.9 6.9
19 69.9 6 6 .8 6 6 13.8 6 .2
41 69.3 67.2 65.6 1 2 .1 7.8
a, See Fig 5.2A ; b, See Fig 5.2B;c, See Fig 5.2C;d, See Fig 5. 2D, ECOLI, E. coli; MALE, maltose E ; PDC-E2, pyruvate dehydrogenase 
complex E2 subunit; HRPA, ATP-dependent helicase hrpA
142
Chapter 5
5,3.4 Affinity o f  anti-peptide antibody
The relative affinity of antibody binding to ECOLI MALE95.109 and PDC-E22i2-226 for 
cases 31 and 53 is illustrated in Figure 5.4 demonstrating higher relative antibody 
affinity to ECOLI MALE95.109 compared to PDC-E22 12-226, the avidity indices being 1.23 
vs 0.83 and 1.3 vs  0.47 mol/1, respectively.
A. Case 31 B. Case 53
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Figure 5.3 Affinity profile o f  anti-peptide antibody. ELISA microplate wells were coated 
with ECOLI MALE95-109 and human PDC-E2212-226. After incubation with individual 
serum samples o f  cases 31 (A) and 53 (B) at a dilution o f  1/1000, urea was added at 
increasing concentrations and allowed to inhibit antibody-antigen interaction for 15 
minutes. Absorbance values were plotted as the percentage o f  initial absorbance 
against urea concentration (mean ± standard deviation). Each point is the average o f  5 
observations. From this the relative affinity index, defined as the concentration o f urea 
that elutes 50% o f  the antibody reactivity, fo r  both ECOLI MALE95-109 (o) and human 
PDC-E2212-226 ( • )  was extrapolated ( - —)■ ECOLI, E. coli; MALE, maltose E; PDC-E2, 
pyruvate dehydrogenase complex-E2; OD, optical density
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5.4 DISCUSSION
The present Chapter has looked for microbial proteins containing peptidyl sequences 
mimicking human PDC-E2 2 12-226 and among a number of hits the best 10 mimics were 
selected for further analysis. Six of these were from E. coli while 4 were, one each, from 
Helicobacter pylori, Pseudomonas aerigunosa, human CMV, and Haemophilus 
influenzae.
The potential biological significance of these homologies was emphasized by the fact 
that their sequences were better mimics to human PDC-E2212-226 than the ECOLI PDC 
or other microbial PDC corresponding sequences. The extent of similarity and the large 
number of non OADC ECOLI mimics of the human PDC-E2212-226 epitope seems more 
than coincidental as indicated by the lack of microbial mimics for the control 
CYP2D6257-27i peptide, representing the immunodominant epitope targeted by LKM-1 
autoantibody in patients with AIH-2 (Alvarez et al., 1999, Manns et al., 1991, 
Yamamoto et al., 1993). So a possibility arises that, if there is a microbial involvement 
in the generation of the characteristic AMA and/or in the pathogenesis of PBC, the 
considerable number o f microbial mimics contributes to the selection of this particular 
sequence on PDC-E2 as a dominant epitope.
Sequence similarity does not necessarily lead to structural/conformational similarity 
and, hence, needs not equate with actual cross-reactivity (antigenic mimicry), 
particularly in the case o f B-cell epitopes (Oldstone, 1987, Dyrberg et al., 1990, 
Quaratino et al., 1995, Bogdanos et al., 2000). In the present work such seems to be the 
case with the ECOLI ClpX peptide. This bears the strongest sequence similarity with the 
human PDC-E22i2-226, but antibodies to it were only seen in 5.4% of PBC cases. 
Nevertheless, two-thirds of the PBC patients react with at least one of the ECOLI 
peptides, up to 1/3 of these 55 patients specifically reacting with ECOLI MALE95.109 
and/or ECOLI HRPA153-167.
Within PBC, reactivity to ECOLI peptides was strongly associated with a history of 
recurrent UTI, reactivity to at least one ECOLI peptide being present in virtually all 
recurrent UTI positive PBC patients and in only a minority of those without recurrent 
UTI. Outside PBC, approximately half of the patients with recurrent UTI had PBC 
specific anti-PDC-E2 antibodies and this was always in association with reactivity to 
ECOLI mimics. Four of these AMA-positive microbial/self reactive patients were
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followed-up for 5 years, remaining positive for AMA and ECOLI/PDC-E2 reactivity in 
the absence of biochemical and clinical signs of PBC. The anti-ECOLI reactivity seen in 
virtually all the patients with PBC and recurrent UTI was shown here to be cross 
reactive with the homologous PDC-E2 sequence in a synthetic peptide, and, 
importantly, in a full length purified ECOLI protein, as shown for the maltose binding 
protein. This latter periplasmic ECOLI gene product was able to abrogate reactivity to 
both ECOLI MALE95 .109 and PDC-E2 212-226- Notably, three-dimensional modelling of 
MALE ECOLI predicts MALE95.109 to be located in a solvent-accessible surface region 
of the protein, compatible with antibody recognition on the whole protein (see Figure 5. 
4) (Laver et al., 1990, Howard et al., 1998).
The findings of the present work strengthen the notion that a microbial exposure, 
especially through ECOLI-urinary tract infection, may be instrumental to the appearance 
and/or maintenance o f AMA responses by a cross-reactive mechanism (Stemerowicz et 
al., 1988, Hopf et al., 1989, Burroughs et al., 1992, Butler et al., 1995a, Butler et al., 
1995b, Shimoda et al., 1998, Shimoda et al., 2000, Parikh-Patel et al., 2001, Butler et 
al., 1993). In view of the remarkable sequence similarities of PDC-E2 across species, 
Burroughs et al. (1992) originally suggested that molecular mimicry between PDC-E2 
of microorganisms, especially o f ECOLI, and PDC-E2 of man could lead to a cross­
reactive immune response manifesting itself as AMA. This suggestion arose in the light 
of early epidemiological considerations, such as an association of AMA with UTI and 
the fact that sera and T-cell clones from patients with PBC are capable of 
human/microbial PDC-E2 cross-recognition (Stemerowicz et al., 1988, Hopf et al., 
1989, Burroughs et al., 1992, Butler et al., 1995a, Butler et al., 1995b, Shimoda et al., 
1998, Shimoda et al., 2000, Parikh-Patel et al., 2001, Butler et al., 1993). A significant 
addition to the present debate is the evidence recently provided by Parikh-Patel et a l, 
who, in the first controlled epidemiological analysis, showed a positive association of 
PBC with UTI (Parikh-Patel et al., 2001).
The role of molecular mimicry and UTI in PBC needs, however, to be revisited, 
especially since the present study has been able to demonstrate cross-reactive immunity 
between human PDC-E22i2-226 and microbial sequences, particularly from E. coli, which 
do not belong to microbial OADC. Furthermore as shown in Figure 5.2 and 5.3 and 
Table 5.4 there appears to be greater antibody affinity for the ECOLI mimics than for 
PDC-E2212-226- This, and the observation that reactivity to non-PDC-E2 mimics in the
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control population is more common than that to PDC-E2212-226, both indicate that 
reactivity to the bacterial sequences may precede that against self.
146
Chapter 5
A
Figure 5.4. Three dimensional structure o f the periplasmic maltose binding protein o f E. coli 
(ECOLI MALE) with a wire frame (A) backbone (grey) coloured by secondary structure 
(purple) and a space fill (B) backbone. The relevant ECOLI MALE95.109 sequence is displayed 
in yellow. The structure was analyzed with the Cn3D visualization tool (see 2.1.2.3)
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Helicobacter pylori and PBC
Chapter 6
6.1 BACKGROUND
In the previous Chapter (see Chapter 5), it was shown that in spite the universal 
antibody recognition of the PDC-E2 2 12-226 autoepitope, its close Helicobacter pylori 
(HELPY) mimic was rarely recognised in serum samples from PBC patients (1/55, 
1.8%). This finding was surprising considering the degree and the nature of the 
microbial/self amino acid homology, on top of experimental evidence linking HELPY 
infection to PBC (Lin et al., 1995, Fox et ah, 1995, Fox et ah, 1998, Figura et ah, 1998, 
Nilsson et ah, 1999, Nilsson et ah , 2000a, Nilsson et ah, 2000b, Monstein et ah, 2002, 
Fallone et ah, 2003). Thus, HELPY and Helicobacter hepaticus (HELHEP) have 
recently been implicated in the pathogenesis of PBC since their DNA has been found in 
liver tissue of patients whose sera contained antibodies to the microbe (Lin et ah, 1995, 
Fox et ah, 1995, Fox et ah, 1998, Figura et ah, 1998, Nilsson et ah, 1999, Nilsson et ah, 
2000a, Nilsson et ah, 2000b, Monstein et ah, 2002, Fallone et ah, 2003). Moreover, the 
PDC-E2 212-226-mimicking HELPY sequence originates from the urease beta (UREB) 
subunit, a protein that with urease A (UREA) represents a major focus of anti-HELPY 
immunity (Pappo et ah, 1995, Suerbaum and Josenhans, 1999, Zevering et ah, 1999, 
Kimmel et ah, 2000, Suerbaum and Michetti, 2002).
In gastric pathology, HELPY has been shown to be cross-reactively targeted at the T- 
cell level with the gastric H+K+-ATPase proton pump, the major autoantigen in 
autoimmune gastritis, with which it shares extensive similarities (Amedei et ah, 2003).
In the present study the nature o f antibody unresponsiveness to the HELPY UREB 
mimic was investigated. Since B- and T-cell epitopes frequently do not co-localise, the 
possibility that the HELPY UREB mimic and PDC-E2 2 12-226 are targets of cross-reactive 
response at the CD4 T-cell level has also been explored. Finally, the disease-specificity 
of antibody reactivity to HELPY antigens in patients with PBC was compared to those 
of a large number of controls including patients with viral hepatitides, autoimmune 
thyroiditis, systemic lupus erythematosus and healthy subjects.
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6.2 METHODS
6.2.1 Subjects
Serum samples were obtained from 112 patients with PBC (mean age 53±14.2 years; 99 
female), all but 15 AMA-positive by IIF, (median titre: 1/1280, range 1/40 -  1/10480), 
median duration of disease 59 months (range 1 -227) attending the out-patient clinic of 
Liver Transplantation and Hepatobiliary Medicine Unit, Royal Free Hospital.
Pathological controls included 98 AMA-negative patients (mean age 54±11.9 years, 89 
female), all positive for anti-HELPY antibodies by ELISA and immunoblotting 
including 25 with chronic HBV infection; 31 with chronic HCV infection; 23 with 
autoimmune thyroid disease and 19 with systemic lupus erythematosus.
Sixteen healthy, AMA-negative, volunteer members of staff (mean age 38±8 years, 13 
female), all anti-HELPY antibody positive, were tested as normal controls.
6.2.2 Antibody detection
AMA was detected by conventional IIFL, immunoblotting and ELISA (see 2.2.2). 
Antibodies to HELPY were tested by commercially available ELISA (see 2.1.6.1) and 
immunoblotting using as antigen a purified HELPY antigen extract containing UREB 
(see 2.1.6.2).
6.2.3 Protein database search and analysis
The UREB HELPY homologue o f human PDC-E2212-226 was identified by scanning the 
SwissProt protein database using the Proteinlnfo programme (see 2.2.2.1). Amino acid 
comparison of full-length human PDC-E2 and HELPY UREB was carried out using the 
BLASTp 2 sequences protein-protein comparison programme (see 2.2.1.2.2). The 
observed similarities were analysed in relation to those between human PDC-E2 and 
UREA HELPY, UREB HELHEP or UREA HELHEP.
6.2.4 Peptide synthesis
Three 15-mer peptides containing the relevant human inner PDC-E2212-226, PDC-E291. 
105, and HELPY UREB22-36 mimics and an irrelevant 15 aa control peptide were 
constructed (see 2 .2.2 .3).
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6.2.5 ELISA
Antibody binding to the peptides was determined by ELISA (see 2.22.3). The final 
peptide concentration was 15pg/ml and the dilution of serum samples was 1/200.
6.2.6 Inhibition studies
6.2.6.1 Peptides
To investigate whether the simultaneous reactivity to HELPY UREB22-36 and human 
PDC-E2 2 12-226 was due to cross-reactivity, competition ELISA was performed, 
measuring residual anti-HELPY UREB22-36 or anti-PDC-E2 2 12-226 reactivity after 
incubation respectively with HELPY UREB22-36, PDC-E2 2 12-226 and a control peptide as 
liquid phase competitors (,see 2.4.2.2.1).
6.2.6.2 Antigens
The possibility that PDC-E2 and HELPY UREB are targets of cross-reactive antibody 
responses at the level of full proteins was addressed through inhibition studies 
investigating inhibition of antibody reactivity to human liver PDC-E2, on immunoblot 
using as solid phase competitor a purified HELPY extract containing the UREB subunit 
(see 2.1.6.2); conversely, antibody recognition of UREB was tested before and after 
solid phase incubation o f serum samples with purified PDC from porcine heart 
mitochondria (see 2 .1.2).
6.2.7 Three-dimensional modelling
Three-dimensional modelling o f the relevant HELPY UREB22-36 was carried out by 
analysing the structure of UREA/UREB HELPY complex with the Cn3D visualization 
tool (see 2.1.2.3).
6.2.8 Proliferation assay of PBMC
Proliferative responses (see 2.2.3.3) to the HELPY UREB22-36, PDC-E2212-226 peptides 
and PDC antigen were investigated in 7 PBC patients and 5 pathological controls (4 
with HCV, 1 with alcoholic hepatitis), all female (median age 54, range 37-68), all 
positive for anti-HELPY antibodies.
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63  RESULTS
6.3.1 Protein database search and analysis
BLASTp 2 sequences comparison revealed the best similarity between the 569 aa long 
UREB protein and the inner lipoyl domain of PDC-E2 to involve the immunodominant 
PDC-E2 2 12-226 epitope. HELPY UREB22-36 shares 13/15 (87%) similarity (7 identities) 
with the human PDC-E2212-226 (see Figure 6.1).
Two other HELPY UREB sequences had similarity with PDC-E2; but the extent of 
similarity was lower; 47% (6 identities) and 53% (5 identities) and the PDC-E2 mimics 
correspond to sequences which are not PDC-E2 epitopes (see Figure 6.1).
The best homology UREA HELPY shares with PDC-E2 is a 8/15 (53%) similarity (5 
identities) between HELPY UREAm4 and PDC-E2424-438 (see Figure 1); no similarity 
exists between the UREA HELPY and the PDC-E2212-226*
The corresponding sequence on UREB of HELHEP shares also homology with human 
PDC-E2212-226, though to a lesser extent compared to that of HELPY (see Figure 6.1).
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Antigen aa Sequence
human PDC-E2 (ILD) (212-226) K L S E G D L L A E  I E T D K
HELPY UREB (22-36) R L G D T D L  I A E V E H D Y
HELPY UREB (463-477) A N A S  I P T P Q P V Y Y R E
human PDC-E2 (293-307) V A A V P P T P Q P L A P T P
HELPY UREB (463-477) A N A S  I P T P Q P V Y Y R E
human PDC-E2 (283-297) P Q V P P P T P P P V A A V P
HELPY UREA (1-14) M K L T P K E L D K L M L H Y
human PDC-E2 (424-438) V L L V R K E L N K  I L E G R
HELHEP UREB (20-34) R L G D T N L F A E  I E K D Y
human PDC-E2 (ILD) (212-226) K L S E G D L L A E  I E T D K
Similarity (%) Identities 
13/15(87%) 7
7/15(47%) 6
8/15(53%) 5
9/15(60%)
13/15 (87%)
Figure 6.1 Sequence alignment between human E2 subunit o f  human pyruvate dehydrogenase complex (PDC-E2), and urease B (UREB) and 
urease A (UREA) o f Helicobacter pylori (HELPY) and Helicobacter hepaticus (HELHEP). Amino acids in standard single-letter code. Identities 
in bold; Conservative substitutions in italic; ILD, inner lipoyl domain
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6,3.2 Reactivity to peptides and antigens
Reactivity to human PDC-E2212-226 was found in a total of 104 PBC patients: 94 (97%) 
of 97 AMA-positive PBC cases, and 10 (67%) of 15 AMA-negative PBC cases.
Among the 104 anti-PDC-E2212-226 positive patients, reactivity to HELPY UREB22-36 
was found in 2 (2%) and reactivity to the HELPY UREB antigen in 72 (69%) including 
the 2 anti-HELPY UREB22-36 positive cases. Among the 10 anti-PDC-E2 2 12-226 negative 
patients, there was no reactivity to HELPY UREB22-36, 7 (70%) reacting with the 
HELPY UREB antigen.
Among the 98 pathological controls, reactivity to human PDC-E2 2 12-226 was found in 3 
(3%) including 2 patients with HCV and one with SLE; and to HELPY UREB22-36 in 2 
(one with HBV and one with HCV) not reacting to human PDC-E2212-226- There was no 
correlation of antibody reactivity to PDC-E2 2 12-226 or PDC-E2 antigen and individual 
UREB or UREA (or other HELPY antigens) (see Figure 6.2A). The pattern of reactivity 
to HELPY antigens by immunoblot was similar between anti-PDC-E2 positive and 
negative PBC cases, as well as between PBC and controls (Figure 6.2B).
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Figure 6.2 Patterns o f reactivity to HELPY and PDC antigens
(A). Antibody reactivity to HELPY (H) and human liver (L) PDC antigens in 
representative PBC cases. Note the presence o f reactivity to both UREB (lane 1) and 
PDC-E2 (lane 2) in the serum sample (I); absence o f reactivity to UREB (lane 3) in the 
presence o f reactivity to PDC-E2 (lane 4) in another PBC case (II); and presence o f 
reactivity to UREB (lane 5 and 7) in the absence o f reactivity to PDC-E2 (lanes 6 and 
8) in two other PBC cases (III and IV)
(B). Patterns o f  reactivity to HELPY antigens in PBC cases -  anti-PDC-E2 positive 
(lanes 1-4) or negative (5-8) and controls (9-15)
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6,3.3 Inhibition studies
6.3.3.1 Peptides
Inhibition of reactivity to HELPY UREB22-36 or human PDC-E2 2 12-226 by pre-incubation 
with the relevant peptides o f the serum samples from the 2 microbial/self double 
reactive PBC cases is detailed in Figure 6.3. Antibody binding to HELPY UREB22-36 
was inhibited in up to 89% after incubation with the HELPY UREB22-36 peptide but not 
with PDC-E2212-226 or the control peptide (Figure 6.3 A-B).
6.3.3.2 Antigens
Incubation of a PDC-E2212-226/ HELPY UREB22-36 double reactive serum sample with 
UREB HELPY antigen as a solid phase competitor was able to abolish reactivity to 
human UREB HELPY but did not have an effect on reactivity to PDC-E2 (Figure 6. 
3C). Conversely, incubation o f the double reactive serum with PDC antigen inhibited 
reactivity to PDC-E2 but did not diminish reactivity to HELPY UREB (Figure 6.3D).
63.4 Three-dimensional modelling
Three dimensional modelling predicts the core of HELPY UREB22-36 not to be exposed 
on the surface of the UREA/UREB complex (see Figure 6.4).
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Legend to Figure 6. 3
A-B: Inhibition o f antibody binding against HELPY UREB22-36 (A) and human PDC- 
E2212-226 (B). Pre-incubation with HELPY UREB22-36 ( ♦ ) ,  human PDC-E2212-226 ( A ) ,  
and control peptide ( X )  o f a HELPY UREB22-36 /PDC-E2 212-226 double reactive serum 
sample. On the vertical axis is the percentage o f inhibition o f antibody binding to the 
peptide in the presence o f competitor peptide or antigen at different concentrations: 0; 
25; 50; 100; 200; 400; 800 pg/ml.
C-D: Antibody binding against HELPY UREB (top band) and human PDC-E2 (bottom 
band) before (lanes 1 and 3) and after pre-incubation (2 and 4) with the HELPY extract 
antigen (C) or PDC antigen (D) o f a HELPY UREB22-36 /PDC-E2212-226 double reactive 
serum. Note that HELPY antigen as inhibitor is able to abolish reactivity to human 
UREB HELPY (lane 2, top) but does not have an effect on reactivity to PDC-E2 (lane 2, 
bottom). Conversely, incubation o f double reactive sera with PDC antigen inhibits 
reactivity to PDC-E2 (lane 4, bottom) but does not diminish reactivity to HELPY UREB 
(lane 4, top). HELPY, Helicobacter pylori; PDC, pyruvate dehydrogenase complex; 
UREB, urease B
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Figure 6.4 Three-dimensional modelling structure o f the urease B (UREB; blue colour) 
and urease A (UREA; pink colour) complex o f Helicobacter pylori (HELPY) with a 
space fill. The PDC-E2212-226 mimicking HELPY UREB22.36 sequence is shown in yellow. 
The structure was analysed with the Cn3D visualisation tool. Note the lack o f exposure 
o f the core o f the peptidyl sequence to the surface o f the molecule in contrast to its 
corners
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6.3.5 Proliferation assay of PBMC
Proliferative responses to peptides and antigens is summarised in Figure 6.5. 
Stimulation o f PBMC with the non-specific stimulator PHA resulted in strong 
proliferative responses in PBC patients (mean SI ± SD: 22.3 ± 4.64) and pathological 
controls (13.6 ± 2.25).
Proliferative responses to the PDC-E2212-226 peptide were found in 6 of the 7 PBC 
patients (4.1 ± 0.8) and 1 (2.9 ± 1.2) o f 5 pathological controls (2 ± 0.3) - a 53-year old 
woman with chronic HCV infection negative for AMA. All seven PBC patients (7.67 ± 
2) and one control (the 53-year HCV infected woman) recognised also the PDC antigen. 
No reactivity was found to the HELPY UREB22-36 in PBC patients (1.44 ± 0.1) or 
pathological controls (1.24 ± 0.3) (Figure 6.5).
PBC (n=7) Controls (n=5)
Figure 6. 5 Proliferative responses o f  peripheral blood mononuclear cells from  7 PBC 
patients and 5 pathological controls to the PDC-E2212-226, HELPY UREB22-36, PDC 
antigen (ag). A stimulation index (SI) > 3 was considered positive; PBC, primary biliary 
cirrhosis; PDC, pyruvate dehydrogenase complex; UREB, urease B
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6.4 DISCUSSION
The present study has investigated the role of molecular mimicry between Helicobacter 
pylori and PDC-E2, the major mitochondrial autoantigen in PBC and found no evidence 
of cross-reactive immunity in PBC patients.
This finding was unexpected in view of the fact that not only do HELPY and PDC-E2 
share a striking similarity in molecular mimicry terms, but also the microbial sequence 
originates from UREB, an antigen which, in complex with urease A (UREA), is a key 
target of anti-HELPY immunity (Pappo et al., 1995, Suerbaum and Josenhans, 1999, 
Zevering et al., 1999, Kimmel et al., 2000, Suerbaum and Michetti, 2002). Moreover, 
the best similarity between microbe and self involves the immunodominant autoepitope 
on PDC-E2 (PDC-E2 2 12-226). O f pathogenic relevance is the fact that Helicobacter DNA 
has been found in bile and liver tissue from patients with PBC, their sera containing 
antibodies to HELPY, a microbe able to induce cross-reactive immune responses 
against gastric antigens, and hepatobiliary pathology in animals (Lin et a l , 1995, Fox et 
al., 1995, Fox et al., 1998, Figura et al., 1998, Nilsson et al., 1999, Nilsson et al., 
2000a, Nilsson et al., 2000b, Monstein et al., 2002, Fallone et al., 2003, Amedei et al., 
2003).
In spite of the universal antibody recognition of the PDC-E2 2 12-226 autoepitope, its close 
HELPY UREB mimic was rarely recognised in serum samples from PBC patients, 
unlike other cases where microbial mimics do exhibit double- and frequently cross- 
reactivity (see Chapter 3, 4 and 5).
A possible explanation for this finding is provided by the molecular modelling study 
which predicts that the native microbial sequence would be inaccessible to B 
lymphocyte receptors (Figure 6.4). Furthermore, the sequence would not be seen by 
antibody to intact PDC-E2 or its dominant epitope in the mimicking PDC-E2 sequence. 
However the synthetic peptide itself would not be in the restricted conformation 
existing in the native protein, and yet it does not react with antibodies recognising the 
PDC-E2 peptide that it so strongly mimics. It seems, therefore, that the similarity UREB 
HELPY shares with PDC-E2, is not enough for cross-recognition in spite of great amino 
acid homology (Dyrberg et al., 1990, Wucherpfennig et al., 1997). Compared to the 
human PDC-E2212-226 autoepitope (KLSEGDLLAEIETDK), the HELPY UREB22-36 
mimic (RLGDTLIAEVEHDY) has a positively-charged and bulky histidine (H34) 
which would not be a conservative substitution for T224 of PDC-E2 or any of the 
residues in the same relative position in any of the other microbial mimics that have
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shown antibody cross-reactivity to P D C -E 2 2i2-226 (see Chapter 5), and this is evident 
also for the bulky and aromatic tyrosine (Y36), replacing the K226 that has been 
identified as an important residue in the P D C -E 2  epitope. These differences could lead 
to a non-recognised conformation in a sequence that is otherwise so similar.
The above considerations would account for the absence of a distinct pattern of PBC- 
specific reactivity to HELPY antigens in PBC patients compared to pathological and 
healthy controls (see Figure 6.2).
In the case of T-cell epitopes there is no conformational restriction as to which peptide 
may be cleaved for presentation by MHC on B-lymphocytes (Delves and Roitt, 2000b, 
Delves and Roitt, 2000a). However, binding for presentation may well be significantly 
impaired by the substitutions referred to (Wucherpfennig et al., 1997). So it is not 
surprising that, in the present case, there is no evidence that the mimicking urease 
peptide is a CD4 epitope either. It seems therefore unlikely that HELPY is involved in 
the induction of AMA antibody responses, either directly or indirectly, by a mechanism 
of molecular mimicry.
These clear-cut negative findings illustrate that sequence similarity does not necessarily 
lead to structural/conformational similarity and, hence, need not equate with actual 
cross-reactivity (antigenic mimicry) (Oldstone, 1987, Quaratino et al., 1995). 
Conversely, they suggest that cross-reactivities between autopitopes and mimicking 
peptides of infecting organisms, when they are observed, are probably not trivial, and 
may well have a bearing on the mechanism of disease.
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Caseinolytic protease complex and PBC
Chapter 7
7.1 BACKGROUND
During the completion period of this Thesis, a study from a Spanish group of 
Investigators reported that antibodies directed to ECOLI ClpP 177-194 are strongly 
associated with PBC being present in one third of patients with PBC but in less than 1% 
of a large number of pathological and normal controls (Mayo et al., 2000). This finding 
was of relevance to the present study because of the following: 1) there are no sequence 
similarities between the ECOLI ClpP and human PDC-E2 antigens that would account 
for association between anti-ClpP and anti-PDC-E2 reactivity; 2) the anti-ClpP and anti- 
PDC-E2 antibodies are not cross-reactive; 3) ECOLI ClpP protein forms an important 
proteolytic complex with ClpX, a peptidyl sequence of which (ECOLI ClpX 280-294) 
bears the strongest sequence similarity to human PDC-E2 2 12-226 but is virtually 
unrecognised by antibodies in patients with PBC as shown in Chapter 5 (Wang et al., 
1997, Mayo et al., 2000, Singh et al., 2000).
These various observations led to the hypothesis (see Figure 1) that during ECOLI 
infection, B-cells with receptors recognising a repetitive, exposed sequence of ClpP, 
internalise the entire ClpP/ClpX complex, and present the human PDC-E2212-226- 
mimicking peptide of ClpX on HLA class II. PBC-specific CD4 T-cells, cross- 
recognising through molecular mimicry the human PDC-E2 2 12-226 epitope and the ClpX 
peptide would provide help in the production of disease specific antibodies against 
ClpP.
This hypothesis leads to three testable predictions that became the focus of the present 
section:
1. The ECOLI CIPP177-194 sequence must be located in a solvent-accessible surface 
region of the protein, compatible with B-cell receptor recognition (Laver et al., 
1990).
2. The ECOLI ClpX28o-294 mimic -but not CIPP177-194 - must be recognised by CD4 
T-cells from PBC patients.
3. Finally, PDC-specific T-cells must be able to provide help for the production of 
anti-ECOLI ClpP 177.194 by virtue of cross-recognition by ECOLI ClpX28o-294 
(Stevens et al., 1988, Mosmann and Coffman, 1989, Mahon et a l , 1995).
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PDC-E2 K• L S E G D L L A E I  E T  • • ■ ■ 9 m m D K
ECOLI CLPX K A S E G E  L L A Q V E P E D
identity;conservative substitution
Figure 7.1
Hypothesis: The P subunit o f the Clp complex o f E. coli is recognised by a specific 
antibody present on the surface o f  a B lymphocyte (I). The complex is internalised (2), 
processed and a peptide o f the X  subunit is inserted in an HLA class II molecule and 
presented to a CD4 helper T lymphocyte possessing the appropriate T-cell receptor 
(TCR) (3). The helper T lymphocyte releases soluble mediators such as IL4 (4) 
stimulating B lymphocyte proliferation and release o f anti-P specific antibodies (5). O f 
note is the fact that the peptide potentially recognised by the helper T lymphocyte 
shares striking similarity with the primary biliary cirrhosis (PBC) specific PDC-E2 
immunodominant epitope (inset). It can be hypothesised that the cross-reactivity 
between these two antigenic determinants at the helper T-cell level may account for the 
PBC-specific antimicrobial response (P subunit o f Clp complex o f ECOLI) described in 
the paper by Mayo et al. (2000)
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12 METHODS 
7.2.1 Three-dimensional modelling
Three-dimensional modelling of the ECOLI ClpPi77_i94 was carried out by analysing the 
structure of the 7-ring ECOLI ClpP with the Cn3D visualization tool (see 2.1.2.3).
7.2.2 T-cell responses
7.2.2.1 Subjects
Proliferative responses (see 2.2.3) to ECOLI C l p X 2 8 o -2 9 4 ,  human PDC-E22 1 2 -2 2 6 , ECOLI 
ClpPi7 7 .1 9 4  and PDC antigen were tested in freshly isolated PBMC (see 2.2.3.1) from 15 
AMA positive PBC women (median age 56 years, range 32-64) attending the out­
patient clinic of the Liver Transplantation and Hepatobiliary Medicine Unit, Royal Free 
Hospital, London, United Kingdom. Among these 15 PBC patients, 9 had antibody 
reactivity in their serum for ECOLI CIPP177.194; all 15 were positive for anti-human 
PDC-E2212-226 antibodies and negative for anti-ECOLI ClpX28o-294 by ELISA. Nine 
demographically matched women were also tested as pathological controls including 4 
women with chronic HCV infection, three with alcoholic hepatitis and 2 with AIH-1. 
Three age-matched healthy female subjects were tested as normal controls. All twelve 
controls were negative for AMA, ECOLI C l p X 2 8 o - 2 9 4 ,  human PDC-E2212-226, and ECOLI 
ClpPi 77.194 reactivity.
7.2.2.2 Standard proliferation assay
A standard proliferation assay (see 2.2.3.3) was performed to investigate cellular 
responses of PBC patients and controls in the presence of individual ECOLI ClpX28o-294, 
human PDC-E22i2.226, ECOLI ClpPi7 7 -1 9 4  and PDC antigen.
7.2.2.3 Intracellular cytokine staining
The antigen-specific cellular response was further evaluated by intracellular cytokine 
staining (see 2.2.3.4). Briefly, PBMC from 5 anti-ECOLI ClpPi77-i94 antibody positive 
PBC women resuspended in complete medium, were cultured for 2 weeks with purified 
PDC antigen in the presence o f IL-2 and irradiated autologous PBMC. At day 14, 1 x 
106 cells/ml were cultured for 72 hours with individual ECOLI C l p X 2 8 o -2 9 4 ,  human 
PDC-E22 i2-226, and ECOLI ClpP 1 7 7 -1 9 4  peptides in complete medium, without IL-2, and
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in the presence of irradiated autologous PBMC. At day 4, cells were washed and 
subjected to intracellular cytokine staining with QRed-conjugated anti-CD4, and PE- 
conjugated anti-IFN-y.
7.2.3 T-cell ‘help * fo r  B-cell antibody production
To test whether ECOLI ClpX28o-294-specific T-cell responses have the ability to provide 
‘help’ for the production of anti-ECOLI ClpPi77.194 antibodies, PBMC from 5 PBC 
patients with proliferative responses to ECOLI ClpX28o-294 and 5 without were cultured 
for 2 weeks in the presence o f purified PDC antigen and IL-2 (see 2.2.4). At day 14, 
cells were washed and 1 x 106/ml PBMC were cultured for 3 days with ECOLI ClpX28o- 
294, in the presence of 0.5 x 106/ml irradiated autologous PBMC but without IL-2. At the 
end of the culture, the cell-free supernatant was collected and tested by ELISA for 
antibody reactivity to ECOLI ClpX28o-294, ECOLI ClpPi77-194, and an irrelevant control 
peptide (see 2.2.2.3).
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7.3 RESULTS
7.3.1 Three-dimensional modelling
A three-dimensional model of ECOLI ClpP predicts CIPP177.194 to be repetitively 
exposed on the surface of the molecule (Figure 7.2).
Figure 7.2 Three dimensional modelling o f the hepta-symmetric caseinolytic protease 
P (ClpP) ring-like structure o f Escherichia coli with a space fill backbone (purple). 
The structure is viewed face-on. The immunodominant ECOLI ClpP 177.194 B-cell 
epitope is exposed on the surface o f the 7-mer molecule (displayed in yellow). The 
structure was analysed with the Cn3D visualisation tool
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7.3.2 T-cell responses
7.3.2.1 Standard proliferation assay
E ig h t o f  th e  n in e  an ti-E C O L I C IP P 1 7 7 .1 9 4  a n tib o d y  p o s it iv e  P B C  w o m e n  sh o w e d  
stro n g  T -c e ll  r e sp o n se s  to  E C O L I C lp X 2 8 o- 2 9 4  (F ig u re  7 .3 ) . T h e se  r e sp o n se s  w e r e  
a b sen t in  th e  6  a n ti-E C O L I C lp P i7 7 .1 9 4  a n tib o d y  n e g a tiv e  P B C  w o m e n  and  in  th e  12  
d e m o g r a p h ic a lly  m a tch ed  co n tro ls . P ro lifera tiv e  r e sp o n se s  to  E C O L I C lp X 2 8 o-2 9 4  w ere  
stro n g er  than  th o se  to  h u m an  P D C -E 2 2 1 2 - 2 2 6  in  a ll but o n e  E C O L I C lp X 2 8 o- 2 9 4  rea c tiv e  
P B C  c a s e s . T h ere  w e r e  n o  T -c e ll r e sp o n se s  to  E C O L I C IP P 1 7 7 . 1 9 4 .
SI
n = 9  1 2 3 4 5 6 7 8 9
Figure 7.3 Proliferative responses o f  peripheral blood mononuclear cells (PBMC) in 
9 PBC patients seropositive fo r  anti-Escherichia coli (ECOLI) caseinolytic protease 
(Clp)P 177.194 antibodies to ECOLI ClpX2so-294, the human pyruvate dehydrogenase 
complex-E2  (PDC-E2)212-226 mimic and the ECOLI ClpP 177-194 epitope. Results are 
expressed as the stimulation index (SI) which is the ratio o f  the mean counts per min 
(cpm) from  triplicate determinations in the presence o f  antigen to the mean cpm 
obtained in the absence o f  antigen. The wells exhibiting a mean SI >3 were 
considered positive. Results are presented as mean+SD fo r  the total number o f  
patients (9 cases) and fo r  individual cases
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7.3.2.2 Intracellular cytokine staining
A mean of 43,000 lymphocyte gated events per sample were collected (minimum 
20,000) by flow cytometry. All experiments were done in triplicate. In all five cases, 
similar or higher numbers of IFN-y producing CD4 cells were seen following 
stimulation with ECOLI ClpX28o-294, mean % of IFN-y producing CD4 cells (12.7%) ± 
SD (3.8) than with human PDC-E2212-226 (10.2± 3.1) (see Figure 7.4). Stimulation 
with ECOLI ClpPi77.194 induced IFN-y-producing CD4 cells comparable in numbers 
to those o f control wells (without peptide) (5.6 ±1.3 vs 4.9 ±1.7).
% 18
15
ECOLI d p X j g ^  PDC-E2 212.226 ECOLI ClpP Control 
(without peptide)
Figure 7.4 Percentage o f  interferon (IFN)-y producing CD4 T-cells in the presence o f  
individual peptides determined by intracellular cytokine staining. PBMC from 5 anti- 
ECOLI ClpP 177.194 antibody positive PBC women resuspended in complete medium, 
were cultured fo r  2 weeks with purified PDC antigen in the presence o f  IL-2 and 
irradiated autologous PBMC. At day 14, cells were washed and cultured fo r  72 hours 
with individual ECOLI ClpX280-294, human PDC-E2212-226,, ECOLI ClpP 177.194 and 
control peptides in complete medium, without interleukin-2. At day 4, cells were 
washed and subjected to intracellular cytokine staining with QRed-conjugated anti- 
CD4, and PE-conjugated anti-IFN-y. The frequency o f  interferon (IFN)-y producing 
CD4 T-cells is similar or higher after stimulation with ECOLI ClpX280-294 than with 
PDC-E2212-226, decreasing in the presence o f  ECOLI CLPP 177.194, or control (without 
peptide). ECOLI, Escherichia coli; Clp, caseinolytic protease X; PDC, pyruvate 
dehydrogenase complex
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7,3,3 T-cell *help * fo r  B-cell antibody production
Anti-ECOLI ClpP 177.194 antibody reactivity was found only in the supernatant of 
patients who had shown proliferative responses to ECOLI ClpX28o-294 (Figure 7.5).
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Figure 7,5 Detection by ELISA o f  anti-peptide antibody in five patients with primary 
biliary cirrhosis (PBC) positive fo r  proliferative responses to E. coli caseinolytic 
protease X  (ClpX)280-294- Cells were cultured with E. coli ClpX2so-294 and cell-free 
supernatant was used to determine antibody reactivity against E. coli ClpX2so-294, 
Escherichia coli ClpP 177-194 and an irrelevant control peptide. A cut o ff for positive 
reaction was determined as absorbance-optical density (OD) = 0.29, this cut o ff 
representing OD values exceeding mean+5SD o f  36 readings using serum from 12 
healthy subjects against E. coli ClpP 177-194 and is represented as a horizontal line
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7.4 DISCUSSION
The aim of the present section of the Thesis was to examine the hypothesis that anti- 
ECOLI ClpP antibodies specifically found in patients with PBC may arise through 
‘help’ given by auto-reactive T-cells that recognise a peptide of ClpX, the regulatory 
sub-unit of the Clp protease complex, that is a structural mimic of a dominant T-cell 
epitope of PDC-E2 (Figure 7.1) (Stevens et al., 1988, Mosmann and Coffman, 1989, 
Mahon et al., 1995, Mayo et a l , 2000, Singh et a l , 2000, Wang et a l , 1997). This 
would account for the facts that anti-ClpP and PDC-E2 antibodies are not cross- 
reactive, (ursurprisingly, since the respective antigens do not share amino acid 
homologies), and that there is no antibody reactivity to ClpX in patients with PBC, 
notwithstanding the strong sequence similarity with the dominant PDC-E2 
autoepitope (see Chapter 5).
This hypothesis generated three predictions which have been tested experimentally: 
Firstly, the ECOLI CIPP177-194 sequence must be located in a solvent-accessible 
surface region of the protein, compatible with B-cell receptor recognition (Laver et 
al., 1990). A three-dimensional model of ECOLI ClpP predicts ClpP 177.194 to be 
repetitively exposed on the surface o f the molecule (Figure 7.2). Furthermore, the 
proposed ClpX T-cell epitope is the core of a segment that is essential for the 
formation o f the ClpP/ClpX complex (Kim et a l , 2001). Secondly, the ECOLI 
ClpX28o-294 mimic - but not CIPP177-194 - must be recognised by CD4 T-cells from 
PBC patients. Both, a standard proliferation assay and intracellular cytokine staining 
revealed that ECOLI ClpX28o-294 is a target of CD4-specific T-cell responses. 
Intriguingly, the ECOLI ClpX28o-294 mimic proved to be a better stimulus for the 
production o f IFN-y not only than the ECOLI ClpPi77.194 peptide but also of the 
homologous human PDC-E2 2 12-226- Finally, PDC-specific T-cells should be able to 
provide ‘help’ for the production of anti-ECOLI CIPP177-194 by virtue of cross- 
recognition by ECOLIClpX28o-294 (Stevens et a l , 1988, Mosmann and Coffman, 1989, 
Mahon et a l , 1995, Mayo et a l , 2000). This seems to be the case as anti-ECOLI 
ClpP 177.194 antibody reactivity was found only in the cell-free supernatant of cultures 
from PBC patients who have been cultured in the presence of ECOLI ClpX28o-294- 
The findings of the present section strengthen the contention that a microbial 
exposure, such as that of recurrent E. co//-urinary tract infection, may be instrumental 
to the appearance and/or the maintenance of anti-mitochondrial responses by complex
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molecular mimicry mechanisms operating at the T-cell level (Stemerowicz et a l,  
1988, Hopf et al., 1989, Burroughs et a l , 1992, Butler et a l , 1995a, Butler et a l,  
1995b, Shimoda et a l ,  1998, Shimoda et a l ,  2000, Parikh-Patel et a l ,  2001, Butler et 
al., 1993). The kind of scenario proposed in this case is analogous to what is 
commonly seen in immune reactions to viral infections (Stavnezer, 1996, Liang and 
Mamula, 2000, Snapper et a l ,  1997, Welsh et a l ,  2004). If correct in the case of 
antibodies to ECOLI ClpP, it may also give an insight into other findings in PBC, 
such as the occurrence o f various, disease-specific anti-nuclear antibodies, where 
again the antigens have no obvious relationship to PDC-E2 (Courvalin and Worman, 
1997, Szostecki et a l ,  1997).
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Hepatitis C and liver kidney microsomal type 1 antibody
Chapter 8
8.1 BACKGROUND
In the previous chapters (Chapters 3-7) the concept of molecular mimicry has been used as 
a tool for the identification of microbial agents sharing homologies with the PDC-E2212-226, 
the major mitochondrial autoepitope in patients with PBC. These studies have been based 
on the assumption that the knowledge of the self target in the form of a peptidyl sequence 
may indirectly provide useful information as to the identity of microbial agents responsible 
for the initiation and/or the maintenance of the autoimmune response through a mechanism 
of immunological cross-reactivity. Molecular mimicry has been also suggested as a 
mechanism accountable for viral triggered autoimmunity. LKM1 antibody, for example, 
which is the serological hallmark of AIH-2, is also present in up to 10% of chronic hepatitis 
C virus (HCV) infected patients.
The only defined target of LKM1, both in AIH2 and HCV infection, is CYP2D6, a 50 kDa 
microsomal enzyme which is also present on the hepatocyte plasma membrane (Alvarez et 
al., 1985, Gueguen et al., 1989), (Robin et al., 1997, Muratori et al., 2000, Sugimura et al.,
2002). The presence of B-cell epitopes on CYP2D6 has been investigated by several groups 
and there is consensus that the region spanning amino acids 252-271 represents the 
immunodominant epitope in LKM1 positive AIH-2, being less frequently recognised by 
LKM1 positive HCV infected patients (Manns et al., 1991, Yamamoto et a l , 1993, 
Muratori et al., 1995, Dalekos et al., 1999).
The mechanism by which this particular short cytochrome sequence becomes the target of 
LKM1 antibody responses remains speculative (Manns and Obermayer-Straub, 1997, 
Bogdanos and McFarlane, 2003). Having noted that CYP2 D6252-271 shares amino acid 
homology with sequences of the NS5B and the El proteins of the HCV polyprotein and the 
ICP4 of HSV1, Manns et al. (1991) proposed that molecular mimicry and immunological 
cross-reactivity could explain reactivity to these short sequences and ultimately result in the 
production of LKM1. This hypothesis has never been addressed experimentally.
The present study investigates whether CYP2 D6252-271 and its viral homologues are targets 
of a humoral immune response and whether this immune response is cross-reactive. 
Peptides spanning the relevant sequences were constructed to test antibody binding by
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ELISA in sera from 23 LKM1 seropositive chronically HCV infected patients, and, as 
control, 23 LKM1 seronegative chronically HCV infected patients.
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8.2 METHODS
8.2.1 Subjects
Twenty-three patients with chronic hepatitis C (median age 47 years, range 22-79; 17 
female), seropositive for LKM1 (LKM ^/HCV1508) by IIFL at a median titre of 1/320 (range 
1/40 - 1/2,560) attending the out-patient clinic of the Department of Internal Medicine, 
Cardioangiology, Hepatology, University of Bologna, Italy, were studied. In 19 the HCV 
genotype was known, being la in seven, lb in eight and 2a in four. Twelve patients were 
under IFNa treatment, with a mean 6.13±3.3SD months duration of therapy. All patients 
were HLA class I and class II typed (see below).
Twenty-three patients with chronic hepatitis C, seronegative for LKM1 (HCV^/LKM"68) 
and matched for age, sex, HCV genotype, and IFNa treatment (type/dose/duration) were 
studied as controls (Table 8.1). All patients attended the out-patient clinic of the 
Department of Internal Medicine, Sismanoglion Hospital, Athens. Greece.
All of the patients with chronic hepatitis C were HCV RNA positive and anti-HCV 
antibody positive by a third generation enzyme-linked immunosorbent assay. All patients 
were negative for HBsAg, anti-HBsAg antibody, anti-Hepatitis B core (anti-HBc) antibody, 
and anti-human immunodeficiency virus.
8.2.2 Antibody detection
LKM1 was detected by IIFL (see 2.2.2.1). A commercially available ELISA was used to 
detect IgG anti-HSVl specific antibodies (see 2.1.6.1).
8.2.3 Protein database search and analysis
The ‘BLASTp 2 sequences' programme was used (see 2.2.1.2.2) to search for aa sequence 
similarity between human CYP2 D6252-271 and HCV polyprotein, and the ICP4 HSV1 
protein, formerly known as 175 kDa immediate early protein (IE175), as they were 
provided by the protein sequence databank SWISS-PROT. The SYFPEITHI programme 
was used for HLA B51 epitope prediction (www.uni-tuebingen.de/uni/kxi/).
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8.2.4 Peptide synthesis
The following five 15-mer biotinylated peptides, NS5B HCV2769-2783 /ICP4 HSVli56. 
170/CYP2 D6257-271; El HCV310.324/CYP2 D6252-266 containing the relevant homologous 
sequences (see Figure 8.1) and an irrelevant control peptide were constructed (see 2.2.23).
8.2.5 ELISA
Antibody binding to the peptides was determined by ELISA (see 2.2.23). The final peptide 
concentration was of 5pg/ml and the dilution of serum samples was of 1/200.
8.2.6 Inhibition studies
To investigate whether the simultaneous reactivity to El HCV3 10-324 and homologous 
CYP2 D6252-266 was due to cross-reactivity, competition ELISAs were performed (see
2.2.2.4.1), measuring residual anti-El HCV310-324 antibody reactivity after incubation with 
El HCV310-324, CYP2 D6252-266, C YP2 D6257-271, recombinant CYP2D6 protein, ICP4 
HSV1156-170, the irrelevant control peptide and the control protein (porcine heart 
mitochondrial PDC antigen) as liquid phase competitors (final concentrations: 5, 10, 25, 50, 
100, 250, 500, 1000 pg/ml). Anti-ICP4 HSV1156-170 reactivity after pre-incubation with 
ICP4 HSV1156-170, CYP2D6257-27i, CYP2 D6252-266, recombinant CYP2D6 protein, El 
HCV310-324, the irrelevant control peptide and the control protein was measured under 
conditions identical to those used for El HCV310-324.
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8.3 RESULTS
8.3.1 Protein database search and analysis
Sequence similarities between published NS5B and El proteins of the HCV genome 
polyprotein and CYP2D6252.27i (peptide CYP2D6252-266 and peptide CYP2D6257.27i) are 
shown in Figure 8.1. The NS5B HCV sequence has 8 similarities (6 identities) with 
CYP2 D6 257.27j. The El HCV sequence has 8 similarities (6 identities) with CYP2 D6 252.266. 
Previous studies have reported 5 aa identities not taking into account that Isoleucine ( 1 ) 3 1 3 ,  
Threonine CD314 and Alanine (A)3i9 of El HCV polyprotein are similar to Leucine (L)255 
(conserved substitution), Threonine (T) 256 and Threonine (T)26i (conserved substitution) of 
CYP2 D6 252.266 (see Figure 8.1).
8.3.2 ELISA
ELISA results of the LKM1 seropositive and LKM1 seronegative patients with hepatitis C 
and absorbance values for individual sera reactive with peptides are detailed in Table 8.1.
8.3.2.1 Reactivity to peptides
Reactivity to NS5B HCV2769.2783 was found in 1 (4%) of LKMl^VHCVP08 and 1 (4%) of 
LKMlncg/HCVpos patients. Reactivity to the El HCV310-324 was present in 14 (61%) of 
LKMlpos/HCVpos and 14 (61%) LKM lneg/HCVpos patients. There was no significant 
difference in absorbance values expressed as ODtest/ODcontro1 peptide between 
LKMl^/HCVP05 (mean OD 4.28 ± 1.46SD) and LKMl^/HCVP08 (mean OD 4.50 ± 
2.50SD) patients.
Reactivity to ICP4 HSV1156-no was present in 16 (70%) LKMl^VHCV*508 (mean OD 2.5 ± 
0.44SD) and in 14 (61%) LKM lneg/HCV^8(mean OD 3 ±0.67SD).
Reactivity to both El HCV310-324 /ICP4 HSVli56-i7o was present in 10 (43%) 
L K M l^/H C V ^and  11 (48%) LKM1 neg/HCV^8.
Reactivity to CYP2D6252.27i was present in 2 (8%) LK M l^/HCV1508 patients reacting also 
with El HCV3io-324 and ICP4 HSV1156-170 and in none of the LKMlneg/HCV1*08 patients 
(Table 1).
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8.3.2.2 Anti-HSVl detection
Antibodies against HSV1 (negative <20 RU/ml) were detected in 18 (78%, mean 71.07 ± 
38.72 SD RU/ml) LK M l^/H CV 1**, including all the 16 reacting against ICP4 HSV1156-170. 
and in 17 (74%, mean 68.9 RU/ml ± 34SD) LK M l^/H CV 1505 patients including all the 14 
reactive with 1CP4 HSV1156-no-
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Antigen sequence aa position
ICP4 HSV1 L S P R P P A Q p p R R R R H
NS5B HCV P P G D P P Q p E Y D L E L
CYP2D6 E H R M T W D P A Q p P R D L
CYP2D6 D E L L T E H R M T W D P A Q
El HCV P G H I T G H R M A W D M M M
156-170
2769-2783
257-271
252-266
310-324
FIGURE 8.1 Amino acid sequence homologies between CYP2D6, E l HCV and protein and ICP4 HSV1. The hexamer -PAQPPR- is 
shared by ICP4 HSV1 and CYP2D6 (underlined). Amino acids in standard single letter code; Colon (:), Identical residues; fu ll stop, 
(.), Conservative substitution; CYP2D6, cytochrome P4502D6; E l HCV, envelope 1 Hepatitis C Virus; ICP4 HSV1, infected cell 
protein 4 o f herpes simplex virus type 1
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Table 8.1. Demographic details and peptide binding (absorbance) values of the 23 LKMlpos/HCVpos and 23 LKM l^/HCV1*05 
patients
H C V pos/L K M lpos group H C V ^ /L K M l ncg group
PATIENT SEX AGE HCV IFN HCV HCV HSVl PATIENT SEX AGE HCV IFN HCV HCV HSVl
NUMBER GENOTYPE NS5B El ICP4 CYP2D6 CYP2D6 NUMBER GENOTYPE NS5B El ICP4 CYP2D6 CYP2D6
2769-83 310-24 156-170 252-266 257-271 2769-83 310-24 156-170 252-266 257-271
1 F 27 la Y neg 4.2 2.3 neg neg 24 F 22 la Y neg 7 4 neg neg
2 F 37 la N neg neg neg neg neg 25 F 42 la N neg neg neg neg neg
3 F 59 la Y 2 2.7 neg neg neg 26 F 64 la Y neg 2.7 neg neg neg
4 M 22 la Y neg 3.3 2.3 6.9 5.7 27 M 27 la Y neg 2.4 5.5 neg neg
5 F 44 la Y neg 5.1 2.1 neg neg 28 F 45 la Y neg neg 2.6 neg neg
6 M 44 la N neg 3.1 neg neg neg 29 M 45 la N neg neg neg neg neg
7 F 79 la N neg 2 neg neg neg 30 F 72 la N neg 3.5 5.7 neg neg
8 F 61 lb Y neg 5.7 2 neg neg 31 F 57 lb Y neg 10.6 4.6 neg neg
9 F 42 lb N neg 5.4 3.1 neg neg 32 F 40 lb N neg 2.4 neg neg neg
10 F 34 lb N neg 2 neg neg neg 33 F 37 lb N neg neg 2.2 neg neg
11 F 39 lb Y neg neg 3.1 neg neg 34 F 36 lb Y 2.7 neg 3 neg neg
12 M 53 lb Y neg neg 2 neg neg 35 M 55 lb Y neg 2.9 2.2 neg neg
13 F 63 lb N neg 3.8 2.7 4.4 3.8 36 F 63 lb N neg 4.6 3.1 neg neg
14 M 34 lb N neg neg neg neg neg 37 M 38 lb N neg 4.9 2.1 neg neg
15 M 36 lb N neg neg 2 neg neg 38 M 39 lb N neg neg neg neg neg
16 M 47 2a Y neg neg 2.2 neg neg 39 M 56 2a Y neg 2.8 3.8 neg neg
17 F 65 2a Y neg 3.9 2.8 neg neg 40 F 62 2a Y neg neg neg neg neg
18 F 47 2a Y neg neg 2.1 neg neg 41 F 51 2a Y neg neg neg neg neg
19 F 62 2a N neg neg 2.3 neg neg 42 F 62 2a N neg neg neg neg neg
20 F 59 nt Y neg 6.1 3.9 neg neg 43 F 63 nt Y neg 8.3 3.4 neg neg
21 F 45 nt N neg 9.3 2.9 neg neg 44 F 45 nt N neg 2 neg neg neg
22 F 52 nt N neg 3.3 2.1 neg neg 45 F 49 nt N neg 2.7 5.4 neg neg
23 F 55 nt N neg neg neg neg neg 46 F 55 nt N neg 2.7 2 neg neg
* 1 14 16 2 2 1 14 14 0 0
(%) (4) (6 !) (70) w (9) (4) (61) (61)
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Footnote to Table 8.1
Absorbance values are expressed as ODIes'/Q p f ontroi peptide, when >2 is considered 
positive (see 2.2.2.3); *, total number and (%) percentage o f  patients recognising an 
individual peptide; HCV, hepatitis C virus; LKM1, liver kidney microsomal antibody type 
1; NS5B, non structural protein 5B; El, envelope 1 protein; HSVl, herpes simplex virus 
type 1; ICP4, infected cell protein 4; CYP2D6, cytochrome P450IID6; F, female; M, male; 
IFN, interferon; Y, treated with IFN; N, without IFN
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8.3.3 Inhibition studies
The degree of binding inhibition to El HCV310-324 in the presence of competitor was up to 
94% (case 4) and 95% (case 13) with El HCV310-324; 81% (case 4) and 79% (case 13) with 
CYP2D6252-266; 62% (case 4) and 48% (case 13) with CYP2D6257-27i; 77% (case 4) and 
52% (case 13) with recombinant CYP2D6 protein; 9% (case 4) and 9% (case 13) with ICP4 
HSVl 156-no; 9% (case 4) and 7% (case 13) with control peptide and 13% (case 4) and 14% 
(case 13) with control protein. In both patients, El HCV310-324 reactivity was better pre­
absorbed by CYP2 D6252-266 than by CYP2 D6257-271 ,81%  (case 4) and 79% (case 13) vs 
62% (case 4) and 48% (case 13), respectively.
The degree of binding inhibition to ICP4 HSVl 156-170 in the presence of competitor was 
87% (case 4) and 78% (case 13) with ICP4 HSVl 156-i 70j 44% (case 4) and 49% (case 13) 
with CYP2 D6252-266; 87% (case 4) and 72% (case 13) with CYP2 D6257-271; 77% (case 4) 
and 72% (case 13) with recombinant CYP2D6 protein; 12% (case 4) and 13% (case 13) 
with El HCV310-324; 11% (case 4) and 15% (case 13) with control peptide and 11% (case 4) 
and 11% (case 13) with control protein. In both cases, liquid-phase ICP4 HSVl 156-170 
reactivity was better pre-absorbed by pre-incubation of the serum with the CYP2 D6257-271 
than with CYP2 D6252-266, 87% (case 4) and 72% (case 13) vs 44% (case 4) and 49% 
(13case ), respectively. Pre-incubation of the two polyreactive sera with El HCV310-324 or 
ICP4 HSVl 156-no was not able to absorb reactivity against ICP4 HSVI156-170 or El HCV310- 
324, respectively.
8.3.4 HLA typing
8.3.4.1 Class I  typing
A l, A2, and A3 antigens were the most common A antigens, being present in 7 (30%), 7 
(30%), and 6 (26%) patients respectively (2 of them were A1/A2 positive). B14, B35, B44 
were the most common B antigens being present in 6 (26%), 9 (39%), 6 (26%), 
respectively. HLA B51 was found in two (8%) patients (case 4, case 13): this allele was 
part of the haplotype A l, A30, B13, B51, Cw6, DR2, DR7, DR53, DQ2 in patient 4 and
184
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Al, B18, B51, DR7, DR11, DR52, DR53, DQ2, DQ3 in patient 13. CW4 and CW7 were 
found in 7 (30%) and 5 (22%) patients.
8.3.4.2 Class II typing
DR7 was present in 14 (61%) patients, DR52 in 10 (43%) and DR53 in 12 (52%) patients; 
DQ2 was present in 17 (74%).
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8.4 DISCUSSION
The results of the present section demonstrate that sera reacting with CYP2D6252-266, a key 
epitope of CYP2D6, also react with El HCV310-324, a hepatitis C virus sequence sharing a 8 
aa homology with CYP2D6252-266* Within a molecular mimicry pathogenic scenario, double 
reactivity is relevant if it is cross-reactive (Oldstone, 1987). The current findings 
unambiguously show that the double reactivity to El HCV310-324/C YP2D6252-266 is cross­
reactive since antibody binding to the viral sequence El HCV310-324 is inhibited by pre­
incubation with CYP2D6252-266, the viral-mimicking cytochrome sequence, but not by a 
scrambled control peptide. Importantly, the binding to the viral sequence is also inhibited 
by the recombinant, eukaryotically expressed, enzymatically active CYP2D6 , 
demonstrating that the cross-reactive virus/self recognition targets the naturally occurring 
autoantigen (Oldstone, 1987). These findings give experimental support to two points of 
Manns’ et al. (1991) proposal, namely that LKM1 arises through a mechanism of molecular 
mimicry and that this process is centred on the homologous sequences they originally 
described.
El HCV310-324/CYP2 D6252-266 cross-reactivity, however, was present in only 2 of the 23 
LKMlpos/HCVpos patients studied raising the questions as to why cross-reactivity is 
infrequent and as to how LKM1 is produced in the 21 non cross-reactive patients. Within 
the scope of molecular mimicry, an infrequent reactivity to the self sequence could simply 
reflect an infrequent reactivity to the corresponding microbial sequence (Oldstone, 1987). 
This possibility was advanced by Michitaka et al. (1994) who speculated that the hepatitis 
C viral sequence investigated in the present study rarely acts as a B cell epitope. Their 
hypothesis (Michitaka et al., 1994) is proven unfounded by the present data showing that 
over 60% of LK M l^/H CV 1505 positive patients, and indeed a similar proportion of the 
LKMr^/HCVP08 patients, react with El HCV310-324. Similar to the present findings are 
those of other workers showing that the El HCV307-330 is a frequently recognised HCV 
epitope being targeted by 39-92% of the sera from HCV infected patients, irrespective of 
their LKM1 status (Ray et al., 1994, Pirisi et al., 1995, Wang et al., 1996, Zibert et al., 
1999). An alternative possibility to explain the infrequent reactivity is that the autoantigenic 
sequence itself is either cryptic or physically unavailable to the antibody (see 1.3.6)
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(Sercarz et al., 1993). This is also not the case, since CYP2D6252.27i has been shown to be 
exposed on the surface of the molecule and is almost universally recognised by the LKM1 
antibody produced by patients with type 2 AIH (Sugimura et a l , 2002). A third possibility 
is the ‘loss of the original antigenic sin’ (Steinman, 1999). According to this theory, 
reactivity to the epitope initiating the autoimmune process is lost while the response 
spreads to new autoepitopes (Steinman, 1999). This mechanism has been clearly 
documented in animal models where it is possible to follow the ontogenesis of the immune 
response, and cannot be excluded in the patients of the present study (Steinman, 1999, 
Tuohye/a/., 1999).
Is there anything setting apart these two cross-reactive patients from the others? The 
possibility that anti-CYP2D6257-27i reactivity results from exposure to more than one self- 
mimicking virus was also considered (Oldstone, 1998, von Herrath et al., 2003). The six aa 
sequence -PAQPPR- contained within the CYP2 D6 257_27i epitope is completely shared by a 
hexameric sequence o f the herpes simplex virus type 1 ICP4 protein (ICP4 HSVli6i-i66), an 
antigen involved in the induction of autoimmunity by molecular mimicry (Manns et a l , 
1991, Douvas and Sobelman, 1991, Misaki et a l , 1993, Boulware and Weber, 2000), 
known to elicit a humoral immune response in recurrently HSVl infected individuals, 
though less frequently than other herpes antigens (Kahlon et a l , 1986, Kuhn et a l , 1987). 
In this study, sera from the two El HCV310-324/ CYP2 D6 257.27i reactive patients also reacted 
with the ICP4 HSVl 156-170 peptide, the reactivity to the herpes viral sequence being itself 
cross-reactive with CYP2 D6 257-27i. There still remain 8 LKMlpos/HCVpos patients who react 
with the El HCV310-324 and ICP4 HSVl 156-170, have evidence of exposure to hepatitis C and 
herpes virus type 1 but do not react against CYP2D6252.27i, suggesting that reactivity to 
more than one mimicking micro-organism may be important in the generation of the 
autoantibody, but that other factors must be involved (Oldstone, 1998, von Herrath et a l , 
2003).
In relation to the immunogenetic make up, the present study found that unique to the two 
patients cross-reactively recognising the cytochrome sequence was their possession of the 
allotype B51. Moreover, the sequence CYP2D6263-27i, contained within the B cell epitope 
CYP2D6252.27i, was found to have the fourth highest score (score: 22, range 1-28) amongst 
the 478 nonameric CYP2D6 sequences predicted to bind to B51. Consequently,
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CYP2D6263-271 almost certainly represents a naturally occurring B51-restricted CD8 
epitope. How possession of this HLA class I allele can predispose to a cross-reactive 
tolerance breakdown and to autoimmune manifestations remains to be established, though 
the following three points may be of relevance. Firstly, B51 is known to confer 
predisposition to autoimmunity and autoimmune diseases, its possession, for example, 
imparting a high relative risk to the development of Behfet's disease (Ohno et al., 1982, 
Mizuki et al., 1992, Mizuki et al., 2000). Secondly, in another autoimmune liver disease 
such as PBC, where B- and CD8 T-cell epitopes co-localise, a functional association has 
been shown between these two types of cells, the suggested link being autoantigen uptake 
by the B cell with cross-presentation to the CD8 T-cell (Kita et al., 2002). Thirdly, the 
predisposing role of B 51 to immune-mediated liver damage has been emphasised by the 
report that 3 LKM1 p°s/HC V1**5 patients undergoing an anti-viral interferon-alpha treatment 
had to stop their medication following an abrupt increase in transaminases: all 3 patients 
were B51 positive (Muratori et al., 1994). Moreover, none of the 16 LKM 1 neg/HC 
Greek patients investigated in the study presented in this Chapter with a known HLA were 
HLA B51 positive.
Recently we have gained an insight on how LKM 1 may be produced in the majority of our 
LKMlpo7HCVpos patients through the discovery that CYP2 D6193-212 represents a new and 
critical epitope (Kerkar et al., 2003). Not only does this sequence act as a target to 100% of 
the AIH-2 patients, but also to half of the LKMl^THCV1508 patients, far exceeding, in 
frequency terms, CYP2 D6252-271 recognition in this latter patient group (Kerkar et a l, 
2003). The newly described autoepitope is target of humoral cross-recognition for 
antibodies directed to HCV and cytomegalovirus (Kerkar et a l, 2003).
In summary, the results of this section offer experimental support to the notion that 
molecular similarity between CYP2D6, hepatitis C and herpes simplex virus can result in 
the production of a cross-reactive response, ultimately leading to the production of LKM 1 
autoantibody in patients with the appropriate immunogenetic background.
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Virus-self cross-reactivity leading to de novo autoimmune hepatitis
Chapter 9
9.1 BACKGROUND
The mechanisms leading to the breakdown of self-tolerance and to the development of AIH 
are unknown (Vergani and Mieli-Vergani, 2003). A role for viruses as triggers of liver 
autoimmunity has been proposed, but never proven because the infections responsible for 
the induction of autoimmune responses are likely to occur years before the onset of 
autoimmune disease (Vento et al., 1990, Manns et al., 1991, Vento et al., 1991, Mackie et 
al., 1994, Vento et al., 1995, Vento et al., 1996, Vento et al., 1997, Salcedo et al., 2002, 
Vento and Cainelli, 2004). Moreover, the virus responsible for the breakdown of tolerance 
can be cleared by the host’s immune system and may not be available for recognition by 
molecular probes or isolation by culture techniques, when the autoimmune process is taking 
place (von Herrath, 2000, Vento and Cainelli, 2004). In relation to AIH, studies of viral/self 
cross-reactive immunity have been focused at the time a full-blown clinical disease is 
present and are unable to provide information as to the pathogenic process taking place 
long before the onset of the disease (Oldstone, 1998, von Herrath, 2000, von Herrath et al., 
2003).
In the present Chapter immunological cross-reactivity was studied in a girl with primary 
and secondary LKM1 response following HCV infection acquired at the time of liver 
transplantation for whom serial retrospective serum samples were available allowing to 
investigate the evolution of cross-reactive immune responses from the day she acquired 
HCV-triggered LKM1 autoimmunity to overt AIH-2, nine years later (Mackie et al., 1994).
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9.2 CASE PRESENTATION
A 10 year-old girl with alpha-1 anti-trypsin deficiency, who received three orthotopic liver 
transplants (OLT) between 1989-1990 [the first, from a cytomegalovirus (CMV) positive 
donor, for end-stage cirrhosis; the following two for chronic rejection], developed a 
primary IgM and secondary IgG LKM1 autoantibody response two weeks after HCV 
infection, acquired at the time of the first transplant (Mackie et al., 1994). Since two short 
amino-acid sequences are shared between the HCV and CYP2D6, at that time it was 
postulated that HCV infection was causally related to the development of LKM1. The 
patient, however, had no evidence of autoimmune liver disease and by 1994 she was 
negative for anti-LKMl (Manns et al., 1991). A routine liver biopsy in 1996 showed 
moderate portal and perivenular fibrosis with mild non-specific inflammation.
She remained well with normal blood tests until 1998, taking tacrolimus (blood levels 5-9 
ng/ml) and prednisolone (2.5 mg/day). In 1998, 6 months after her steroids were stopped by 
her attending physician because of long-term normal liver function, blood tests showed: 
bilirubin 23 pmol/1 (nv <20), aspartate aminotransferase 780 IU/1 (nv <50), gamma 
glutamyl transpeptidase 159 IU/ (nv <50), tacrolimus level 7.4 ng/ml. LKM1 antibody was 
positive again by IFL at a titre of 1/2560. Serum HCV RNA by PCR was negative. A liver 
biopsy suggested de-novo post-OLT AIH (Figure 9.1). Prednisolone 30 mg/day, gradually 
decreased to 5 mg/day, led to persistent normalization of transaminases within four months. 
Anti-LKMl decreased to 1/320 and 1/40 five and 12 months after restarting steroids. A 
liver biopsy during biochemical remission, showed severe porto-septal and bridging 
fibrosis with architectural distortion, but only minimal residual inflammation. Because of 
de-novo AIH and moderate renal dysfunction, tacrolimus was decreased (levels 3-5 ng/ml) 
and mycophenolate mofetil (500 mg twice daily) added. At 23 years of age, the patient is 
well, with normal liver function, negative anti-LKMl and no signs of chronic liver disease, 
apart from mild splenomegaly.
To characterise the evolving LKM1 autoimmunity and investigate the role of virus/self 
molecular mimicry in its development, as part of this Thesis, 10 serum samples, collected 
between 1989-2000, and stored at -70°C were tested by ELISA, for fine specificity and 
immunoglobulin isotype of the evolving LKM1 autoantibody response using 34
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biotinylated peptides spanning the entire CYP2D6 sequence, and for possible cross-reactive 
responses between CYP2 D6252-271, the major epitope of LKM1 reactivity and its HCV 
homologues. Moreover, having found through database searches that common viruses such 
as Herpes simplex virus type 1 (HSV1), CMV, Epstein-Barr virus (EBV) and adenovirus 
(ADV) contain sequences highly homologous to CYP2D6 (Figure 9.2), evidence of 
infection with these viruses and of cross-reactivity between virus and self mimics were 
also investigated.
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A
B
Figure 9. 1. Liver biopsy at the time o f diagnosis o f de novo autoimmune hepatitis showing 
chronic hepatitis with moderate portal tract infiltration by lymphocytes and plasma cells 
(A), and porto-septal and bridging fibrosis (B)
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9.3 METHODS
9.3.1 Protein database search and analysis
The ‘Advanced Proteininfo’ and ‘BLASTp 2 sequences' programmes were used (see 2..2.1) 
to search for aa sequence similarity between human CYP2D6252-271 and viral mimics 
deposited in the SWISS-PROT protein sequence databank.
9.3.2 Peptide synthesis
Thirty-four 20-mer synthetic biotinylated peptides spanning the entire 517 aa sequence of 
the CYP2D6 protein and overlapping by 5 amino acids (see Table 9.1), 8 CYP2D625254-271 
viral mimics (see Figure 9.2) and an irrelevant control peptide were constructed (see
2.2.23).
9.3.3 ELISA
Antibody binding to the peptides was determined by ELISA (see 2.2.23). The final peptide 
concentration was that of 5pg/ml and the dilution of serum samples was of 1/200.
9.3.4 Inhibition studies
To investigate whether the simultaneous reactivity to El HCVI310-324 and CYP2 D6252-266 
was due to cross-reactivity, competition ELISA (see 2.2.2A) were performed, measuring 
residual anti-viral antibody reactivity after incubation respectively with El HCV1310-324, 
CYP2 D6252-266, recombinant CYP2D6 antigen, the irrelevant control peptide and control 
protein as solid phase competitors. Antibody detection was carried out under identical 
conditions to those described under ELISA.
9.3.5 Anti-LKMl and anti-viral antibody detection
LKM1 was detected by IIFL (see 2.2.2.1, immunoblotting (see 2.2.2.2), and ELISA (see
2.2.23). Commercially available ELISA were used to detect IgG antibodies against HSVl 
and human CMV (see 2.1.6.1). Reactivity against the full ICP4 HSVl protein was tested 
by immunoblotting using as antigen infected-cell extract enriched for HSVl proteins (see
2.1.6.1). Detection of the characteristic band of 175 kDa was carried out using an affinity
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purified ICP4 HSVl specific monoclonal antibody (mouse IgGl(k), as positive control. A 
commercially available immunoblot was used to detect antibodies against specific EBV 
antigens including Epstein-Barr nuclear antigen (EBNA).
9.3.6 Proliferation assay
A standard proliferation assay (see 2.2.3.3) was performed to investigated T-cell responses 
of PBMC from the patient (obtained in 2000) in response to stimulation with individual 
CYP2D6 peptides, and viral mimics.
9.3.7 HLA typing
The patient’s HLA type originally determined by cytotoxicity (A3,24 B5,22 Bw4,6 DR7,16 
DQ2,5), was retested using molecular techniques. Class I genotyping for HLA A and B was 
performed using sequence specific polymerisation (SSP)/PCR kits; class II genotyping for 
HLA DRB & DQB was performed by PCR/sequence specific oligonucleotide (SSO) 
probing using probes obtained from the British Society for Histocompatibility and 
Immunogenetics (BSHI). HLA typing was performed by the HLA typing Service at the 
Institute of Hepatology.
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Table 9.1 Amino acid (aa) sequences of 34 synthetic peptides in standard single letter code, 
spanning the full length of the cytochrome P450 2D6 (CYP2D6) molecule. Each peptide 
overlaps by 5 aa with the preceding and subsequent peptide.
P ep tid e A n tig e n A a
1 CYP2D6 lav-20
2 CYP2D6 16-35
3 CYP2D6 31-50
4 CYP2D6 46-65
5 CYP2D6 61-80
6 CYP2D6 76-95
7 CYP2D6 91-110
8 CYP2D6 106-125
9 CYP2D6 121-140
10 CYP2D6 136-155
11 CYP2D6 151-170
12 CYP2D6 166-185
13 CYP2D6 181-200
14 CYP2D6 193-212
15 CYP2D6 208-227
16 CYP2D6 223-242
17 CYP2D6 238-257
18 CYP2D6 252-271
19 CYP2D6 268-287
2 0 CYP2D6 283-302
21 CYP2D6 298-317
22 CYP2D6 313-332
23 CYP2D6 328-347
24 CYP2D6 343-362
25 CYP2D6 358-377
2 6 CYP2D6 373-392
27 CYP2D6 388-407
28 CYP2D6 403-422
2 9 CYP2D6 418-437
30 CYP2D6 433-452
31 CYP2D6 448-467
32 CYP2D6 463-482
33 CYP2D6 478-497
34 CYP2D6 498-517
Sequence 
MGLEALVPLAVIVAIFLLLV 
FLLLVDLMHRRQRWAARYPP 
ARYPPGPLPLPGLGNLLHVD 
LLHVDFQNTPYCFDQLRRRF 
LRRRFGDVFSLQLAWTPVW 
TPVWLNGLAAVREALVTHG 
LVTHGEDTADRPPVPITQIL 
IT Q I  LG FG PRSQGV F L ARYG 
LARYGPAWREQRRFSVSTLR 
VSTLRNLGLGKKSLEQWVTE 
QWVTEEAACLCAAFANHSGR 
NHSGRPFRPNGLLDKAVSNV 
AVSNVIASLTCGRRFEYDDP 
RRFEYDDPRFLRLLDLAQEG 
LAQEGLKEESGFLREVLNAV 
VLNAVPVLLHIPALAGKVLR 
GKVLRFQKAFLTQLDELLTE 
DELLTEHRMTWDPAQPPRDL 
PRDLTEAFLAEMEKAKGNPE 
KGNPESSFNDENLRIWADL 
W AD L F S AGM VTTSTTL AWG 
TLAWGL L LMILH PDVQRRVQ 
QRRVQQEIDDVIGQVRRPEM 
RRPEMGDQAHMPYTTAVIHE 
AVIH EVQRFGDIVPLGMTHM 
GMTHMTSRDIEVQGFRIPKG 
RIPKGTTLITNLSSVLKDEA 
LKDEAVWEKPFRFHPEHFLD 
EHFLDAQGHFVKPEAFLPFS 
FLPFSAGRRACLGEPLARME 
LARM E L F L F FTS L LQH FS FS 
H FS FSVPTGQPRPSHHGV FA 
HGVFAFLVSPSPYELCAVPR 
NGVPS PQPAPS PEALMYNKA
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Hepatitis C virus (HCV) Non structural protein 5B NS5B P P G D P P Q P E Y D L
Hepatitis C virus (HCV) Envelope 1 El /  T G H R M A W D M M M
Human Cytochrome P450IID6 CYP2D6254-270 L T E H R M T w D P A Q P P R D L
Herpes simplex virus-11 (HSV-1) Infected cell protein 4 ICP4 L S P R P P A Q P P R R R
Human adenovirus-41 (ADE41) E1B small T-antigen E1BS V L G C S P A Q P P H G L
Human cytomegalovirus (HCMV) UL69-protein UL69 I A A A P P A Q P P S Q P
Human cytomegalovirus (HCMV) Hypothetical protein J1L JIL R T A P A P A Q P P S P A
Epstein-Barr virus (EBV) Nuclear protein EBNA EBNA P P P A A P A Q P P P G V
Epstein-Barr virus (EBV) Virion protein BVRF1 UL25 H V L I D P A R L P R D T
Figure 9.2 Local amino acid homology between CYP2D6254-270 and viral mimics from hepatitis C virus (HCV), herpes simplex virus-1 
(HSVl), human cytomegalovirus (HCMV), human adenonovirus-41 (ADE41) and Epstein-Barr virus (EBV). Amino acids in single 
letter code; identities in bold; conservative substitutions in italic
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9.4 RESULTS
Results are summarised in Figure 9.3. Before the first liver transplant, LKM1 was 
undetectable by IFL, immunoblotting (human liver antigen), and ELISA (recombinant 
CYP2D6). There was an IgG antibody response to CYP2D646-65 and HSV1 ICP4i56-i7o. 
IgG, but not IgM, to HSV1 were detected by ELISA. CMV and ADV reactivities were 
negative by complement fixation test. Serum HCV RNA, negative before transplantation, 
became positive on day 1 after surgery. On day 12, IgM anti-CYP2D6i.35, - CYP2D6252-27i 
-CYP2D6313-332, and -EIHCV310-324 were detected. At the same time LKM1 antibody 
belonging exclusively to the IgM isotype, was found. On day 23, there was an additional 
IgM CYP2D6i2i-i4o response and both IgG and IgM responses to CYP2 D616-35 and 
CYP2D6252-27i. Both IgM and IgG LKM1 were detectable. Reactivities to the CYP2 D6252- 
27i mimicking peptides EIHCV 310-324, HSV1 ICP4i56-i70 and CMV UL69594-608 were also 
present; serum HCV RNA was positive and IgG antibodies directed to HSV1 ICP4 protein 
were detected by immunoblot. EIHCV 310-324/CYP2 D6252-271 double reactivity was cross­
reactive by competition ELISA (Figure 9.4). On day 62, IgG reactivity to 7 CYP2D6 
peptides was detected. LKM1 titre was 1/320. Viral serology was unchanged. On day 77 
(second liver transplant), 9 CYP2D6 peptides were recognised by LKM1 antibody (titre 
1/1280). A new reactivity to the mimic EBNA296-310 and to full-length EBNA EBV was 
demonstrated by immunoblot. On day 196, (third liver transplant), 13 CYP2D6 peptides 
were recognised by LKM1 (1/2560). Similar reactivities were detected 19 and 54 months 
after the first transplant. When de novo AIH was diagnosed, 8 years and 8 months after the 
first transplant, anti-CYP2D6 reactivity involved a total of 12 CYP2D6 peptides defining 5 
epitopes: CYP2 D6252-271, CYP2D6313-347, CYP2 D6358.377, CYP2D6i-8o, and CYP2 D6121-170, 
the first three being LKM1 targets in both AIH-2 and HCV infection. HCV polymerase 
chain reaction was then negative and antibody responses to viral sequences were limited to 
El HCV and ICP4 HSV1. Identical LKM1 reactivity was detected 11 years after the first 
liver transplant, when a standard proliferation assay revealed 8 T-cell epitopes (Figure 9.3), 
4 of which overlapped with with corresponding B-cell epitopes. Repeating by molecular 
techniques the HLA typing, the patient was found to be HLA B51.
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Legend to Figure 9.3
Reactivity against 34 overlapping 20-mer peptides spanning residues 1-517 o f  cytochrome 
P450 2D6 (CYP2D6) and to microbial mimics o f the epitope CYP2 D6252-271: envelope 1 
(El) ( ^  ) and non-structural 5B (NS5B) o f  hepatitis C virus (HCV) polyprotein, infected 
cell protein 4 (ICP4) o f  herpes simplex virus type 1 (HSV1) (  ^  ), E1B small antigen 
(E1BS) o f  human adenovirus 41 (ADV41), UL69 o f  human cytomegalovirus (HCMV) ( ^ ) ,  
hypothetical protein J1L o f  HCMV, Epstein-Barr nuclear antigen (EBNA) ( | |  ) o f
Epstein-Barr virus (EBV) and the UL25 virion protein o f  EBV Absorbance values (optical 
density, OD) on the y-axis (cut-off 0-22) are plotted against the 34 individual peptides 
boxed in white fo r  IgM, black fo r  IgG and grey fo r  both IgM and IgG anti-peptide 
responses. Peptides inducing a T-cell stimulation index (SI) exceeding 3 are given in bold 
in the box at the bottom o f  the picture. Anti liver-kidney-microsomal 1 (LKM1) titres by 
immunofluorescence (IFL) are given on the right.
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Figure 9.4 Inhibition of antibody (ab) binding to El HCV310-324 (C-I) and CYP2 D6252-271 (C-II) by pre-incubation of the sera with El 
HCV310-324 (♦ ), human CYP2 D6252-266 (■)» human CYP2D6 protein (A ), control peptide (■£) and control protein (M2 antigen) (o), in 
the presence of competitor peptides at concentrations of 0; 2-5; 5; 10; 15; 25; 50; 100; 125; 250; 500; 1000 pg/ml. The experiment 
demonstrates the cross-reactive nature of the viral/self reactivity
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9.5 DISCUSSION
This section of the Thesis investigates the evolution from a primary autoantibody response, 
triggered by HCV infection, to florid autoimmune hepatitis 9 years later. Fine specificity of 
anti-CYP2D6 responses revealed two major findings: epitope spreading from a single to 
several other autoepitopes, and a cross-reactive response involving C Y P 2 D 6 252-27i, a key 
autoepitope which shares homology with HCV, HSV, CMV and EBV. The patient was 
exposed to HSV before surgery as demonstrated by the presence of antibodies to HSV and 
acquired HCV and CMV infections at the time of the first transplant. It is conceivable that a 
potentially CYP2 D6252-271 cross-reactive lymphocyte population, primed by HSV, 
underwent expansion following exposure to mimicking sequences of HCV, CMV and EBV 
with consequent production of anti-CYP2D6.
A chronological and possibly causal link between HCV infection and LKM1 AIH has been 
highlighted by the case of a nurse who developed LKM1 antibodies 4 months after an 
accidental needlestick injury while caring for an HCV-infected patient, and histologically 
proven AIH 14 months later (Vento et al., 1997). In support of the involvement of 
molecular mimicry, HCV and CMV sequences cross-recognised by a mimicking 
C Y P 2 D 6193-212, a major B cell epitope o f LKM1 antibodies, have been recently identified as 
targets of viral/self cross-reactive responses (Kerkar et al.9 2003). Moreover, Salcedo et al.
(2002), found that all patients developing de novo AIH had evidence of infection with 
common viruses such as CMV, EBV or parvovirus.
The fact that viral/self antibodies belong to the IgG isotype, implicate T-cell ‘help’ in their 
generation, a notion relevant to the present finding that 4 of the 8 T-cell epitopes on 
CYP2D6 are identical to those of B-cells and that viral/self cross-reactivity operates at the 
CD4-T cell level, at least in the case of HCV and HSV (Stevens et a l , 1988, Mosmann and 
Coffman, 1989, Mahon et a l , 1995). This raises the possibility that CYP2D6 tolerance 
breakdown occurs not only at B cell level, but also at the CD4 (Vergani and Mieli-Vergani,
2003). If this is the case, HLA, the most important gene in determining susceptibility to 
autoimmune diseases, may also be critical for selecting the appropriate viral/self mimics 
and presenting them to the immune system (Delves and Roitt, 2000b, Delves and Roitt, 
2000a). In the present study, initial typing revealed that the girl was HLA B5 positive. As
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described in Chapter 8 CYP2D6263-27i/viral mimics were cross-recognised only when 
LKM1/HCV infected patients possessed the allotype B51, one of the split antigens of HLA 
B5. Repeating by molecular techniques the HLA typing, the patient was found to be HLA 
B51. An algorithm predicts B51 to bind CYP2D6263-271- How possession of this HLA class 
I allele predisposes to a virus/self cross-reactive break of immunological tolerance remains 
to be established. In primary biliary cirrhosis, another autoimmune liver disease where B 
and CD8 T-cell epitopes co-localise, a functional association has been shown between these 
two types of cells, the suggested link being autoantigen uptake by the B cell with cross­
presentation to the CD8 T cell, indicative of a unique role for autoantibodies and T-cells in 
the pathogenesis of the disease (Kita et al., 2002).
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Hepatitis B vaccination associated autoimmunity
Chapter 10
10.1 BACKGROUND
Molecular mimicry has long been proposed as a pathogenic mechanism for autoimmune 
disease but documentation o f this mechanism has been elusive in humans (Dyrberg and 
Oldstone, 1986, Oldstone, 1989, Oldstone, 1998, Van de Water et a l , 2001). Presently, 
proof for molecular mimicry relies on the availability of viral mimics able to induce 
cross-reactive immune responses leading to tissue damage in experimental animals such 
as Experimental Autoimmune Encephalomyelitis (EAE), the animal model of multiple 
sclerosis and herpes stromal keratitis (see 1.9.1)(01dstone, 1998, Wucherpfennig, 2001, 
von Herrath et a l , 2003).
The information derived from animal studies is of undoubted value but experimental 
models of human disease are not always able to reproduce faithfully the human 
condition. Case studies o f immunological cross-reactivity, such as the one presented in 
the previous Chapter are o f interest but there are few (Mackie et a l , 1994, Vento et a l , 
1997, Vento et a l , 1996, Vento et a l , 1991, Vento et a l , 1995). Studies of 
immunological cross-reactivity in serum samples before and after vaccination against 
viruses may provide useful information as to how a viral stimulus can induce cross­
reactive autoimmune responses. Indeed, it has been proposed that vaccination against 
infectious agents may activate pathways o f molecular mimicry in genetically susceptible 
hosts, and this may be the basis o f adverse reactions to vaccines (Cohen and Shoenfeld, 
1996, Poirriez, 2004, Ravel et a l , 2004). The present study used vaccination against 
HBV (HBVacc) as a model for the study o f viral/self cross-reactivity.
The current HBVacc is a non-infectious viral subunit consisting of the small hepatitis B 
virus surface antigen (SHBsAg), a 226 aa long recombinant antigen identical to the 
‘wild’ SHBsAg (Shouval, 2003). Extrahepatic autoimmune manifestations, such as 
demyelinating disorders and MS have increasingly been linked to HBVacc 
administration suggesting that the exposure to SHBsAg may be capable of inducing 
autoimmune adverse reactions (Herroelen et al., 1991, Cohen and Shoenfeld, 1996, 
Poirriez, 2004, Ravel et a l , 2004, Vital et a l , 2002, Aron-Maor and Shoenfeld, 2001, 
Shoenfeld and Aron-Maor, 2000, Maillefert et a l , 1999). The fact that the HBVacc is 
administered in three doses over a period of seven months gives the opportunity to 
study the emergence o f the humoral antiviral immune response and, at the same time, to
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witness appearance and evolution of the possible cross-reactive autoimmunity as a 
consequence of exposure to SHBsAg.
Among various myelin antigens, myelin basic protein (MBP) is the major target of EAE 
(Raine and Bomstein, 1970, Martin et a l ,  1992, Steinman, 1996). More recent studies 
indicate that humoral immunity against myelin oligodendrocyte glycoprotein (MOG) is 
associated with myelin damage in MS (Genain et a l ,  1999, Wekerle, 1999, Devaux et 
a l, 1997). Having found through screening of protein databases that known epitopic 
regions on SHBsAg share extensive homologies with MBP and MOG, the present study 
investigated whether the viral/self mimics serve as target of cross-reactive immune 
responses following HBVacc administration in healthy individuals.
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10.2 METHODS
10.2.1 Subjects
A total of 234 serum samples stored in the Liver Unit, Institute o f Liver Studies, King’s 
College Hospital, London, were tested including 147 samples pre- and post-HB 
vaccination from 58 adults (median age 42, range 31-62, 38 male), negative for hepatitis 
B viral markers. Samples were collected before HBvacc (58/58), and post-HBvacc, at 
three months (48/58) before the second boost, and six months post-HBvacc (41/58) 
before the third boost. As pathological controls, 87 anti-HBsAg antibody negative 
patients (median age 45, range 22-74, 59 female) were tested including 23 with PBC, 27 
with ALD, 19 with autoimmune thyroiditis, and 18 with SLE.
10.2.2 Anti-viral antibody detection
Commercially available ELISA were used to detect IgG antibodies against SHBsAg 
{see 2.1.2).
10.2.3 Protein database search and analysis
The ‘BLASTp 2 sequences' programme was used (see 2.2.1.2.2) to search for aa 
sequence similarity between SHBsAg and the MBP and MOG myelin antigens.
10.2.4 Peptide synthesis
Twenty-mer biotinylated peptides spanning the SHBsAg/myelin mimics (see Figure 
10.1) and an irrelevant control peptide were constructed (see 2.2.2.3).
10.2.5 Anti-peptide antibody detection
Antibody binding to the peptides was determined by ELISA (see 2.2.2.3). The final 
peptide concentration was 5pg/ml and the dilution of serum samples was 1/100 (see 
2.223).
10.2.6 Inhibition studies
To investigate whether the simultaneous reactivity to SHBsAgi3o-i49 and M O G 5 - 2 4  was 
due to cross-reactivity, competition ELISA (see 22.2.4) were performed, measuring
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residual anti-SHBsAgi 30-14 antibody reactivity after incubation respectively with 
SHBsAgi3o-i4, M O G 5 - 2 4 ,  recombinant SHBsAg antigen, the irrelevant control peptide 
and control protein as liquid phase competitors. Antibody detection was carried out 
under identical conditions to those described in ELISA.
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10.3 RESULTS
10.3.1 Protein database search and analysis
Amino acid similarities between SHBsAg (226 aa) and the MPB (304 aa) and MOG 
(247 aa) antigens are illustrated in Figure 10.1. Overlapping sequences within MOG10-22 
share a 66-86% local homology with SHBsAgi35-i40 and SHBsAg83.98. Another pair of 
viral/self mimics involves SHBsAg9-i5 and MOG218-224 (100% homology). SHBsAgi35. 
140 is part of the immunodominant ‘a’ B-cell epitope on SHBsAg; SHBsAg83-98 is part of 
the leucine zipper pattern o f SHBsAg and MOG10-22 extensively overlaps with the 
encephalitogenic epitope MOGi.2o(Landschulz et al., 1988, Genain et a l , 1999).
The best homology between SHBsAg and MBP is that of the SHBsAg67-8o/MBP82-95 pair 
(8/14 homology) (see Figure 10.1).
Antigens aa position Identities Similarities
SHBsAg (135-140) P S C C C T
P S C C . 4 5/6(82%)
MOG (10-15) P S c L C S
MOG (12-20) C L C S F L L L L
c L L . L L 5 6/9 (66%)
SHBsAg (89-98) L c L I F L L V L L
L c L L . L L 6 7/10 (70%)
MOG (13-22) L c S F L L L L L L
SHBsAg (83-89) F L F I L L L
F L L L L L 6 6/7 (86%)
MOG (16-22) F L L L L L L
SHBsAg (9-15) L G P L L V L
L G P L . . L 5 7/7 (100%)
MOG (218-224) L G P L V A L
SHBsAg (67-80) P I C P G Y R W M C L R R F
P P G R . R F 6 8/14 (57%)
MBP (82-95) P A D P G S R P H L I R L F
Figure 10,1 Amino acid sequence homology between small Hepatitis B surface antigen 
(SHBsAg) and myelin antigens. Amino acids in standard single letter; Full stop (.), 
conservative substitution. MOG, myelin oligodendrocyte glycoprotein; MBP, myelin 
basic protein
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10.3.2 ELISA
10.3.2.1 Before vaccination
Reactivity to at least one o f the SHBsAg peptides was found in 8 (14%) pre-vaccinated 
subjects (including 3 cases with antibodies to the full-length SHBsAg) who were 
excluded from the study.
Amongst the remaining 50 cases, reactivity to at least one of the MOG peptides was 
present in 4 (8%) (see Table 10.1).
10.3.2.2 At 3 months post-vaccination
Reactivity to at least one o f the SHBsAg peptides was present in 41/45 (91%) of the 
cases (Table 10.1), all o f whom reacted with SHBsAgi30-i49 (see Table 10.2). 
Antibodies against the full-length SHBsAg were present in 40/45 (89%) of the cases. 
Reactivity to at least one o f the M O G  mimics was present in 24/45 (53%) of the cases, 
all but one reacting with M O G 5 - 2 4  (see Table 10.1 and Table 10.2).
Double reactivity to at least one SHBsAg/MOG mimicking pairs was present in 24/45 
(53%) of the cases (see Table 10.1 and Table 10.2).
10.3.2.3 At 6 months post-vaccination
Reactivity to at least one o f the SHBsAg peptides was present in 36/39 (92%) of the 
cases (Table 10.1), all o f whom reacted with SHBsAgi3o-i49. All 36 cases also had 
antibodies against the full-length SHBsAg.
Overall, 47/50 (94%) o f the post vaccinated cases had anti-SHBsAg antibody protective 
immunity (median anti-SHBsAg antibody titre:386 mlU/ml, range 16-1000 mlU/ml, cut 
off = 10 mlU/ml).
Reactivity to at least one o f the MOG mimics was present in 17/39 (44%) o f the cases. 
At 6 months post-vaccination, 3 o f the 4 anti-MOG reactive cases before vaccination 
and 7 of the 24 (29%) o f the anti-MOG reactive cases at 3 months post-vaccination had 
lost their reactivity to MOGs-24-
Double reactivity to at least one SHBsAg/MOG mimicking pairs was present in 16/39 
(41%) of the cases.
Overall 30/50 (60%) vaccinees had SHBsAg/MOG double reactivity on at least one 
occasion (either at 3 or 6 months post-vaccination) compared to none before­
vaccination (p<0.001) and in 2/87 (2%, p<0.001) o f the pathological controls (a 52-year
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old woman with PBC and a 28-year old woman with SLE). None of the vaccinees or the 
pathological controls had double reactivity to the SHBsAg/MBP mimicking pair.
None of the vaccinees experienced any signs or symptoms of demyelinating disorders at 
the 6-month post-vaccination follow-up.
211
Chapter 10
Table 10.1 Single and double reactivity to SHBsAg and myelin mimics in absolute 
numbers and percentages (%), in 50 vaccinees before and after vaccination.
Pre-HBVacc Post-HBVacc Post-HBVacc
baseline 3 months 6 months
n=50 n=45 n=39
S H B sA gi30-149 0/50 (0%) 41/45(91%) 37/39 (95%)
S H B s A g 80-99 0/50 (0%) 1/45 (2%) 0/39 (0%)
S H B s A g  i-2o 0/50 (0%) 10/45 (22%) 13/39 (33%)
SH B sA g65-84 0/50 (0%) 5/45(11%) 5/39 13(%)
M O G 5.24 4/50 (8%) 24/45 (53%) 14/39 (36%)
M O G 210-229 1/50 (2%) 8/45 (17%) 5/39 (13%)
M B P  80-99 0/50 (0%) 0/45 (0%) 0/39 (0%)
SHBsAgi30-149/MOG5-24 0/50 (0%) 23/45 (51%) 16/39 (41%)
SHBsAg80-99/MOG5-24 0/50 (0%) 1/45 (2%) 0/39 (0%)
SHBsAg 1.20/MOG210-229 0/50 (0%) 7/45 (16%) 5/39 (13%)
SHBsAg/ (at least 1 peptide) 0/50 (0%) 21/45 (47%) 16/39 (41%)
MOG (at least 1 peptide) 4/50 (8 %) 24/45 (53%) 16/39 (41%)
SHBsAg (full protein) 0/50 (0%) 40/45 (89%) 36/39 (92%)
SHBsAg/MOG (at least lpair) 0/50 (0%) 21/45 (47%) 16/39 (41%)
HBVacc, hepatitis B vaccination; SHBsAg, small hepatitis B surface antigen; 
MOG, myelin oligodendrocyte glycoprotein; MBP, myelin basic protein
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Table 10.2 Antibody reactivity to SHBsAgi30-i49 and MOG5.24 before and after 
vaccination
!ase # SHBsAg130_i49 M O G  5 .2 4 SHBsAg, 3 o_ i49 M O G 5_24 SHBsAgj30_149 M O G 5_24
pre-HBVacc pre-Hbvacc post-HBVacc post-HBVacc post-HBVacc post-HBVac
baseline baseline 3 months 3 months 6 months 6 months
1 0 3.7 na na 7.1 0
2 0 0 4.7 3.3 5.5 0
3 0 0 3.4 0 na na
4 0 0 6.7 0 6.9 0
5 0 0 3.8 3.3 4.2 0
6 0 0 4.2 4 6 4.8
7 0 0 0 0 0 0
8 0 4.1 7.1 5.2 7.8 0
9 0 0 6.8 0 5.6 0
10 0 0 6.6 2.3 na na
11 0 0 na na 6.5 5
12 0 0 4.3 0 5.7 3.7
13 0 0 2.8 2.8 3.9 3.9
14 0 0 2.3 0 2.7 0
15 0 0 na na 8.1 0
16 0 0 0 0 0 0
17 0 0 3.3 0 6.8 0
18 0 0 3.3 4 4.9 0
19 0 0 2.8 0 2.9 0
20 0 3.2 4.1 2.9 4.1 0
21 0 0 4.7 0 na na
22 0 0 4.8 0 na na
23 0 0 3.2 2.3 3.1 3.8
24 0 0 0 0 0 0
25 0 0 3.2 0 3.1 4.4
26 0 0 na na 7.8 3
27 0 0 2.9 0 2.9 0
28 0 0 3 0 na na
29 0 0 3 3.2 na na
30 0 0 3.1 0 3 0
31 0 0 5.1 3 5.1 2.2
32 0 0 3.8 3.7 6.5 3.5
33 0 0 3.3 3 4.8 4.8
34 0 0 2.9 2.7 na na
35 0 0 5 5.9 5 0
36 0 0 6.1 5 na na
37 0 0 3.4 3 3.4 3
38 0 0 na na 4.8 2.9
39 0 4.2 5.2 0 5.9 0
40 0 0 3.5 3 3.5 2.6
41 0 0 2.9 2.4 2.9 2.9
42 0 0 7 0 7 0
43 0 0 3.3 0 3.3 3.1
44 0 0 2.9 2.1 7.8 2.9
45 0 0 0 0 3.8 3.1
46 0 0 5.1 4 na na
47 0 0 3.3 2.2 3.2 0
48 0 0 3.8 0 na na
49 0 0 4.6 3.5 na na
50 0 0 4.9 0 4.7 0
HBVacc, hepatitis B vaccination; SHBsAg, small hepatitis B surface antigen; MOG, 
myelin oligodendrocyte glycoprotein; na, not available
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1 0 3 3  Inhibition studies
Antibody binding to SHBsAgi3(M49 was inhibited by 73-92% after pre-incubation with 
the SHBsAgi3o-i49; by 69-85% after pre-incubation with MOG5-24 and by 74-88% after 
pre-incubation with full-length SHBsAg, in all 3 cases tested (Figure 10.2). 
Insignificant inhibition was observed by pre-incubation with the irrelevant control 
peptide and antigen (Figure 10.2).
Case 30 Case 33
■s
00 <
to
CO1
C/3
100
10 25 50 100 200 500 1000
100
2.5 5 10 25 50 100 200 500 1000
Competitor peptide concentrations (pg/m l)
Figure 10.2 Inhibition o f  antibody binding against SHBsAgi3o-i49 by pre-incubation 
with SHBsAg 130.149 (♦ ) , MOG5.24 (®), SHBsAg (A), control antigen (o) and control 
peptide (*) o f  case 30 and 33. On the vertical axis is the percentage o f  inhibition o f  
antibody binding to the peptide in the presence o f  competitor peptide or antigen at 
different concentrations. SHBsAg 130.149, Small Hepatitis B surface antigen; MOG, 
myelin oligodendrocyte glycoprotein; ab, antibody
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10.4 DISCUSSION
This section of the Thesis has looked for evidence of cross-reactivity between SHBsAg 
and myelin mimics in normal subjects undergoing hepatitis B vaccination. Not only 
does SHBsAg share strong homologies with major myelin antigens such as MBP and 
MOG but specific viral/self pairs were found to be targets of antibody responses 
induced by the administration of the viral vaccine. As for other mimics described in this 
Thesis, sequence similarity per se did not necessarily lead to anti-peptide reactivity and 
immunological cross-reactivity (Oldstone, 1987). In the present study the 
SHBsAg/MBP mimicking sequences and two of four sets of SHBsAg/MOG mimics 
were not antibody targets (see Table 10.1). Inhibition studies have demonstrated the 
cross-reactive nature of the observed SHBsAg/MOG antibody responses. The selective 
appearance of viral/myelin cross-reactive responses in some but not all of the 
mimicking pairs supports the biological significance of the present findings (Oldstone, 
1987, Oldstone, 1989, Oldstone, 1998).
The question of a connection between vaccination and autoimmune disorders is 
surrounded by controversy (Shoenfeld and Aron-Maor, 2000). A heated debate is going 
on regarding the causality between anti-HBV vaccination and demyelinating disorders 
such as multiple sclerosis (Shoenfeld and Aron-Maor, 2000). The focus of the present 
study was the application of HBV vaccination as a model for the study of 
immunological cross-reactivity rather than the study of the safety and efficacy of the 
anti-HBV vaccination. Serum samples from HBV vaccination recipients with 
established autoimmune disorders have not been tested in the present study. All of the 
vaccinees were free of autoimmune phenomena before vaccination and remain free of 
any adverse reactions during the follow up. Clues as to the pathogenic link between the 
vaccine and specific autoimmune disorders, therefore, could not be established. Cross­
reactive immunity was found only after vaccination, though decreasing in magnitude 
over time with a significant proportion of vaccinated subjects maintaining the anti-viral 
response but losing that against self. These findings suggest that upon vaccination, 
induction of an anti-viral response is initially capable of inducing cross-reactive anti­
self immune responses which decrease over time, possibly as a result of peripheral 
tolerance mechanisms (see 1.2.2). This scenario may explain why very rarely adverse 
post-vaccination autoimmune reactions occur (Herroelen et al., 1991, Cohen and
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Shoenfeld, 1996, Shoenfeld and Aron-Maor, 2000). Equally important may be the 
finding that the minority of vaccinees with an anti-myelin reactivity pre-HBV 
vaccination almost universally lost this reactivity post-vaccination. It is possible to 
speculate that the viral components of the vaccine and in particular the self mimicking 
SHBsAg sequences may play a role as altered peptide ligand, i.e. may represent 
sequences unable to induce cross-reactive responses but able to promote tolerance to a 
given autoepitope (Sloan-Lancaster and Allen, 1996). Such mechanism could probably 
be of benefit in patients with multiple sclerosis in whom HBV vaccination or 
immunomodulatory treatment with SHBsAg mimics as altered peptide ligand might 
contribute to restoration of tolerance towards myeling antigens (Sloan-Lancaster and 
Allen, 1996).
The hepatitis B vaccine is the first vaccine which has been shown to prevent cancer, and 
it has saved - and will save - millions of lives (Shouval, 2003). But is also a vaccine 
against a virus which has been pathogenetically linked to autoimmune adverse reactions 
(Herroelen et al., 1991, Cohen and Shoenfeld, 1996, Poirriez, 2004, Ravel et al., 2004, 
Vital et a l , 2002, Aron-Maor and Shoenfeld, 2001, Shoenfeld and Aron-Maor, 2000, 
Maillefert et a l , 1999). In view o f the observed SHBsAg/MOG cross-reactivity, the 
vaccine’s possible role as a trigger for the induction of demyelinating adverse reactions 
through molecular mimicry must be further investigated.
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General Discussion
Chapter 11
This Thesis has focused on the investigation of molecular mimicry and immunological 
cross-reactivity as a possible mechanism involved in the induction and/or maintenance 
of liver autoimmunity.
In the first part (Chapters 3-7), the principle of molecular mimicry was exploited to 
reveal microbial agents able to cross-react with PDC-E2212-226? the major mitochondrial 
autoepitope in PBC (Oldstone, 1989). Evidence for mimicry is readily obtained by 
scanning databases for sequence homologies between proteins of microbial and human 
origin (Oldstone, 1998, Bogdanos et al., 2000). Through protein database searches, the 
present study has found that human PDC-E22 12-226 shares remarkable amino acid 
similarities with microbial mimicking sequences of proteins unrelated to PDC. Previous 
studies demonstrating microbial PDC-E2/self PDC-E2 cross-reactivity have failed to 
convince several investigators who have argued that such homologies (and the observed 
cross-reactive responses) are not pathogenetically meaningful since they can readily be 
predicted, taking into account the phylogenetically highly conserved nature of PDC-E2 
among species (Van de Water et al., 2001). The potential significance of the present 
findings is emphasized by the fact that the identified microbial homologues were better 
mimics of human PDC-E22j2-226 than other microbial PDC-E2 mimics such as E. coli 
PDC-E2231.245 which has been repeatedly suggested to be involved in the induction of 
human anti-PDC-E2 autoimmunity.
It has to be stressed, however, that sequence similarity does not necessarily lead to 
structural/conformational similarity and, hence, need not equate with actual cross­
reactivity (antigenic mimicry) (Oldstone, 1987, Quaratino et al., 1995). On the other 
hand, there is a growing number of examples where evidence of microbial infection in 
autoimmune disease is also associated with immunological cross-reactivity between 
autoepitopes and mimicking microbial peptides (Oldstone, 1998). These cases have 
been taken as evidence of a pathogenetic role for such molecular mimicry. However, 
they may also be interpreted as trivial epiphenomena: strong structural similarity 
between epitopes of different antigens simply leading to cross-recognition by 
independently stimulated lymphocyte populations. In such a debate therefore it is 
important to bear in mind cases where such trivial cross-reactivity might be expected, 
but is not observed.
In the case of PBC three variants of such non-reactivity might be cited.
1) Mycobacterial heat shock proteins contain a unique peptide sequence that is a close 
structural mimic of the dominant autoepitope of PDC-E2, and cross-reactivity
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between those peptides is seen in sera from a significant proportion of Spanish PBC 
patients, but not in a large number of pathological controls from the same region 
(see Chapter 3). Moreover, in a large group of British PBC patients and controls no 
such disease-specific recognition of mycobacterial antigen was observed indicating 
a geographical/genetic restriction of the observed phenomenon.
2) On various clinical grounds Helicobacter pylori would have seemed to be an 
excellent candidate in a pathogenetic scenario for PBC. Yet sera (as well as T-cells), 
from PBC patients, whilst reacting against the immunodominant PDC-E2212-226 and 
the PDC antigen do not recognise the urease peptide that very closely mimics it (see 
Chapter 6).
3) The X sub-unit of the caseinolytic Clp complex (ClpX) of E. coli contains a peptide 
sequence that is the closest mimic of PDC-E2212-226- Nevertheless, sera from PBC 
patients do not recognise the ClpX peptide. However, there is disease-specific 
recognition of the ClpP component of that complex in a significant percentage of 
PBC patients. In this case, it seems likely that, in a proportion of patients, mimicry 
is operative at the CD4 T-cell level, helping in the production of antibodies against 
the other constituent of the same complex (see Chapter 7).
These findings indicate that cross-reactivities between autopitopes and mimicking 
peptides of infecting organisms, when they are observed, are probably not trivial, and 
may well have a bearing on the mechanism of disease. This seems to be the case of E. 
coli mimics cross-reactively recognising human PDC-E2212-226, particularly in those 
patients with evidence of recurrent urinary tract infection (Chapter 5). These 
observations expand further our view of a microbial involvement and in particular of 
ECOLI-urinary tract infection in the appearance and/or maintenance of anti- 
mitochondrial antibody responses by a cross-reactive mechanism.
More complex and less well understood is the finding that one third of patients with 
PBC had an IgG3 subclass antibody response against a lactobacillus sequence that 
mimics the major anti-mitochondrial autoepitope, which was not found in control 
subjects (Chapter 4). That the disease-specific anti-BGAL LACDE responses are of 
IgG3 isotype, implicates T-cell ‘help’ in their production, and further supports the view 
that cellular immune responses are ‘key’ players in the perpetuation of the autoimmune 
attack (Snapper and Mond, 1993, Stavnezer, 1996, Snapper et al., 1997,Stevens et a l , 
1988, Mosmann and Coffman, 1989, Mahon et a l , 1995).
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These results also raise additional questions, which need to be addressed, particularly 
about the precise mechanisms by which B and T cell cross-reactive immune responses 
are implicated in the induction of PBC-specific antimitochondrial immune responses 
(Gershwin et al., 2000, Van de Water et al., 2001). If a B-cell receptor happens to 
recognise an epitope on a microbial protein that is a mimic of an existing auto-reactive 
T-cell epitope, and this mimicking sequence is preferentially presented by the cell (by 
virtue of its protection from degradation during antigen processing), then there may be 
an enhancement of production of antibodies recognising that microbial sequence. 
Moreover, new T-cell clones would be recruited into this expansion of the immune 
response whenever an APC, such as a dendritic cell, happened to present a further 
mimicking epitope derived from the processing of another microbial protein, and hence 
prime another potentially auto-reactive T-cell receptor (Liang and Mamula, 2000, James 
and Harley, 1998). Furthermore, if the repertoire of B-cell antigen receptors, generated 
in such a scenario, catalysed the uptake of other microbial proteins bearing mimicking 
sequences that were then themselves presented to the T-cell repertoire, there would be a 
further enhancement of the autoimmune cascade.
The findings of the present work and those of recent studies demonstrating the existence 
of PDC-E2 cross-reactive microbial mimics of common pathogens support the concept 
of a ‘multiple hit’ mechanism of molecular mimicry whereby a short sequence on 
human PDC-E2 becomes a cross-reactive target of several microbial mimics, a process 
that, in susceptible individuals, may culminate in tolerance breakdown (Vilagut et al., 
1997, Selmi et al., 2003, Van de Water et al., 2001, Shimoda et al., 2000).
Three further points need to be made: Firstly, microbial involvement in autoimmune 
disease is likely to be a ‘hit and run’ phenomenon, so the lack of bacterial products in 
the liver of PBC patients may be anticipated and is not incompatible with 
immunological evidence of previous infection (see Chapter 9) (Oldstone, 1987, von 
Herrath, 2000). Secondly, while the results presented here are relevant to the evolution 
of the antibody repertoire in PBC, they do not shed direct light on the identity of the 
autoantigen abnormally expressed in biliary epithelium in the disease, which is 
recognised by these antibodies (Van de Water et al., 1993, Gershwin et al., 2000). 
Finally, although the observed microbial/self cross-reactive responses are specifically 
found in patients with PBC, their pathogenic significance is still unclear (Neuberger and 
Thomson, 1999, Gershwin et al., 2000, Van de Water et al., 2001). It has to be stressed 
that these responses have been studied at the time of overt disease and therefore may
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just represent ‘footprints’ of an ongoing process that took place several years before the 
onset of the full-blown clinical picture or may well be secondary to the immunological 
breakdown in the disease (von Herrath, 2000).
In the second part of the Thesis (Chapters 8-10), the role of immunological 
cross-reactivity has been similarly investigated in viral hepatitis-associated 
autoimmunity. Of interest, in the case of HCV associated LKM1 autoimmunity, it was 
found that a ‘multiple hit’ mechanism of molecular similarity between CYP2D6, HCV 
and HSV did probably underpin the production of a cross-reactive response (Chapter 8). 
The finding of the present study that the possession of HLA B51 allele differentiates the 
cross-reactive from the non-cross-reactive LKM1 positive HCV infected patients needs 
further investigation.
These cross-reactive responses have been demonstrated in patients’ serum samples 
obtained long after the disease has been established, and are therefore unable to provide 
clues as to the underlying mechanisms preceding the full blown clinical picture. To 
circumvent this limitation the present study has employed two different approaches. The 
first has focused on the investigation of immunological cross-reactivity in a girl with 
primary and secondary LKM1 response following HCV infection acquired at the time 
of liver transplantation and followed-up for 14 years (Chapter 9). This girl developed a 
florid autoimmune hepatitis nine years after the first appearance of disease-specific 
autoantibodies in her serum (Mackie et al., 1994). The study of the fine specificity of 
her anti-CYP2D6 responses revealed both an epitope spreading from a single to several 
other CYP2D6 epitopes, and additionally, and most importantly, a cross-reactive 
response involving the major CYP2D6 autoepitope and its HCV, HSV, CMV, and EBV 
mimics indicating that a ‘multiple hit’ viral/self cross-reactive mechanism may have 
been instrumental in the appearance of the autoimmune response. The second approach 
involved the study of cross-reactive immunity between the hepatitis B surface antigen, 
the viral component o f the hepatitis B virus vaccine, and its mimics on myelin antigens 
(Chapter 10). Cross-reactive immunity was found only after vaccination, though in 
decreasing magnitude over time, and with the vaccinated subjects maintaining the anti­
viral response but losing that against self. The finding that a cross-reactive viral/self 
immune response frequently occurs after vaccination but decreases with time, possibly 
as a result of peripheral tolerance mechanism(s), may explain why post-vaccination 
autoimmune adverse reactions are rare (Shoenfeld and Aron-Maor, 2000). Of interest is
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the finding that the minority of vaccinees with an anti-myelin reactivity pre-HBV 
vaccination lost this reactivity post-vaccination. This suggests that the viral components 
of the vaccine and in particular the self mimicking SHBsAg sequences, may well play a 
role in the suppression of pre-existing autoreactive responses giving support to the 
notion that molecular mimicry can be a mechanism of prevention (instead of 
acceleration) of autoimmunity (Sloan-Lancaster and Allen, 1996, Christen and von 
Herrath, 2004).
In summary, this Thesis has highlighted potentially different aspects of molecular 
mimicry in liver autoimmunity and presented examples demonstrating the complexity 
and diversity in which immunological cross-reactivity may affect autoimmunity. The 
present studies have demonstrated that disease-specific microbial/self cross-reactive 
responses do occur and may be of pathogenic significance. Tracking and quantitating 
the cross-reactive immunological process following viral infection in large number of 
individuals at risk of developing autoimmune manifestations may provide an insight 
into the real impact of molecular mimicry in human autoimmune liver diseases.
However, as for other autoimmune disease, definitive proof for molecular mimicry as an 
initiator or perpetuator of autoimmunity will remain difficult to obtain in humans.
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Cytochrome P4502D6193_212: A New Immunodominant Epitope 
and Target of Virus/Self Cross-Reactivity in Liver Kidney 
Microsomal Autoantibody Type 1-Positive Liver Disease1
Nanda Kerkar,** Kaushik Choudhuri,* Yun Ma,* Ayman Mahmoud,* Dimitrios P. Bogdanos,* 
Luigi Muratori,* Francesco Bianchi,* Roger Williams,* Giorgina Mieli-Vergani,+ and 
Diego Vergani2*1
Cytochrome P4502D6 (CYP2D6), target of liver kidney microsomal autoantibody type 1 (LKM1), characterizes autoimmune 
hepatitis type 2 (AIH2) but is also found in patients with chronic hepatitis C virus (HCV) infection. To provide a complete linear 
epitope B cell map of CYP2D6, we tested peptides spanning the entire sequence of CYP2D6. In addition to confirming previously 
described antigenic sites, we identified four new epitopes (193-212, 238-257, 268-287, and 478-497). CYP2D6,93_2I2 is immu­
nodominant and was the target of 12 of 13 (93%) patients with A1H2 and 5 of 10 (50%) HCV/LKM1 -positive patients. Because 
LKM1 is present in both AIH2 and a viral infection, we tested whether Abs to CYP2D6,93_212 arise through cross-reactive 
immunity between virus and self. We identified a hexameric sequence “RLLDLA” sharing 5 of 6 aa with “RLLDLS” of
i5. Of 17 CYP2D6,93_2,2-reactive sera, 11 (7 AIH and 4 HCV) reacted by ELISA withHCV, and all 6 aa with CMV.
the HCV homologue, 8 (5 AIH and 3 HCV) with the CMV homologue, and 8 (5 AIH and 3 HCV) showed double reactivity. 
Autoantibody binding to CYP2D6I93_2I2 was inhibited by preincubation with HCV2977_2996 or CMV12I_140. Recombinant HCV- 
nonstructural protein 5 and CMV-UL98 proteins also inhibited Ab binding to CYP2D6I93_212. Affinity-purified CYP2D6193_212- 
specific Ab inhibited the metabolic activity of CYP2D6. The demonstrated similarity and cross-reactivity between CYP2D6,93_2I2 
and two unrelated viruses suggests that multiple exposure to viruses mimicking self may represent an important pathway to the 
development of autoimmunity. The J o u rn a l o f  Im m u n o lo g y , 2003, 170: 1481-1489.
L iver kidney microsomal Ab type 1 (LKM1)3 is the diag­nostic marker of autoimmune hepatitis type 2 (AIH2), AIH1 being characterized by the presence of antinuclear 
Ab and/or smooth muscle Ab (1). LKM1 is also present in up to 
10% of patients with chronic hepatitis C virus (HCV) infection, 
where it appears to confer severity to the disease process, as shown 
by Giostra et al. (2), and to predispose to adverse reactions during 
treatment with IFN (3). LKM1, first described by Rizzetto et al. in 
1973 (4), is known to recognize a 50-kDa protein in rat micro­
somes located primarily in the smooth endoplasmic reticulum (5) 
and a 48-kDa protein in human liver microsomes (6). This protein 
in human liver was later identified as cytochrome P4502D6
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(CYP2D6) (7-9). The catalytic function of this cytochrome is in­
hibited in vitro by incubation with LKM1-positive serum (7).
The presence of B cell epitopes on CYP2D6 has been investi­
gated by several groups (Fig. 1 A), and the region spanning 254- 
271 has been reported to be highly antigenic in LKM 1-positive 
AIH (10-12). Within this region, Manns et al. (11) reported that 
CYP2D6263_270 is recognized by 62% of AIH2 patients, and 
Yamamoto et al. (12) reported that CYP2D62S7_269 is the most 
frequently recognized antigenic site in LKM1 AIH (85% of sera 
tested). They also described three other epitopes spanning 321— 
351, 373-389, and 410-429 regions of CYP2D6, recognized re­
spectively by 53, 7, and 13% of the AIH2 cases (12). In contrast 
to patients with AIH2, reactivity to the CYP2D6254_271 region was 
not detected in chronic HCV patients seropositive for LKM1 (13). 
Two epitopes (200-214 and 321-339) recognized by LKM1 in 
chronic HCV infection were described by Parez et al. (14). More 
recently, Klein et al. (15) reported that the CYP2D6 sequence 
196-218 is recognized by 68% of patients with AIH2, but by only 
18% of LKM1/HCV-positive patients. Common to all of the above 
reports is the selection of putative antigenic sites for testing, an 
approach that could ignore other important epitopes. The aim of 
the present study was to provide a complete B cell map of 
CYP2D6 linear epitopes using a representative number of LKM1- 
positive sera from patients with AIH2 or chronic HCV infection. 
Epitopes recognized by LKM1-positive serum would then be an­
alyzed for similarities with HCV and other pathogens, possible 
triggers of LKM1 production.
Materials and Methods
Subjects
Tw enty-three LKM  1-positive patients w ere studied. T hirteen  had  classical 
LKM  1-positive AIH (AIH 2) diagnosed according  to the recently  revised
Copyright O 2003 by The American Association of Immunologists, Inc. 0022-1767/03/S02.00
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F IG U R E  1. A, Epitope m ap o f  C Y P2D 6 illustrating docum ented epitopes: CYP2D 6254_27| by G ueguen et al. (8); CYP2D 6263_270 by M anns et al. (9); 
C Y P2D 62J7_269, C Y P2D 632I_35|, C Y P2D 6373_3X9, and C Y P2D 6410_429 by Y am am oto et al. (12); C Y P2D 6200_2)4 and CYP2D 632,_339 by Parez et al. (14); 
C Y P 2D 6196_2|„ by K lein et al. (15); C Y P 2D 6193_212, C Y P2D 623g_257, CYP2D626g_2g7, and CYP2D 647g_497 as described in this report. B, Detailed epitope 
m ap o f  C Y P 2 D 6 |93_2| H. Bi, C Y P2D 6200 2I4 described by Parez et al. (14) and recognized by 62.5%  o f  LKM  1-positive HCV patients, but not by AIH2 
patients. Bii, C Y P 2D 6I9(, ,2lg described  by K lein et al. (15) and recognized by 68%  o f  AIH2 and 18% o f LKM 1/HCV patients. Biii, C Y P2D 6,93_2,2, the 
new  epitope described in this report recognized by 92%  o f  AIH2 and 50% o f LK M 1/HCV patients.
criteria  o f  the International A utoim m une H epatitis Group (16). All had 
raised transam inases at p resentation  and w ere negative for HCV by PCR as 
w ell as o ther serological m arkers for hepatitis A -E and IgM  to EBV and 
CM V. A ll had characteristic  interface hepatitis on liver biopsy and re­
sponded to im m unosuppressive treatm ent (Prednisolone w ith and w ithout 
A zathioprine). E leven patients w ere fem ale w ith a m edian age o f  10.6 
years and a range from  3.1 to 18 years. LKM1 was detected by standard 
im m unofluorescence, and  the LKM 1 titers at the tim e o f  testing ranged 
from  1/40 to 1/5120 w ith  a m edian o f  1/640. Four children had other 
autoim m une conditions: au to im m une thyroiditis in one, insulin-dependent 
diabetes m ellitus in the second, sclerosing cholangitis in the third, and 
inflam m atory bowel d isease in the fourth. Three children were tested at 
diagnosis, four during rem ission on im m unosuppressive therapy, and six 
during relapse.
Ten sera were from  patients w ith liver disease attributed to chronic HCV 
infection. Six were fem ale w ith a m edian age o f  37 years and a range o f  19 
to 55 years. All were HC V  R N A -positive (Am plicor; Hoffm ann-LaRoche, 
Basel, Sw itzerland). LKM 1 titers at the tim e o f  testing were 1 /160-1/640 
w ith a m edian o f  1/640. O ne w as receiving IF N -a, two had stopped IFN -a 
5 m o and 4 years before this study, and one was on steroid treatm ent after 
having developed a transam inase flare 4 m o into IF N -a  treatment. These 
patients have been previously described w ithin a larger series o f  LKM 1/ 
H CV-positive patients treated w ith IF N -a  (17). Six patients were not 
treated. Serum  from  seven healthy  controls, four m ale and three female 
w ith a m edian age o f  13 years (range 10 -30  years), w ere also studied.
Peptides
Thirty-four 20-m er synthetic peptides spanning the entire 517-aa sequence 
o f  the protein and overlapping by 5 aa were constructed by 9-fluorenyl- 
methyloxycarbony! chem istry (M imotopes, Clayton, V ictoria, Australia) 
(Table 1). Biotin was linked to the peptides through a spacer w ith alter­
nating serine (S) and glycine (G) residues to avoid steric hindrance and 
reduce hydrophobicity (18). Peptides conform ed to the following format: 
biotin-SG SG -peptide-am ide, where SGSG is the spacer. A peptide encod­
ing a random ly generated sequence o f  amino acids, biotin-SGSG- 
H EDYVNQSLRPTPLEISVRA-am ide, was used as the negative control 
peptide. All peptides were > 9 0 %  pure after reverse-phase HPLC. The 
identity o f  each peptide was confirmed by mass spectrom etry. The reac­
tivity o f  LKM  1 -positive serum against each o f  the 34 peptides constructed 
was tested by ELISA.
Recombinant proteins
CM V alkaline exonuclease, the UL98 gene product, was a kind gift from 
Dr. D. J. Tenney from Bristol-M yers Squibb (Pharm aceutical Research 
Institute, W allingford, CT). Recombinant human CM V-UL98 was pro­
duced using a baculovirus-insect cell expression system and w as purified 
by high salt cell lysis, Q Sepharose chromatography, and phosphocellulose 
chrom atography. The final material was dialysed against 20 mM  Tris-HCl 
(pH 7.5), 25%  glycerol, 0.1 mM EDTA, and 1 mM D TT to an NaCl 
concentration o f  5 mM . The protein resolved as a single ~ 6 5 -k D a  band on
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T able I. Peptide keya
Peptide
No. Protein Sequence No. Amino Acid Sequence
1 C Y P2D 6 1-20 M GLEALVPLAVIVAIFLLLV
2 C Y P2D 6 1 6 -3 5 FLLLVDLMHRRQRWAARYPP
3 C Y P2D 6 3 1 -5 0 ARYPPGPLPLPGLGNLLHVD
4 C Y P2D 6 4 6 - 6 5 LLHVDFQNTPYCFDQLRRRF
5 C Y P2D 6 6 1 -8 0 LRRRFGDVFSLQLAWTPVW
6 C Y P2D 6 7 6 -9 5 TPVWLNGLAAVREALVTHG
7 C Y P2D 6 9 1 -1 1 0 LVTHGED TA D RPPV PITQ IL
8 C Y P2D 6 106-125 ITQILGFGPRSQGVFLARYG
9 C Y P2D 6 121-140 LARYGPAWREQRRFSVSTLR
10 C Y P2D 6 136-1 5 5 VSTLRNLGLGKKSLEQWVTE
11 C Y P2D 6 151-170 QWVTEEAACLCAAFANHSGR
12 C Y P2D 6 166-1 8 5 NHSGRPFRPNGLLDKAVSNV
13 C Y P2D 6 181-200 AVSNVIASLTCGRRFEYDDP
14 C Y P2D 6 193 212 RRFEYDDPRFLRLLDLAQEG
15 C Y P2D 6 2 0 8 -2 2 7 LAQEGLKEESGFLREVLNAV
16 C Y P2D 6 2 2 3 -2 4 2 VLNAVPVLLHIPALAGKVLR
17 C Y P2D 6 2 3 8 -2 5 7 GKVLRFQKAFLTQLDELLTE
18 C Y P2D 6 2 5 3 -2 7 2 ELLTEHRMTWDPAQPPRDLT
19 C Y P2D 6 2 6 8 -2 8 7 PRDLTEAFLAEMEKAKGNPE
20 C Y P2D 6 2 8 3 -3 0 2 KGN P E S S FND E N L R IW A D L
21 C Y P2D 6 2 9 8 -3 1 7 WADLFSAGMVTTSTTLAWG
22 C Y P2D 6 3 1 3 -3 3 2 TLAWGLLLMILHPDVQRRVQ
23 C Y P2D 6 3 2 8 -3 4 7 QRRVQQEIDDVIGQVRRPEM
24 C Y P2D 6 3 4 3 -3 6 2 RRPEMGDQAHMPYTTAVIHE
25 C Y P2D 6 3 5 8 -3 7 7 AVIHEVQRFGDIVPLGMTHM
26 C Y P2D 6 3 7 3 -3 9 2 GMTHMTSRDIEVQGFRIPKG
27 C Y P2D 6 3 8 8 -4 0 7 RIPK G TTLITN LSSV LK D EA
28 C Y P2D 6 4 0 3 -4 2 2 LKDEAVWEKPFRFHPEHFLD
29 C Y P2D 6 4 1 8 -4 3 7 EHFLDAQGHFVKPEAFLPFS
30 C Y P2D 6 4 3 3 -4 5 2 FLPFSAGRRACLGEPLARME
31 C Y P2D 6 4 4 8 -4 6 7 LARM ELFLFFTSLLQHFS FS
32 C Y P2D 6 4 6 3 -4 8 2 HFSFSVPTGQPRPSHHGVFA
33 C Y P2D 6 4 7 8 -4 9 7 HGVFAFLVS P S PYELCAVPR
34 C Y P2D 6 4 9 8 -5 1 7 NGVPSPQPAPSPEALMYNKA
35 CM V 121-140 GSDDYVWLSRLLDLAPNYRQ
36 HCV 2 9 7 7 -2 9 9 6 KLTPLPEARLLDLSSW FTVG
37 HCV ALA* AAAAAPEARLLDLSSWFTVG
38 H CV A LA KLTAAAAARLLDLSSWFTVG
39 HCV A LA KLTPLPEAAAAAASSWFTVG
40 HC V ALA KLTPLPEARLLDLAAAAAVG
41 HCV A LA KLTPLPEARLLDLSSAAAAA
42 C ontro l HEDYVNQSLRPTPLEISVRA
“ 1-34, Amino acid sequences of 34 synthetic peptides in standard single letter 
code, spanning the full length of the CYP2D6 molecule Each peptide overlaps by 5 
aa with the preceding and subsequent peptide. 35, 36, Viral peptide homologues of 
CYP2D6,,,, , , , .  37-41, Alanine-substituted peptides derived from HCV2977 2996. 
42, Control peptide.
h ALA, Alanine-substituted peptides.
a Coom assie-stained SDS-PAGE. It had a specific activity o f  28 m g o f  acti­
vated ca lf  thym us DNA digest/m g protein/30 min w ith a protein concentration 
o f  83 p%/m\. HCV-nonstructurai protein 5B (N S5B) (genotype 3a) was a kind 
gift from Dr. Seong o f  Yonsei Engineering Com plex (Yonsei University, 
Seoul, Korea). Recombinant protein m igrated as a single band at —60 kD a on 
SD S-PA G E and was enzym atically active as assessed by a gel-based biochem ­
ical RdRp assay. The protein was dialyzed into 25 mM  sodium  phosphate (pH 
6.8), 150 m M  NaCl, 0.5 mM EDTA, 5 mM  DTT, 0.5%  Tween 20, and 55% 
glycerol at a final concentration o f  60 /t-g/ml. Recom binant m etabolically ac­
tive CYP2D 6, produced in a baculovirus-insect cell expression system  and 
extracted as a microsomal preparation (10 mg/ml), was purchased from C am ­
bridge B ioScience (Cam bridge, U.K.).
ELISA
A total o f  200 ml/well o f  2%  BSA/PBS was added for 1 h at 20°C to a 96-well 
polysterene plate precoated with 5 mg/ml strcptavidin (M im otopes) to prevent 
nonspecific binding. After addition to each well o f  100 ml o f  biotinylated 
peptide diluted to 1/1000 in PBS containing 0.1%  sodium  azide and 0.1%  
BSA, the plate was mildly agitated in a shaker (Dynex Technologies, G uern­
sey, U.K.) for 1 h at 20°C. O ne hundred microliters o f  patient serum  diluted to 
1/200 in 2%  BS A/PBS containing 0.1%  sodium azide was added to each well 
and incubated under m ild agitation at 20°C for another hour. Thereafter, 100
1483
ml o f  HRP-conjugated goat anti-human IgG (Sigm a-Aldrich, Poole, Dorset, 
U.K.) diluted to 1/1000 in 2%  BSA/PBS was added and incubated for 1 h 
w ithout shaking at 20°C. The optimum concentrations o f  reagents at various 
steps o f  the im m unoassay were determined in prelim inary experim ents by 
checkerboard titration. Initially, using a wide range o f  dilutions, the working 
conditions o f  the assay were identified and, subsequently, using sm aller dilu­
tions around the optimum, the final concentration o f  the test sam ples and 
reagents was determined (19). After each o f  the above steps, the plate was 
washed five times w ith PBS containing 0.1%  Tw een 20. Freshly prepared 
o-phenyiene-diamine in citrate phosphate buffer was used as substrate, and the 
reaction was stopped with 4N sulfuric acid. Absorbance values were read at 
490 nm on a spectrophotometer. In each plate, two wells w ere used as blanks, 
in which serum and peptide were omitted, and two additional w ells were used 
for a positive and a negative control. The positive control consisted o f  an 
LKM  1-positive serum (titer 1/5120), which in prelim inary experim ents was 
shown to react with C Y P2D 6253_272, containing a previously described im­
m unodominant epitope (10). A randomly generated scram bled control peptide 
incubated with serum from a healthy individual was used as negative control. 
Each serum tested against experimental peptides was also tested against the 
control peptide. The final absorbance value was calculated by subtracting con­
trol peptide from the experimental peptide absorbance. Subtracted values ex­
ceeding 0.11 were considered positive, this value representing m ean +  3 SD 
o f  126 readings using serum from seven healthy subjects against 14 randomly 
selected CYP2D6 peptides. A synthetic peptide was considered to encom pass 
an epitope when the subtracted absorbance was > 0.5 .
CM V  IgG was tested by ELISA using C M V  IgG kit (C aptia; Trinity  
B iotech, Bray, Ireland).
Serum  from  the 10 LKM  1-positive patients w ith chronic H C V  infection 
was tested for rheum atoid facto r IgM  A bs using  a com m ercially  available 
kit (R heum atoid Factor kit; S igm a-A ldrich).
Database search
Protein databases SW IS S-PR O T  and PIR  w ere searched using PR O TE IN - 
IN FO  to search for hom ologies betw een the new ly  identified epitopes and 
hum an m icroorganism s. H om ologous peptides w ere constructed  by 9-flu- 
orenylm ethyloxycarbonyl chem istry  as deta iled  above (M im otopes) 
(T able I).
Inhibition studies
To investigate w hether the reactiv ity  to C Y P 2 D 6 |93_2| 2 and hom ologous 
viral peptides w as due to cross-reactiv ity , com petition  E L ISA s w ere per­
form ed using C Y P 2D 6I9 3 2 | 2 in solid  phase and using  C Y P 2 D 6 I93_212, 
H C V 2977 2996, C M V I2|. mo, and the irrelevant peptide  as com petitors in 
liquid phase. Test serum  w as diluted 1/400 w ith peptide  so lu tions to give 
final peptide concentrations o f  0.1 m g/m l, 0.5 m g/m i, and 1 m g/m l, re­
spectively. The solutions w ere  incubated a t 37°C  for 2 h and then  tested  for 
an ti-C Y P2D 6193 212 reactiv ity  by ELISA.
Alanine substitution studies
To further investigate the contribution  o f  the H C V 2977_2996 region 
291t5RLLDL (w hich is identical w ith C Y P2D 6204_20g and C M V I30. I34) to 
A b reactivity  to the full 20-aa sequence, five peptides w ere  constructed  in 
the form at b io tin-SG SG -peptide-am ide, each w ith five con tiguous alanine 
substitutions across the length o f  H C V 2977 299ft (T able I). A lan ine-substi­
tuted peptides w ere tested for reactivity  to patien t serum  by  ELISA. 
L K M 1+ patient serum  w as tested at a d ilution o f  1/400, and H R P-con ju­
gated goat anti-hum an IgG A b w as used at a d ilution o f  1/2000. A ll other 
experim ental conditions w ere as described in ELISA.
Reactivity o f LKMI-positive serum to recombinant proteins
ELISA m icrotiter p lates (N unc International, R oskilde, D enm ark) were 
coated overnight at 4°C  w ith recom binant C Y P2D 6, H C V -N S5, and CM V - 
UL98 proteins at a concentration o f  2 p.g/ml in sodium  b icarbonate  buffer 
(pH 9.6). A fter w ashing, plates w ere blocked w ith 100 pi o f  5%  BSA in 
PBS for 1 h at 37°C. O ne hundred m icroliters o f  serum  from  a patien t w ith 
LK M I-positive  AIH  at a dilution o f  1/200 was added after w ashing . Fur­
ther steps were as described in ELISA.
Inhibition of reactivity to CYP2D6IVJ 2I2 by recombinant 
proteins
Inhibition o f  reactivity to the im m unodom inant epitope by w hole protein was 
investigated by performing a competition ELISA using C Y P 2D 6193_2| 2 in 
solid phase and using recombinant HCV-NS5 and CM V -U L98 pro-
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F IG U R E  2. R eactivities o f  sera from  13 patients w ith AIH2 (A) and 10 LK M I-positive patients with chronic HCV infection (3) against 34 overlapping 
20-m er peptides spanning residues 1-517 on CYP2D6. Absorbance values on the y-axis are plotted against the 34 individual peptides on the x-axis. The 
filled arrow s m ark the four new ly identified epitopes: CYP2D6 193_2, 2 (peptide 14) is recognized by 12 A1H2 (patients 1-9, 11, 12, and 13) and 5 
LKM  1/H C V  cases (patients 14, 15, 17, 18, and 20); CYP2D6238 257 (peptide 17), recognized by LKM 1/HCV patient num ber 22; (Figure legend continues)
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F IG U R E  2. continued.
C Y P 2D 6 j 68 21t7 (peptide 19), recognized by tw o AIH2 cases (patients 1 and 9); and C Y P2D 647S 497 (peptide 33), recognized by LK M 1/H C V  patient 
num ber 21. The open arrow s m ark previously described epitopes: C Y P2D 6253 272 (peptide 18), is recognized by 11 A1H2 cases (patients 1-7 , 9, 10, 12, 
and 13) and LKM  1/H C V  patient num ber 21; C Y P2D 6328_347 (peptide 23), recognized by AIH2 patient num ber 2; C Y P2D 6343 3fl2 (peptide 24), recognized 
by LK M 1/H C V  patient num ber 16; C Y P2D 6373_392 (peptide 26), recognized by AIH2 patient num ber 3; CY P2D 64l(i_437 (peptide 29), recognized  by three 
A1H2 cases (patients 3, 4 , and 7) and LKM  1/H C V  patient num ber 14.
teins as com petitor in liquid phase. Test serum (at a final dilution o f  1/200) and 
recombinant proteins (at a final concentration o f 0.3 pig/ml) were incubated for 
2 h at 37°C and subsequently were tested for reactivity to CY P2D 6193 212 as 
described in ELISA.
Affinity purification of LKMI-positive serum
An LK M I-positive serum sam ple (reactive to CY P2D 6193_212, HCV2Q77„299f„ 
and C M V i30_ ,34) was affinity purified over a T etralink tetram eric avidin 
colum n (Prom ega, Southam pton, U .K .) com plexed w ith biotinylated
C Y P2D 6,93 212 per the m anufacturer’s instructions. Briefly, 1 ml o f  b io­
tinylated C Y P 2D 6,9V 2 | 2  at a concentration o f  0.25 m g/m l w as passed over 
a tetram eric avidin colum n (equilibrated in PBS). C Y P 2D 6193_2,2-specific 
Ab was captured by passing 5 ml o f  a “ trip le-reactive” L K M I-positive  
serum  (diluted 1/4 in PBS) over the prepared colum n a total o f  five times. 
The colum n w as w ashed w ith PBS to rem ove unbound m aterial and cap­
tured Ab w as eluted into 2 M Tris-H C l (pH 8.0) using 50 m M  glycine (pH 
3.0). The eluted Ab was concentrated to give a final volum e o f  1 ml (to 
match the original serum  volum e).
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Inhibition of CYP2D6 metabolic activity by LKMI-positive 
serum
A com m ercially available kit was used  to assess inhibition o f  CYP2D6 
m etabolic activity  by L K M I-positive  serum  and affinity-purified Ab 
(CY P2D 6/3-[2-(Y ,/V -diethyl-Y -m ethylam ino)ethyl]-7-m ethoxy-4-m ethyl- 
coum arin (A M M C ) inhibitor screening kit; G entest). The assay uses 
recom binant m icrosom al C Y P2D 6 (1.5 pM ) in conjunction w ith AM M C as 
substrate (1.5 m M ) and cofactor, producing a fluorescent m etabolite 
(3-[2-(/V ,/V-diethylam ino)ethyI]-7-hydroxy-4-m ethylcoum arin hydrochlo­
ride) that is detected using a fluorescence plate reader (CytoFluor Series 
4000; A pplied B iosystem s, Foster C ity, CA; excitation at 390 nm, emission 
at 460 nm). Serial dilutions o f  1/25 to 1/18,225 o f  a known CYP2D6 
inhibitor (quinidine, initial concentration 0.5 p.m) and LK M I-positive 
serum  from patients w ith AIH  and HCV infection, as well as the affinity- 
purified Ab, w ere added to 96-w ell black m icrotiter plates (Labsystem s 
Fluoro 96; Therm o Labsystem s, Vantaa, Finland) containing CYP2D6 
followed by  the addition o f  substrate. Control reactions included CYP2D6 
w ith  no substrate, C Y P2D 6 w ith substrate (no inhibitor), and blank wells, 
w hich w ere o therw ise subjected to the sam e experim ental conditions. The 
reaction w as allow ed to progress for 30 min at 37°C, after which it was 
term inated w ith 80%  acetonitrile, 100 mM  Tris. Plates were read using the 
param eters described  above. Percentage inhibition was calculated as fol­
lows: [(1 — (m ean fluorescence w ith test com pound — m ean fluorescence 
o f  blank w ell/m ean fluorescence w ithout inhibitor -  m ean fluorescence o f  
blank w ell)] X 100.
Structural homology modeling of CYP2D6
Swiss-M odel and the Swiss-Pdb Viewer (http://www.expasy.org/swissmod) 
were used for investigating and analyzing the derived CYP2D6 protein struc­
ture (20). C Y P2D 6,,,3_2I2 was modeled locally on the homologous region in 
Bacillus megaterium cytochrome P450 BM-3 (21, 22).
Results
Seven sera from healthy individuals were tested against 14 ran­
domly selected peptides to establish a cutoff for Ab reactivity. The 
mean (SD) subtracted (from the random control peptide) OD was 
0.0137(0.0366), giving a cutoff value of 0.11 (mean + 3 SD).
Sequences incorporating previously described epitopes (12) 
were recognized at the following frequencies: CYP2 D6 253_272 by 
11 of 13 (85%) AIH2 and 1 of 10 (10%) LKM1/HCV patients, 
CYP2D64 I 8 _ 437 by 3 of 13 (23%) AIH2 and 1 of 10 (10%) LKM1/ 
HCV patients, and CYP2D6343_362 by 1 of 10 (10%) LKM 1/HCV 
patients. Individual serum from AIH2 patients recognized the se­
quences CYP2D6328_ 347 and CYP2D6373_392 (Fig. 2, A and B, 
open arrows). Four new epitopes were identified (Fig. 2, A and B, 
filled arrows). These comprised CYP2D6193 2)2, which was rec­
ognized by the serum from 12 of 13 (93%) AIH2 and 5 of 10 
(50%) LKMI-positive patients with chronic HCV infection, 
CYP2D6268 
CYP2D6^„
by two AIH2 sera, and CYP2D6238_257 and 
by individual sera from LKM 1/HCV patients.
Within the immunodominant epitope CYP2D6193^ 212, the motif 
“RLLDLA” was found to have 5 of 6  aa identical and one similar 
to the hexameric sequence “RLLDLS” of HCV2985_2990 (located 
within HCV-NS5, the RNA-dependent DNA polymerase), A and S 
being conserved residues (23). The same motif also shared a 6 -aa 
identity with CMVI3 0 _ , 35 (located within the CMV alkaline exo-
H C V , KLTPLPEA RLLDLISSWFTVG
C Y P 2D 6193.212 RRFEYDDPRFL jRLLDLAj QEG 
C M V 121. 140 GSDDYVWLS fcLLDLAlPNYRQ
F IG U R E  3. A m ino acid sequence hom ology between the HCV2977_2996, 
C M V |21_i40, and C Y P 2D 6,93_2,2. A m ino acids are in standard single letter 
code. Identical residues betw een C Y P2D 6193_212 and the homologous viral 
peptides are w ithin the box.
Table II. Recognition o f  homologous viral peptides CMVl21_l40 and 
HCV2 9 7 7 -2 9 9 6  by LKMl-positive sera all reactive with the 
immunodominant epitopea
Patient HCV2977_2996 CMV I 2 | _ 140 CYP2D6|93_ ,i2
AIH 1 0.47 0.13 3.16
AIH 2 0.75 0.26 2.70
AIH 3 0.45 0.01 1.50
AIH 4 0.01 0.02 2.25
AIH 5 0.01 0.01 0.48
AIH 6 0.02 0.01 1.37
AIH 7 0.25 0.25 1.03
AIH 8 0.06 0.01 0.23
AIH 9 0.01 0.01 0.10
AIH 10 0.16 0.05 0.24
AIH 11 0.39 0.39 3.01
AIH 12 0.48 0.56 1.36
HCV 1 0.02 0.01 0.97
HCV 2 0.11 0.20 2.10
HCV 3 0.26 0.08 0.95
HCV 4 0.27 0.10 1.10
HCV 5 0.53 0.24 1.20
“ Twelve patients with AIH2 and five with chronic HCV infection. Values denote 
absorbance values obtained at 490 nm. Sera were considered positive when absor­
bance was S:0.11 (in bold).
nuclease) (Fig. 3). All 17 sera (12 AIH2 and 5 LKMl/HCV) re­
acting with the newly identified epitope CYP2D6193_212 were 
tested by ELISA against the homologous HCV and CMV biotin- 
ylated viral peptides. Seven AIH2 and four LKMl /HCV sera re­
acted with both CYP2D6, and HCV, whereas five
AIH2 and three LKMl/HCV sera reacted with both CYP2D6I93_212
•  CYP2D6, 
A h c v 2977.2 
▼ CMV12I.w 
■  Control
ODa
*3
•S
a
<ubJDea
(ju
Pm
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I/)t"
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F IG U R E  4. Inhibition o fA b  binding to C Y P2D 6,93 212 after incubation 
w ith increasing am ounts o f  C Y P2D 6,93_2I2 ( • ) ,  HCV2977 2996 (A), 
C M V 121 140 (▼), and control peptide (■ ). Percentage binding is on the 
y-axis. Decrease in binding o f  > 75%  is seen after preincubation with 1 
m g/m l o f  s e lf  and hom ologous viral peptides, but not w ith the control 
peptide.
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F IG U R E  5. R eactivity  o f  L K M I-positive  se ­
rum to peptide H C V 2977_299<iand its alanine-sub­
stituted hom ologues. A, H C V 2977_299<;. B-F , Sub­
stitution o f  H C V 2977_2 9 9 <; w ith five contiguous 
alanine residues across the full length o f  the na­
tive peptide. A m ino acids are represented in stan­
dard single letter code. A lanine-substituted re ­
gions are indicated  in bold. The region o f  identity 
betw een C Y P 2 D 6 ,,,  2I2 and viral peptides is 
boxed. G, C Y P 2 D 6 I93 2t2. The previously estab­
lished cutoff for a positive reaction is indicated 
by a line in the x-axis. R eactivity to H C V 2977 2W(1 
is abolished by alanine substitution o f  the region 
o f  hom ology and the contiguous dow nstream  five 
residues.
A KLTPLPEAiRLLDIjSSWFTVG
B AAAAAPEAjRLLDIjSSWFTVG
C KLTAAAAAfcLLDljsSWFTVG
D KLTPLPEAjAAAAAjSSWFTVG
E KLTPLPEARLLDLiAAAAAVG
F KLTPLPEAPLLDliSSAAAAA
G RRFEYDDPRFLjRLLDLAQEG
0.2 0.3 0.4
Absorbance at 490 nm
and CMVI21_140. Triple reactivity to CYP2D6|93_2|2/HCV2977_2996/ 
CMV)2,_140 was observed in five AIH2 and three LKM1/HCV pa­
tients (Table II). Ab binding to CYP2D6I93_212 was inhibited by ad­
dition of increasing amounts of competitor peptide. In the presence of 
1 mg/ml of competitor, absorbance was reduced by 70-90%, whereas 
it remained virtually unaltered by addition of the scrambled control 
peptide (Fig. 4).
Alanine substitution of the HCV2977 2996 region 2985RLLDL 
completely abolished reactivity by LKMl Abs, as did substitution 
of the contiguous downstream 5-aa segment. All other alanine- 
substituted peptides produced comparable serum reactivities to 
wild-type HCV2977_2996 and to the homologous CYP2D6 immu­
nodominant peptide CYP2D6,93_2|2 (Fig. 5).
Of eight patients reactive with CMVI2,_I40 whose serum was 
available for testing, four (one AIH2 and three LKMl/HCV) were 
positive for anti-CMV IgG. All 10 sera from LKM1/HCV patients 
were negative for rheumatoid factor IgM Abs.
Local homology modeling of CYP2D6 using the cytochrome 
P450 BM-3 crystal coordinates as a template predicts CYP2 D6 I93 2I2 
to be located within a helical domain in a solvent-accessible sur­
face region of the protein, compatible with Ab recognition on
ICYP2D6 rHCV-NS5 rCMV-UL98 
F IG U R E  6. Reactivity  o f  L K M I-positive  serum  to recom binant 
C Y P2D 6 (rC Y P2D 6), H C V-N S5 protein (rH C V -N S5), and CM V -U L98 
protein (rC M V -U L 98) by ELISA. A cutoff for positive reaction was de­
term ined as O D 490 =  0.07 using serum  from  healthy individuals and is 
represented as a horizontal line.
whole protein. Therefore, we tested the ability of LKMI-positive 
sera to recognize whole protein to confirm the physiological sig­
nificance of the observed peptide reactivities. Two LKMI-positive 
sera, one from a patient with AIH and another from a patient with 
HCV infection, were tested for reactivity to recombinant CYP2D6, 
HCV-NS5, and CMV-UL98. A cutoff for recognition was estab­
lished as the mean absorbance at 490 nm + 3 SD of 43 serum 
samples from healthy individuals (cutoff OD490 = 0.07) (24). Both 
LKMI-positive sera strongly recognized the recombinant proteins 
(Fig. 6). We then investigated the ability of these recombinant 
proteins to inhibit reactivity to the immunodominant CYP2D6 
peptide, CYP2D6193_212, by a liquid phase ELISA inhibition as­
say. Preincubation of LKMI-positive serum with HCV-NS5 and 
CMV-UL98 resulted in 60.5 and 61.2% inhibition of reactivity 
against CYP2D6i93_212 (Fig. 7), confirming that LKMl Abs that 
recognize CYP2D6ig3_212 are cross-reactive with the HCV and 
CMV peptide homologues.
To further test recognition of conformationally intact CYP2D6 
by LKMl serum and the LKMl Ab species reactive to 
CYP2 D6 I9 3 2I2, we assessed the ability of LKMI-positive serum 
and affinity-purified LKMl Abs specific for the CYP2D6,93_2I2 
epitope to inhibit CYP2D6 enzymatic activity using a fluorometric 
assay. Both LKM-positive serum from a patient with AIH and 
from another with HCV infection inhibited CYP2D6 enzymatic 
activity, producing —40% inhibition at a dilution of 1/225. Affin­
ity-purified Ab specific for the cross-reactive immunodominant 
CYP2D6 epitope, CYP2D6193_212, was also able to inhibit meta­
bolic activity of CYP2D6, producing —20% inhibition at a dilution 
of 1/225. This suggests that CYP2D6193_212-specific Abs contrib­
ute —50% of the inhibitory activity of LKMl serum, demonstrat­
ing the preservation and antigenicity of this epitope within native
No Proloin rHCV-NS5 rCMV-UL98
F IG U R E  7. Inhibition o f  Ab reactivity o f  L K M I-positive  serum  to 
C Y P 2D 6,93 2)2 by preincubation w ith 0.3 u g /m l o f  rH C V -N S5 and 
rCM V-UL98 or in the absence o f  com petitor protein. Residual A b reac­
tivity to C Y P 2D 6 |93_2|2 was detected by ELISA. Error bars represent + 
SD o f  six separate experim ents.
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F IG U R E  8. Inhibition o f  the m etabolic activity o f  CYP2D6 by L K M I- 
positive serum . A M M C  was used as substrate and form ation o f  the fluo­
rescent m etabolite 3-[2-(AL/V-diethylamino)ethyl]-7-hydroxy-4-methylcou- 
m arin hydrochloride detected using excitation and em ission param eters o f  
390 nm  and  460 nm , respectively. Q uinidine was used as a standard pos­
itive control (starting concentration =  0.5 p,M) and serum from a healthy 
ind iv idua l used  as a negative  con tro l (N orm al). In addition  to sera  from  
p a tien ts  w ith  L K M I-p o s itiv e  A IH  (L K M lA IH ) and L K M I-positive  
HCV infection (L K M lH C V ), affinity-purified Ab (against CYP2D6,93_2I2) 
from  an L K M I-positive  patien t w as tested for inhibitory activity 
(ap L K M l). Data are represented as percentage decrease in metabolite for­
m ation  relative to no test sam ple/inhibitor. Fifty percent inhibition is in­
d icated  as a  dashed horizontal line. E rror bars represent ±  SD o f  duplicate 
sam ples; w here no error bars are shown both sam ples gave identical 
readings.
CYP2D6 (Fig. 8). In contrast, serum from a healthy individual 
failed to inhibit enzymatic activity.
Discussion
In this study of complete B cell epitope mapping, we found a new 
immunodominant epitope on cytochrome P4502D6, CYP2D6,93_212, 
recognized by LKMI-positive serum both from patients with 
AIH2 and chronic HCV infection, which is likely to be the target 
of virus/self cross-reactive immunity. The fact that reactivity to 
this epitope has gone unnoticed to date is probably due to the 
selective epitope construction used in the past to map antigenic 
sites on the cytochrome. Searching for LKMl epitopes, Gueguen 
et al. (10) produced 10 CYP2D6 constructs through the expression 
of CYP2D6 cDNA or its rat orthologous fragments in a prokary­
otic system. Through the analysis of the results of Ab binding to 
these constructs, they inferred that a region of 33 aa (239-273) 
was the major antigenic site in AIH, being recognized by all 
LKMl AIH sera tested. Reactivity in this region was dissected 
further by the use of three synthetic peptides (241-260, 254-271, 
and 264-281), and the sequence 254-271 was found to be the 
focus of recognition. Although describing CYP2D6254_27) as a 
major epitope on CYP2D6, the authors acknowledged that their 
strategy might have overlooked other epitopes. Based on Gueguen 
et al.’s (10) and Yamamoto et al.’s additional data (12) with new 
CYP2D6 constructs and using information derived from algorith­
mic prediction of antigenic sites (25), Yamamoto et al. (12) con­
structed 12 peptides spanning the region 241-429. Epitope 257— 
269, 5 aa shorter than the epitope described by Gueguen et al. (10), 
was recognized by 14 of 15 sera from patients with AIH2, con­
firming that this region is a major antigenic site. They also found 
that the sequences 321-351, 373-389, and 410-429 were recog­
nized by eight, one, and two of the 15 sera, respectively. Akin to 
the previous study, however, a selective approach was used, with
the possibility of failing to detect other reactive epitopes. In con­
trast, in the present study all potential epitopes were investigated 
systematically using peptides spanning the entire length of the 
CYP2D6 protein. With this approach, we were able to confirm 
both existence and recognition frequency of the previously de­
scribed epitopes. In agreement with Yamamoto et al. (12), we 
found that CYP2D6253_272, encompassing the hitherto considered 
main epitope (10), was recognized by 85% of our patients with 
LKMl AIH and by only 1 of 10 LKMI-positive HCV-infected 
patients.
Of the four new epitopes identified in the present study 
(CYP2D61Q3_212, CYP2D6238_257, CYP2D62f)8_287, and CYP2D6478 _4<)7), 
CYP2D6193_212 is immunodominant. Hints were already present in 
the literature, indicating the antigenic importance of this CYP2D6 
region. After the previous finding of Yamamoto et al. (13) that 
LKMl sera from HCV-infected patients react preferentially with a 
region comprised within amino acids 208-349 of CYP2D6, Parez 
et al. (14) constructed a series of peptides selected on the basis of 
their high probability of being antigenic sites, as predicted by com­
puter analysis. They found that peptide 200-214 contained an 
epitope recognized by LKMl in HCV infection, but not in AIH. 
On the basis of this finding and in the apparent unawareness of our 
initial reports describing the new epitopes (26,27), Klein et al. (15) 
constructed a peptide 4 aa longer than that of Parez et al. (14) at 
both the N and C ends (CYP2D6l9r>^ 218) and obtained surprising 
results. In contrast with Parez et al. (14), they found that only 18% 
of LKMI-positive HCV-infected patients, but 68% of LKMl-pos­
itive AIH patients, reacted with the new peptide.
The methodological strategy used in the present paper has en­
abled us to clarify the antigenic characteristics of the region 193— 
218 on CYP2D6 and to explain, at least in part, these contrasting 
results (Fig. 15). We demonstrate that the “AIH epitope” resides 
within the 193-212 sequence, with arginine, arginine, and phenyl­
alanine at positions 193-195 conferring virtually universal recog­
nition. Sequences after 212 do not appear to have antigenic prop­
erties, as suggested by the fact that our own peptide 208-227 is 
ignored by both AIH and HCV LKMI-positive sera. This also 
indicates that the “HCV epitope” is contained in the preceding 
peptide spanning amino acids 193-212, recognized by 50% of our 
HCV-positive patients. Though it may be argued that the 3-aa dif­
ference at the N terminus could explain this higher reactivity fre­
quency among our HCV-positive patients when compared with an 
18% frequency described by Klein et al. (15), this contention is not 
supported by the data of Parez et al. (14), who found a frequency 
similar to ours using peptide 200-214, not containing amino acids 
193-199. Because the three studies have used assays of similar 
sensitivity, methodological differences are unlikely to explain 
these discrepancies. It is possible that the autoantibody concentra­
tion was lower in the patients studied by Klein et al. (15), who 
defined their LKMl sera as exceeding a 1/80 dilution without pro­
viding the exact titer. Our data show that the epitope recognized in 
HCV infection is not present beyond amino acid 208, because 
CYP2D6208_227 was not recognized by any LKMl/HCV-positive 
sera (28).
Interestingly, the dominant CYP2D6,93 _212 epitope found in the 
present study shares similarities with HCV and CMV. Modeling 
studies locate the immunodominant CYP2D6,93_2I2 peptide to the 
surface of CYP2D6, making it accessible to Ab recognition in the 
context of the physiologically folded protein (21, 22). Similarly, 
the homologous HCV2977_2996 peptide, part of the HCV RNA- 
dependent DNA polymerase (NS5), lies within a solvent-accessi­
ble loop structure of the “thumb” domain of this protein, allowing 
it to serve as an epitope on the native folded protein (23). No 
crystal coordinates are available for the CMV alkaline exonucle­
ase, which contains the region CMVI21_140 homologous to
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CYP2D6193_2I2, but preliminary secondary structure analysis sug­
gests it to be solvent accessible.
We have experimentally demonstrated these homologous self 
and viral sequences to be targets of cross-reactive virus/self Abs, 
suggesting the involvement of a molecular mimicry mechanism
(29), where the physiological immune response to a pathogen tar­
gets sequence-sharing self Ags. This mechanism was invoked by 
Manns et al. (11) to explain the production of LKM1 in HCV 
infection, after having noted that CYP2D6263_27, and the HCV 
polyprotein HCV2772_27ho share sequence similarities. This hy­
pothesis, however, was not tested in studies of cross-inhibition. 
We demonstrate that serum from LKM1 -positive patients with 
AIH or HCV infection react concurrently with CYP2D6,93_2I2, 
HCV2977_2996, and CMV121_140. Multiple reactivity is due to an 
Ab capable of recognizing both virus and self, as demonstrated by 
inhibition studies. Furthermore, we confirm by alanine substitution of 
the homologous HCV epitope HCV2977 299A that Ab reactivity to this 
sequence maps to the region with homology to CYP2D6,93 2I2 and 
CMV12I 140. Finally, we show by ELISA and a CYP2D6 metabolic 
assay that CYP2D6I93 212-specific Abs recognize and inhibit the ac­
tivity of the native enzyme and that the observed peptide cross-reac­
tivities among CYP2D6, HCV-NS5, and CMV-UL98 also operate on 
the whole Ags when tested in a competition assay.
The cross-reactive Abs detected are of the IgG isotype, impli­
cating T cell “help” in their generation. Because T and B cell 
epitopes frequently overlap, it is possible that the cross-reactive 
humoral epitopes identified may also serve as T cell epitopes (29). 
Thus, the emergence of LKM1 may be the ultimate manifestation of 
molecular mimicry at the level of the T cell, giving rise to a T-de- 
pendent and class-switched cross-reactive humoral response (30).
In conclusion, we found a new immunodominant epitope of 
LKM on CYP2D6, reactivity to which is likely to arise as a con­
sequence of its similarity with viral Ags. Multiple exposure to viral 
sequences shared with self may lead to the break of immunological 
tolerance through a multihit mechanism in predisposed individuals.
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